Primary-source diligence for biotech.

[INCY-1] Incyte is testing tafasitamab in Marginal Zone Lymphoma: a Phase 2 trial (NCT04646395), active not recruiting at 26 patients, est. primary completion 2028-03-15.
    source: https://clinicaltrials.gov/study/NCT04646395  (ORIGIN)
    verbatim: "NCT identifier NCT04646395: 'Study of Acalabrutinib and Tafasitamab in MZL Patients' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 26"
    as of: 2026-06-11T19:18:16.336Z

[INCY-2] Incyte is testing tafasitamab in Diffuse Large B-cell Lymphoma: a Phase 3 trial (NCT04824092), active not recruiting at 899 patients, est. primary completion 2027-11-01.
    source: https://clinicaltrials.gov/study/NCT04824092  (ORIGIN)
    verbatim: "NCT identifier NCT04824092: 'Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients' - Phase: Phase 3, Status: ACTIVE_NOT_RECRUITING, Enrollment: 899"
    as of: 2026-06-11T19:18:16.336Z

[INCY-3] Incyte is testing tafasitamab in Follicular Lymphoma: a Phase 2 trial (NCT07585747), not yet recruiting at 27 patients, est. primary completion 2030-12-31.
    source: https://clinicaltrials.gov/study/NCT07585747  (ORIGIN)
    verbatim: "NCT identifier NCT07585747: 'A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide' - Phase: Phase 2, Status: NOT_YET_RECRUITING, Enrollment: 27"
    as of: 2026-06-11T19:18:16.336Z

[INCY-4] Incyte is testing tafasitamab in Diffuse Large B-Cell Lymphoma: a Phase 2 trial (NCT04978584), active not recruiting at 62 patients, est. primary completion 2027-01-16.
    source: https://clinicaltrials.gov/study/NCT04978584  (ORIGIN)
    verbatim: "NCT identifier NCT04978584: 'Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 62"
    as of: 2026-06-11T19:18:16.336Z

[INCY-5] Incyte is testing tafasitamab in Hematologic Malignancies: a Phase 2 trial (NCT06465433), recruiting toward 25 patients, est. primary completion 2027-08-29.
    source: https://clinicaltrials.gov/study/NCT06465433  (ORIGIN)
    verbatim: "NCT identifier NCT06465433: 'Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab' - Phase: Phase 2, Status: RECRUITING, Enrollment: 25"
    as of: 2026-06-11T19:18:16.336Z

[INCY-6] Incyte is testing tafasitamab in Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma: a Phase 2 trial (NCT05821088), recruiting toward 37 patients, est. primary completion 2026-12-31.
    source: https://clinicaltrials.gov/study/NCT05821088  (ORIGIN)
    verbatim: "NCT identifier NCT05821088: 'Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma' - Phase: Phase 2, Status: RECRUITING, Enrollment: 37"
    as of: 2026-06-11T19:18:16.336Z

[INCY-7] Incyte is testing tafasitamab in Mantle Cell Lymphoma: a Phase 2 trial (NCT05788289), terminated at 4 patients, primary completion on record 2024-08-01.
    source: https://clinicaltrials.gov/study/NCT05788289  (ORIGIN)
    verbatim: "NCT identifier NCT05788289: 'A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma' - Phase: Phase 2, Status: TERMINATED, Enrollment: 4"
    as of: 2026-06-11T19:18:16.336Z

[INCY-8] Incyte is testing tafasitamab in Large B Cell Lymphoma: a Phase 2 trial (NCT07126236), recruiting toward 80 patients, est. primary completion 2031-12.
    source: https://clinicaltrials.gov/study/NCT07126236  (ORIGIN)
    verbatim: "NCT identifier NCT07126236: 'Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma' - Phase: Phase 2, Status: RECRUITING, Enrollment: 80"
    as of: 2026-06-11T19:18:16.336Z

[INCY-9] Incyte is testing tafasitamab in Lymphoma, B-Cell: a Phase 1/Phase 2 trial (NCT04882163), withdrawn, primary completion on record 2029-04-07.
    source: https://clinicaltrials.gov/study/NCT04882163  (ORIGIN)
    verbatim: "NCT identifier NCT04882163: 'Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma' - Phase: Phase 1/Phase 2, Status: WITHDRAWN, Enrollment: 0"
    as of: 2026-06-11T19:18:16.336Z

[INCY-10] Incyte is testing tafasitamab in Diffuse Large B Cell Lymphoma: a Phase 1/Phase 2 trial (NCT05222555), active not recruiting at 53 patients, est. primary completion 2027-11-30.
    source: https://clinicaltrials.gov/study/NCT05222555  (ORIGIN)
    verbatim: "NCT identifier NCT05222555: 'Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients' - Phase: Phase 1/Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 53"
    as of: 2026-06-11T19:18:16.336Z

[INCY-11] Incyte is testing tafasitamab in Mantle Cell Lymphoma: a Phase 1/Phase 2 trial (NCT06029309), recruiting toward 27 patients, est. primary completion 2032-05-01.
    source: https://clinicaltrials.gov/study/NCT06029309  (ORIGIN)
    verbatim: "NCT identifier NCT06029309: 'Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma' - Phase: Phase 1/Phase 2, Status: RECRUITING, Enrollment: 27"
    as of: 2026-06-11T19:18:16.336Z

[INCY-12] Incyte is testing tafasitamab in Diffuse Large B-Cell Lymphoma: a Phase 1/Phase 2 trial (NCT05626322), terminated at 6 patients, primary completion on record 2025-05-01.
    source: https://clinicaltrials.gov/study/NCT05626322  (ORIGIN)
    verbatim: "NCT identifier NCT05626322: 'Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma' - Phase: Phase 1/Phase 2, Status: TERMINATED, Enrollment: 6"
    as of: 2026-06-11T19:18:16.336Z

[INCY-13] Incyte is testing tafasitamab in Non Hodgkin Lymphoma: a Phase 1 trial (NCT07225439), not yet recruiting at 15 patients, est. primary completion 2027-12.
    source: https://clinicaltrials.gov/study/NCT07225439  (ORIGIN)
    verbatim: "NCT identifier NCT07225439: 'Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)' - Phase: Phase 1, Status: NOT_YET_RECRUITING, Enrollment: 15"
    as of: 2026-06-11T19:18:16.336Z

[INCY-14] Incyte is testing tafasitamab in Diffuse Large B-cell Lymphoma: a N/A trial (NCT05883709), unknown at 15 patients, est. primary completion 2024-12-30.
    source: https://clinicaltrials.gov/study/NCT05883709  (ORIGIN)
    verbatim: "NCT identifier NCT05883709: 'A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL' - Phase: N/A, Status: UNKNOWN, Enrollment: 15"
    as of: 2026-06-11T19:18:16.336Z

[INCY-15] Incyte is testing tafasitamab in DLBCL: a Phase 3 trial (NCT06521255), recruiting toward 244 patients, est. primary completion 2029-12.
    source: https://clinicaltrials.gov/study/NCT06521255  (ORIGIN)
    verbatim: "NCT identifier NCT06521255: 'Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma' - Phase: Phase 3, Status: RECRUITING, Enrollment: 244"
    as of: 2026-06-11T19:18:16.336Z

[INCY-16] Incyte is testing tafasitamab in Large B-Cell Lymphoma: a Phase 3 trial (NCT05429268), active not recruiting at 82 patients, est. primary completion 2027-04-01.
    source: https://clinicaltrials.gov/study/NCT05429268  (ORIGIN)
    verbatim: "NCT identifier NCT05429268: 'Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)' - Phase: Phase 3, Status: ACTIVE_NOT_RECRUITING, Enrollment: 82"
    as of: 2026-06-11T19:18:16.336Z

[INCY-17] Incyte is testing parsaclisib in Non Hodgkins Lymphoma: a Phase 1/Phase 2 trial (NCT04661007), active not recruiting at 72 patients, est. primary completion 2026-12-31.
    source: https://clinicaltrials.gov/study/NCT04661007  (ORIGIN)
    verbatim: "NCT identifier NCT04661007: 'To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)' - Phase: Phase 1/Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 72"
    as of: 2026-06-11T19:18:16.336Z

[INCY-18] Incyte is testing axatilimab in Coronavirus: a Phase 2 trial (NCT04415073), terminated at 1 patients, primary completion on record 2020-07-13.
    source: https://clinicaltrials.gov/study/NCT04415073  (ORIGIN)
    verbatim: "NCT identifier NCT04415073: 'A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19' - Phase: Phase 2, Status: TERMINATED, Enrollment: 1"
    as of: 2026-06-11T19:18:15.408Z

[INCY-19] Incyte is testing axatilimab in Healthy Participants: a Phase 1 trial (NCT06713590), completed at 72 patients, primary completion (registry) 2025-06-10.
    source: https://clinicaltrials.gov/study/NCT06713590  (ORIGIN)
    verbatim: "NCT identifier NCT06713590: 'A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants' - Phase: Phase 1, Status: COMPLETED, Enrollment: 72"
    as of: 2026-06-11T19:18:15.408Z

[INCY-20] Incyte is testing axatilimab in Hodgkin Lymphoma: a Phase 2 trial (NCT05723055), active not recruiting at 9 patients, est. primary completion 2028-11.
    source: https://clinicaltrials.gov/study/NCT05723055  (ORIGIN)
    verbatim: "NCT identifier NCT05723055: 'Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 9"
    as of: 2026-06-11T19:18:15.408Z

[INCY-21] Incyte is testing axatilimab in Solid Tumor: a Phase 1 trial (NCT03238027), completed at 45 patients, primary completion (registry) 2020-11-20.
    source: https://clinicaltrials.gov/study/NCT03238027  (ORIGIN)
    verbatim: "NCT identifier NCT03238027: 'A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors' - Phase: Phase 1, Status: COMPLETED, Enrollment: 45"
    as of: 2026-06-11T19:18:15.408Z

[INCY-22] Incyte is testing axatilimab in Chronic Graft Versus Host Disease: a Phase 2 trial (NCT07011810), recruiting toward 50 patients, est. primary completion 2030-02-10.
    source: https://clinicaltrials.gov/study/NCT07011810  (ORIGIN)
    verbatim: "NCT identifier NCT07011810: 'Axatilimab for Sclerotic Chronic Graft-versus-Host Disease' - Phase: Phase 2, Status: RECRUITING, Enrollment: 50"
    as of: 2026-06-11T19:18:15.408Z

[INCY-23] Incyte is testing axatilimab in Chronic Graft-versus-host-disease: a Phase 1/Phase 2 trial (NCT03604692), completed at 41 patients, primary completion (registry) 2024-10-18.
    source: https://clinicaltrials.gov/study/NCT03604692  (ORIGIN)
    verbatim: "NCT identifier NCT03604692: 'A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD' - Phase: Phase 1/Phase 2, Status: COMPLETED, Enrollment: 41"
    as of: 2026-06-11T19:18:15.408Z

[INCY-24] Incyte is testing axatilimab in Chronic Graft Vs. Host Disease: a N/A trial (NCT05544032), available.
    source: https://clinicaltrials.gov/study/NCT05544032  (ORIGIN)
    verbatim: "NCT identifier NCT05544032: 'Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)' - Phase: N/A, Status: AVAILABLE, Enrollment: None"
    as of: 2026-06-11T19:18:15.408Z

[INCY-25] Incyte is testing axatilimab in Chronic Graft-versus-host-disease: a Phase 2 trial (NCT07124078), recruiting toward 60 patients, est. primary completion 2029-07-31.
    source: https://clinicaltrials.gov/study/NCT07124078  (ORIGIN)
    verbatim: "NCT identifier NCT07124078: 'A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)' - Phase: Phase 2, Status: RECRUITING, Enrollment: 60"
    as of: 2026-06-11T19:18:15.408Z

[INCY-26] Incyte is testing ruxolitinib in Chronic Graft-versus-host-disease: a Phase 2 trial (NCT06388564), active not recruiting at 130 patients, est. primary completion 2029-12-01.
    source: https://clinicaltrials.gov/study/NCT06388564  (ORIGIN)
    verbatim: "NCT identifier NCT06388564: 'A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 130"
    as of: 2026-06-11T19:18:15.408Z

[INCY-27] Incyte is testing axatilimab in Diffuse Large B Cell Lymphoma (DLBCL): a Phase 1 trial (NCT07638982), not yet recruiting at 29 patients, est. primary completion 2029-12-31.
    source: https://clinicaltrials.gov/study/NCT07638982  (ORIGIN)
    verbatim: "NCT identifier NCT07638982: 'Axatilimab + CAR-T for High-Risk Lymphoma' - Phase: Phase 1, Status: NOT_YET_RECRUITING, Enrollment: 29"
    as of: 2026-06-11T19:18:15.408Z

[INCY-28] Incyte is testing axatilimab in TNBC - Triple-Negative Breast Cancer: a Phase 2 trial (NCT05491226), recruiting toward 35 patients, est. primary completion 2026-12-01.
    source: https://clinicaltrials.gov/study/NCT05491226  (ORIGIN)
    verbatim: "NCT identifier NCT05491226: 'Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation' - Phase: Phase 2, Status: RECRUITING, Enrollment: 35"
    as of: 2026-06-11T19:18:15.408Z

[INCY-29] Incyte is testing axatilimab in Chronic Graft Versus Host Disease: a Phase 2 trial (NCT06663722), recruiting toward 49 patients, est. primary completion 2030-05-05.
    source: https://clinicaltrials.gov/study/NCT06663722  (ORIGIN)
    verbatim: "NCT identifier NCT06663722: 'Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease' - Phase: Phase 2, Status: RECRUITING, Enrollment: 49"
    as of: 2026-06-11T19:18:15.408Z

[INCY-30] Incyte is testing axatilimab in Hematopoietic and Lymphatic System Neoplasm: a Phase 2 trial (NCT07349771), not yet recruiting at 72 patients, est. primary completion 2033-06-01.
    source: https://clinicaltrials.gov/study/NCT07349771  (ORIGIN)
    verbatim: "NCT identifier NCT07349771: 'Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial' - Phase: Phase 2, Status: NOT_YET_RECRUITING, Enrollment: 72"
    as of: 2026-06-11T19:18:15.408Z

[INCY-31] Incyte is testing axatilimab in Atypical Chronic Myeloid Leukemia: a Phase 1/Phase 2 trial (NCT06523556), recruiting toward 52 patients, est. primary completion 2028-10-31.
    source: https://clinicaltrials.gov/study/NCT06523556  (ORIGIN)
    verbatim: "NCT identifier NCT06523556: 'Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia' - Phase: Phase 1/Phase 2, Status: RECRUITING, Enrollment: 52"
    as of: 2026-06-11T19:18:15.408Z

[INCY-32] Incyte is testing axatilimab in Acute Myeloid Leukemia: a Phase 1 trial (NCT07511062), not yet recruiting at 32 patients, est. primary completion 2030-08-01.
    source: https://clinicaltrials.gov/study/NCT07511062  (ORIGIN)
    verbatim: "NCT identifier NCT07511062: 'Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML' - Phase: Phase 1, Status: NOT_YET_RECRUITING, Enrollment: 32"
    as of: 2026-06-11T19:18:15.408Z

[INCY-33] Incyte is testing axatilimab in Chronic Graft-versus-host-disease: a Phase 1/Phase 2 trial (NCT06843408), recruiting toward 30 patients, est. primary completion 2027-12-31.
    source: https://clinicaltrials.gov/study/NCT06843408  (ORIGIN)
    verbatim: "NCT identifier NCT06843408: 'A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD' - Phase: Phase 1/Phase 2, Status: RECRUITING, Enrollment: 30"
    as of: 2026-06-11T19:18:15.408Z

[INCY-34] Incyte is testing axatilimab in Breast Cancer: a Phase 1 trial (NCT06488378), recruiting toward 20 patients, est. primary completion 2029-03-01.
    source: https://clinicaltrials.gov/study/NCT06488378  (ORIGIN)
    verbatim: "NCT identifier NCT06488378: 'Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer' - Phase: Phase 1, Status: RECRUITING, Enrollment: 20"
    as of: 2026-06-11T19:18:15.408Z

[INCY-35] Incyte is testing axatilimab in Breast Cancer: a Phase 1 trial (NCT06959537), recruiting toward 24 patients, est. primary completion 2029-01-31.
    source: https://clinicaltrials.gov/study/NCT06959537  (ORIGIN)
    verbatim: "NCT identifier NCT06959537: 'A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)' - Phase: Phase 1, Status: RECRUITING, Enrollment: 24"
    as of: 2026-06-11T19:18:15.408Z

[INCY-36] Incyte is testing ruxolitinib in Myelofibrosis (MF): a Phase 1/Phase 2 trial (NCT07128381), recruiting toward 66 patients, est. primary completion 2033-07-31.
    source: https://clinicaltrials.gov/study/NCT07128381  (ORIGIN)
    verbatim: "NCT identifier NCT07128381: 'Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)' - Phase: Phase 1/Phase 2, Status: RECRUITING, Enrollment: 66"
    as of: 2026-06-11T19:18:15.408Z

[INCY-37] Axatilimab appears in 421 FDA adverse-event reports (FAERS); the most frequent are anxiety (10), cough (10), off label use (10).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"axatilimab"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='axatilimab': total=421, top_reactions=[{"term": "ANXIETY", "count": 10}, {"term": "COUGH", "count": 10}, {"term": "OFF LABEL USE", "count": 10}]"
    as of: 2026-06-11T19:18:15.924Z

[INCY-38] Tafasitamab appears in 4574 FDA adverse-event reports (FAERS); the most frequent are disease progression (672), diffuse large b-cell lymphoma (382), off label use (350).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"tafasitamab"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='tafasitamab': total=4574, top_reactions=[{"term": "DISEASE PROGRESSION", "count": 672}, {"term": "DIFFUSE LARGE B-CELL LYMPHOMA", "count": 382}, {"term": "OFF LABEL USE", "count": 350}]"
    as of: 2026-06-11T19:18:16.840Z

[INCY-39] Incyte is testing ruxolitinib in Myelofibrosis: a Phase 1 trial (NCT04279847), active not recruiting at 140 patients, est. primary completion 2027-04-30.
    source: https://clinicaltrials.gov/study/NCT04279847  (ORIGIN)
    verbatim: "NCT identifier NCT04279847: 'Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms' - Phase: Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 140"
    as of: 2026-06-11T19:18:13.936Z

[INCY-40] Incyte is testing its candidate in Prurigo Nodularis: a Phase 2 trial (NCT05061693), completed at 146 patients, primary completion (registry) 2024-02-28.
    source: https://clinicaltrials.gov/study/NCT05061693  (ORIGIN)
    verbatim: "NCT identifier NCT05061693: 'A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis' - Phase: Phase 2, Status: COMPLETED, Enrollment: 146"
    as of: 2026-06-11T19:18:13.936Z

[INCY-41] Incyte is testing ruxolitinib in Pregnancy Related: a N/A trial (NCT06627335), recruiting toward 5621 patients, est. primary completion 2028-08-15.
    source: https://clinicaltrials.gov/study/NCT06627335  (ORIGIN)
    verbatim: "NCT identifier NCT06627335: 'An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis' - Phase: N/A, Status: RECRUITING, Enrollment: 5621"
    as of: 2026-06-11T19:18:13.936Z

[INCY-42] Incyte is testing its candidate in Solid Tumors: a Phase 3 trial (NCT07522073), recruiting toward 588 patients, est. primary completion 2029-03-19.
    source: https://clinicaltrials.gov/study/NCT07522073  (ORIGIN)
    verbatim: "NCT identifier NCT07522073: 'A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma' - Phase: Phase 3, Status: RECRUITING, Enrollment: 588"
    as of: 2026-06-11T19:18:13.936Z

[INCY-43] Incyte is testing ruxolitinib in Solid Tumors: a Phase 1 trial (NCT01822756), terminated at 42 patients, primary completion on record 2016-08.
    source: https://clinicaltrials.gov/study/NCT01822756  (ORIGIN)
    verbatim: "NCT identifier NCT01822756: 'An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors' - Phase: Phase 1, Status: TERMINATED, Enrollment: 42"
    as of: 2026-06-11T19:18:13.936Z

[INCY-44] Incyte is testing its candidate in Chronic Graft-versus-host Disease: a Phase 2/Phase 3 trial (NCT03584516), terminated at 155 patients, primary completion on record 2023-11-03.
    source: https://clinicaltrials.gov/study/NCT03584516  (ORIGIN)
    verbatim: "NCT identifier NCT03584516: 'GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease' - Phase: Phase 2/Phase 3, Status: TERMINATED, Enrollment: 155"
    as of: 2026-06-11T19:18:13.936Z

[INCY-45] Incyte is testing its candidate in Hidradenitis Suppurativa: a Phase 2 trial (NCT03607487), completed at 35 patients, primary completion (registry) 2019-08-13.
    source: https://clinicaltrials.gov/study/NCT03607487  (ORIGIN)
    verbatim: "NCT identifier NCT03607487: 'A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa' - Phase: Phase 2, Status: COMPLETED, Enrollment: 35"
    as of: 2026-06-11T19:18:13.936Z

[INCY-46] Incyte is testing its candidate in Metastatic Squamous Non-Small Cell Lung Cancer: a Phase 3 trial (NCT04205812), active not recruiting at 583 patients, est. primary completion 2026-08-28.
    source: https://clinicaltrials.gov/study/NCT04205812  (ORIGIN)
    verbatim: "NCT identifier NCT04205812: 'Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer' - Phase: Phase 3, Status: ACTIVE_NOT_RECRUITING, Enrollment: 583"
    as of: 2026-06-11T19:18:13.936Z

[INCY-47] Incyte is testing its candidate in Solid Tumors and Hematologic Malignancy: a Phase 1/Phase 2 trial (NCT02712905), terminated at 116 patients, primary completion on record 2022-04-14.
    source: https://clinicaltrials.gov/study/NCT02712905  (ORIGIN)
    verbatim: "NCT identifier NCT02712905: 'An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies' - Phase: Phase 1/Phase 2, Status: TERMINATED, Enrollment: 116"
    as of: 2026-06-11T19:18:13.936Z

[INCY-48] Incyte is testing ruxolitinib in Chronic Hand Eczema (CHE): a Phase 3 trial (NCT05233410), withdrawn, primary completion on record 2024-09-22.
    source: https://clinicaltrials.gov/study/NCT05233410  (ORIGIN)
    verbatim: "NCT identifier NCT05233410: 'Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2' - Phase: Phase 3, Status: WITHDRAWN, Enrollment: 0"
    as of: 2026-06-11T19:18:13.936Z

[INCY-49] Incyte is testing its candidate in Rheumatoid Arthritis: a Phase 2 trial (NCT01626573), completed at 106 patients, primary completion (registry) 2013-10.
    source: https://clinicaltrials.gov/study/NCT01626573  (ORIGIN)
    verbatim: "NCT identifier NCT01626573: 'A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis' - Phase: Phase 2, Status: COMPLETED, Enrollment: 106"
    as of: 2026-06-11T19:18:13.936Z

[INCY-50] Incyte is testing its candidate in Squamous Cell Carcinoma of the Anal Canal: a Phase 3 trial (NCT04472429), completed at 308 patients, primary completion (registry) 2025-09-26.
    source: https://clinicaltrials.gov/study/NCT04472429  (ORIGIN)
    verbatim: "NCT identifier NCT04472429: 'Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).' - Phase: Phase 3, Status: COMPLETED, Enrollment: 308"
    as of: 2026-06-11T19:18:13.936Z

[INCY-51] Incyte is testing ruxolitinib in Prostate Cancer: a Phase 2 trial (NCT00638378), terminated at 22 patients, primary completion on record 2009-01.
    source: https://clinicaltrials.gov/study/NCT00638378  (ORIGIN)
    verbatim: "NCT identifier NCT00638378: 'Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer' - Phase: Phase 2, Status: TERMINATED, Enrollment: 22"
    as of: 2026-06-11T19:18:13.936Z

[INCY-52] Incyte is testing its candidate in Insulin Resistance: a Phase 1 trial (NCT00398619), completed, primary completion (registry) 2007-03.
    source: https://clinicaltrials.gov/study/NCT00398619  (ORIGIN)
    verbatim: "NCT identifier NCT00398619: 'A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes' - Phase: Phase 1, Status: COMPLETED, Enrollment: None"
    as of: 2026-06-11T19:18:13.936Z

[INCY-53] Incyte is testing ruxolitinib in Cutaneous Lichen Planus: a Phase 2 trial (NCT05593432), completed at 64 patients, primary completion (registry) 2024-02-26.
    source: https://clinicaltrials.gov/study/NCT05593432  (ORIGIN)
    verbatim: "NCT identifier NCT05593432: 'A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus' - Phase: Phase 2, Status: COMPLETED, Enrollment: 64"
    as of: 2026-06-11T19:18:13.936Z

[INCY-54] Incyte is testing its candidate in Advanced Solid Tumor: a Phase 1 trial (NCT04242199), completed at 182 patients, primary completion (registry) 2024-11-21.
    source: https://clinicaltrials.gov/study/NCT04242199  (ORIGIN)
    verbatim: "NCT identifier NCT04242199: 'Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors' - Phase: Phase 1, Status: COMPLETED, Enrollment: 182"
    as of: 2026-06-11T19:18:13.936Z

[INCY-55] Incyte is testing its candidate in Advanced Solid Tumors: a Phase 1/Phase 2 trial (NCT05949632), terminated at 5 patients, primary completion on record 2025-06-06.
    source: https://clinicaltrials.gov/study/NCT05949632  (ORIGIN)
    verbatim: "NCT identifier NCT05949632: 'A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors' - Phase: Phase 1/Phase 2, Status: TERMINATED, Enrollment: 5"
    as of: 2026-06-11T19:18:13.936Z

[INCY-56] Incyte is testing its candidate in Graft-versus-host Disease (GVHD): a Phase 1 trial (NCT02614612), completed at 31 patients, primary completion (registry) 2018-08.
    source: https://clinicaltrials.gov/study/NCT02614612  (ORIGIN)
    verbatim: "NCT identifier NCT02614612: 'Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD' - Phase: Phase 1, Status: COMPLETED, Enrollment: 31"
    as of: 2026-06-11T19:18:13.936Z

[INCY-57] Incyte is testing its candidate in Solid Tumors and Hematologic Malignancy: a Phase 2 trial (NCT02355431), withdrawn, primary completion on record 2015-09.
    source: https://clinicaltrials.gov/study/NCT02355431  (ORIGIN)
    verbatim: "NCT identifier NCT02355431: 'Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations' - Phase: Phase 2, Status: WITHDRAWN, Enrollment: 0"
    as of: 2026-06-11T19:18:13.936Z

[INCY-58] Incyte is testing ruxolitinib in Advanced Cutaneous Squamous Cell Carcinoma: a Phase 2 trial (NCT04807777), terminated at 3 patients, primary completion on record 2023-10-04.
    source: https://clinicaltrials.gov/study/NCT04807777  (ORIGIN)
    verbatim: "NCT identifier NCT04807777: 'Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma' - Phase: Phase 2, Status: TERMINATED, Enrollment: 3"
    as of: 2026-06-11T19:18:13.936Z

[INCY-59] Incyte is testing parsaclisib in B-cell Lymphoma: a Phase 1 trial (NCT03424122), completed at 50 patients, primary completion (registry) 2022-06-27.
    source: https://clinicaltrials.gov/study/NCT03424122  (ORIGIN)
    verbatim: "NCT identifier NCT03424122: 'INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)' - Phase: Phase 1, Status: COMPLETED, Enrollment: 50"
    as of: 2026-06-11T19:18:14.831Z

[INCY-60] Incyte is testing parsaclisib in Warm Autoimmune Hemolytic Anemia (wAIHA): a Phase 3 trial (NCT05073458), terminated at 13 patients, primary completion on record 2024-04-29.
    source: https://clinicaltrials.gov/study/NCT05073458  (ORIGIN)
    verbatim: "NCT identifier NCT05073458: 'Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia' - Phase: Phase 3, Status: TERMINATED, Enrollment: 13"
    as of: 2026-06-11T19:18:14.831Z

[INCY-61] Incyte is testing parsaclisib in Lymphoma: a Phase 2 trial (NCT03126019), completed at 126 patients, primary completion (registry) 2024-06-07.
    source: https://clinicaltrials.gov/study/NCT03126019  (ORIGIN)
    verbatim: "NCT identifier NCT03126019: 'A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma' - Phase: Phase 2, Status: COMPLETED, Enrollment: 126"
    as of: 2026-06-11T19:18:14.831Z

[INCY-62] Incyte is testing parsaclisib in Lymphoma: a Phase 1 trial (NCT03314922), completed at 17 patients, primary completion (registry) 2023-03-09.
    source: https://clinicaltrials.gov/study/NCT03314922  (ORIGIN)
    verbatim: "NCT identifier NCT03314922: 'A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)' - Phase: Phase 1, Status: COMPLETED, Enrollment: 17"
    as of: 2026-06-11T19:18:14.831Z

[INCY-63] Incyte is testing parsaclisib in Autoimmune Hemolytic Anemia: a N/A trial (NCT07149818), not yet recruiting at 22 patients, est. primary completion 2027-01-01.
    source: https://clinicaltrials.gov/study/NCT07149818  (ORIGIN)
    verbatim: "NCT identifier NCT07149818: 'A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia' - Phase: N/A, Status: NOT_YET_RECRUITING, Enrollment: 22"
    as of: 2026-06-11T19:18:14.831Z

[INCY-64] Incyte is testing ruxolitinib in Myelofibrosis: a Phase 3 trial (NCT04551053), terminated at 177 patients, primary completion on record 2024-08-21.
    source: https://clinicaltrials.gov/study/NCT04551053  (ORIGIN)
    verbatim: "NCT identifier NCT04551053: 'To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)' - Phase: Phase 3, Status: TERMINATED, Enrollment: 177"
    as of: 2026-06-11T19:18:14.831Z

[INCY-65] Incyte is testing its candidate in Colorectal Cancer (CRC): a Phase 1 trial (NCT02646748), completed at 159 patients, primary completion (registry) 2020-11-20.
    source: https://clinicaltrials.gov/study/NCT02646748  (ORIGIN)
    verbatim: "NCT identifier NCT02646748: 'Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors' - Phase: Phase 1, Status: COMPLETED, Enrollment: 159"
    as of: 2026-06-11T19:18:14.831Z

[INCY-66] Incyte is testing parsaclisib in PI3K Inhibitor: a Phase 1/Phase 2 trial (NCT05238064), unknown at 30 patients, est. primary completion 2025-12.
    source: https://clinicaltrials.gov/study/NCT05238064  (ORIGIN)
    verbatim: "NCT identifier NCT05238064: 'Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL' - Phase: Phase 1/Phase 2, Status: UNKNOWN, Enrollment: 30"
    as of: 2026-06-11T19:18:14.831Z

[INCY-67] Incyte is testing parsaclisib in Peripheral T-Cell Lymphoma: a Phase 1 trial (NCT05083208), terminated at 12 patients, primary completion on record 2025-08-01.
    source: https://clinicaltrials.gov/study/NCT05083208  (ORIGIN)
    verbatim: "NCT identifier NCT05083208: 'PI3K Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma' - Phase: Phase 1, Status: TERMINATED, Enrollment: 12"
    as of: 2026-06-11T19:18:14.831Z

[INCY-68] Incyte is testing its candidate in Unresectable or Metastatic Solid Tumors: a Phase 1 trial (NCT03589651), completed at 83 patients, primary completion (registry) 2022-11-21.
    source: https://clinicaltrials.gov/study/NCT03589651  (ORIGIN)
    verbatim: "NCT identifier NCT03589651: 'INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors' - Phase: Phase 1, Status: COMPLETED, Enrollment: 83"
    as of: 2026-06-11T19:18:14.831Z

[INCY-69] Incyte is testing parsaclisib in Advanced Malignancies: a Phase 1 trial (NCT04831996), completed at 48 patients, primary completion (registry) 2022-07-08.
    source: https://clinicaltrials.gov/study/NCT04831996  (ORIGIN)
    verbatim: "NCT identifier NCT04831996: 'To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.' - Phase: Phase 1, Status: COMPLETED, Enrollment: 48"
    as of: 2026-06-11T19:18:14.831Z

[INCY-70] Incyte is testing its candidate in Relapsed Diffuse Large B-Cell Lymphoma: a Phase 1 trial (NCT03688152), completed at 9 patients, primary completion (registry) 2020-09-01.
    source: https://clinicaltrials.gov/study/NCT03688152  (ORIGIN)
    verbatim: "NCT identifier NCT03688152: 'A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma' - Phase: Phase 1, Status: COMPLETED, Enrollment: 9"
    as of: 2026-06-11T19:18:14.831Z

[INCY-71] Incyte is testing parsaclisib in Lymphoma: a Phase 2 trial (NCT03235544), completed at 162 patients, primary completion (registry) 2024-04-30.
    source: https://clinicaltrials.gov/study/NCT03235544  (ORIGIN)
    verbatim: "NCT identifier NCT03235544: 'A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor' - Phase: Phase 2, Status: COMPLETED, Enrollment: 162"
    as of: 2026-06-11T19:18:14.831Z

[INCY-72] Incyte is testing parsaclisib in B-Cell Malignancies: a Phase 1/Phase 2 trial (NCT02018861), completed at 88 patients, primary completion (registry) 2021-04-12.
    source: https://clinicaltrials.gov/study/NCT02018861  (ORIGIN)
    verbatim: "NCT identifier NCT02018861: 'A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)' - Phase: Phase 1/Phase 2, Status: COMPLETED, Enrollment: 88"
    as of: 2026-06-11T19:18:14.831Z

[INCY-73] Incyte is testing ruxolitinib in Myelofibrosis: a Phase 3 trial (NCT04551066), terminated at 252 patients, primary completion on record 2024-11-25.
    source: https://clinicaltrials.gov/study/NCT04551066  (ORIGIN)
    verbatim: "NCT identifier NCT04551066: 'To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)' - Phase: Phase 3, Status: TERMINATED, Enrollment: 252"
    as of: 2026-06-11T19:18:14.831Z

[INCY-74] Incyte is testing parsaclisib in Breast Cancer: a Phase 1 trial (NCT04142554), withdrawn, primary completion on record 2020-09-07.
    source: https://clinicaltrials.gov/study/NCT04142554  (ORIGIN)
    verbatim: "NCT identifier NCT04142554: 'Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer' - Phase: Phase 1, Status: WITHDRAWN, Enrollment: 0"
    as of: 2026-06-11T19:18:14.831Z

[INCY-75] Incyte is testing its candidate in Solid Tumors: a Phase 1/Phase 2 trial (NCT02265510), terminated at 83 patients, primary completion on record 2019-02-27.
    source: https://clinicaltrials.gov/study/NCT02265510  (ORIGIN)
    verbatim: "NCT identifier NCT02265510: 'An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies' - Phase: Phase 1/Phase 2, Status: TERMINATED, Enrollment: 83"
    as of: 2026-06-11T19:18:14.831Z

[INCY-76] Ruxolitinib appears in 23545 FDA adverse-event reports (FAERS); the most frequent are off label use (1222), drug ineffective (927), product use in unapproved indication (779).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"ruxolitinib"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='ruxolitinib': total=23545, top_reactions=[{"term": "OFF LABEL USE", "count": 1222}, {"term": "DRUG INEFFECTIVE", "count": 927}, {"term": "PRODUCT USE IN UNAPPROVED INDICATION", "count": 779}]"
    as of: 2026-06-11T19:18:14.729Z

[INCY-77] Incyte is testing ruxolitinib in GVHD, Acute: a Phase 2 trial (NCT07509749), recruiting toward 54 patients, est. primary completion 2027-12-30.
    source: https://clinicaltrials.gov/study/NCT07509749  (ORIGIN)
    verbatim: "NCT identifier NCT07509749: 'Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)' - Phase: Phase 2, Status: RECRUITING, Enrollment: 54"
    as of: 2026-06-11T19:18:14.031Z

[INCY-78] Incyte is testing ruxolitinib in Myelofibrosis: a Phase 3 trial (NCT07623161), not yet recruiting at 324 patients, est. primary completion 2034-03-30.
    source: https://clinicaltrials.gov/study/NCT07623161  (ORIGIN)
    verbatim: "NCT identifier NCT07623161: 'A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib' - Phase: Phase 3, Status: NOT_YET_RECRUITING, Enrollment: 324"
    as of: 2026-06-11T19:18:14.031Z

[INCY-79] Incyte is testing ruxolitinib in Covid19: a Phase 3 trial (NCT04424056), unknown at 216 patients, est. primary completion 2022-11-01.
    source: https://clinicaltrials.gov/study/NCT04424056  (ORIGIN)
    verbatim: "NCT identifier NCT04424056: 'A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease' - Phase: Phase 3, Status: UNKNOWN, Enrollment: 216"
    as of: 2026-06-11T19:18:14.031Z

[INCY-80] Incyte is testing ruxolitinib in Acute Myeloid Leukemia in Remission: a Phase 1 trial (NCT02528877), withdrawn.
    source: https://clinicaltrials.gov/study/NCT02528877  (ORIGIN)
    verbatim: "NCT identifier NCT02528877: 'Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis' - Phase: Phase 1, Status: WITHDRAWN, Enrollment: 0"
    as of: 2026-06-11T19:18:14.031Z

[INCY-81] Incyte is testing ruxolitinib in Polycythemia Vera: a Phase 2 trial (NCT03669965), unknown at 20 patients, est. primary completion 2022-10.
    source: https://clinicaltrials.gov/study/NCT03669965  (ORIGIN)
    verbatim: "NCT identifier NCT03669965: 'KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera' - Phase: Phase 2, Status: UNKNOWN, Enrollment: 20"
    as of: 2026-06-11T19:18:14.031Z

[INCY-82] Incyte is testing ruxolitinib in Myelofibrosis: a Phase 1 trial (NCT06388759), terminated at 9 patients, primary completion on record 2025-08-12.
    source: https://clinicaltrials.gov/study/NCT06388759  (ORIGIN)
    verbatim: "NCT identifier NCT06388759: 'TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients' - Phase: Phase 1, Status: TERMINATED, Enrollment: 9"
    as of: 2026-06-11T19:18:14.031Z

[INCY-83] Incyte is testing ruxolitinib in Polycythemia Vera: a Phase 3 trial (NCT04116502), recruiting toward 586 patients, est. primary completion 2030-04-01.
    source: https://clinicaltrials.gov/study/NCT04116502  (ORIGIN)
    verbatim: "NCT identifier NCT04116502: 'MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera' - Phase: Phase 3, Status: RECRUITING, Enrollment: 586"
    as of: 2026-06-11T19:18:14.031Z

[INCY-84] Incyte is testing ruxolitinib in Myelofibrosis With High Molecular Risk Mutations: a Phase 3 trial (NCT02598297), terminated at 49 patients, primary completion on record 2017-10-23.
    source: https://clinicaltrials.gov/study/NCT02598297  (ORIGIN)
    verbatim: "NCT identifier NCT02598297: 'Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.' - Phase: Phase 3, Status: TERMINATED, Enrollment: 49"
    as of: 2026-06-11T19:18:14.031Z

[INCY-85] Incyte is testing ruxolitinib in Myelofibrosis: a Phase 2 trial (NCT05037760), recruiting toward 135 patients, est. primary completion 2030-02-28.
    source: https://clinicaltrials.gov/study/NCT05037760  (ORIGIN)
    verbatim: "NCT identifier NCT05037760: 'A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis' - Phase: Phase 2, Status: RECRUITING, Enrollment: 135"
    as of: 2026-06-11T19:18:14.031Z

[INCY-86] Incyte is testing ruxolitinib in Primary Myelofibrosis (PMF): a Phase 1 trial (NCT03935555), terminated at 11 patients, primary completion on record 2022-11-04.
    source: https://clinicaltrials.gov/study/NCT03935555  (ORIGIN)
    verbatim: "NCT identifier NCT03935555: 'Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib' - Phase: Phase 1, Status: TERMINATED, Enrollment: 11"
    as of: 2026-06-11T19:18:14.031Z

[INCY-87] Incyte is testing ruxolitinib in Myelofibrosis: a N/A trial (NCT03959371), unknown at 620 patients, est. primary completion 2021-12-31.
    source: https://clinicaltrials.gov/study/NCT03959371  (ORIGIN)
    verbatim: "NCT identifier NCT03959371: 'Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy' - Phase: N/A, Status: UNKNOWN, Enrollment: 620"
    as of: 2026-06-11T19:18:14.031Z

[INCY-88] Incyte is testing ruxolitinib in Solid Tumor, Adult: a Phase 1 trial (NCT04328844), active not recruiting at 210 patients, est. primary completion 2027-03.
    source: https://clinicaltrials.gov/study/NCT04328844  (ORIGIN)
    verbatim: "NCT identifier NCT04328844: 'A Study to Assess a PI3K Inhibitor (IOA-244) in Patients With Metastatic Cancers' - Phase: Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 210"
    as of: 2026-06-11T19:18:14.031Z

[INCY-89] Parsaclisib appears in 287 FDA adverse-event reports (FAERS); the most frequent are off label use (23), disease progression (15), pneumonia (11).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"parsaclisib"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='parsaclisib': total=287, top_reactions=[{"term": "OFF LABEL USE", "count": 23}, {"term": "DISEASE PROGRESSION", "count": 15}, {"term": "PNEUMONIA", "count": 11}]"
    as of: 2026-06-11T19:18:15.348Z

[INCY-90] A 2026 paper in Frontiers in oncology reports that management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review (PMID 42245690).
    source: https://pubmed.ncbi.nlm.nih.gov/42245690/  (ACCOUNTABLE_RELAY)
    verbatim: "Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, constitutional symptoms, cytopenias, and splenomegaly. Splenic enlargement, driven primarily by extramedullary hematopoiesis, represents a hallmark of MF and contri..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-91] A 2026 paper in Hematology (Amsterdam, Netherlands) reports that distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study (PMID 42237068).
    source: https://pubmed.ncbi.nlm.nih.gov/42237068/  (ACCOUNTABLE_RELAY)
    verbatim: "Myelofibrosis (MF) includes primary myelofibrosis (PMF) and secondary myelofibrosis (SMF) evolving from essential thrombocythemia (ET) or polycythemia vera (PV). The clinical and molecular heterogeneity of MF remains incompletely characterized in real-world cohorts.
We retrospectively analyzed 56 pa..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-92] A 2026 paper in Journal of clinical oncology : official journal of the American Society of Clinical Oncology reports that selinexor Plus Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis: Phase 3 SENTRY Trial (PMID 42227656).
    source: https://pubmed.ncbi.nlm.nih.gov/42227656/  (ACCOUNTABLE_RELAY)
    verbatim: "Ruxolitinib improves splenomegaly and symptoms in myelofibrosis but lacks reliable clonal burden reduction. Selinexor, an oral inhibitor of exportin 1, has demonstrated activity in myelofibrosis. We evaluated selinexor plus ruxolitinib versus ruxolitinib alone in JAK inhibitor-naive myelofibrosis.
I..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-93] A 2026 paper in Frontiers in immunology reports that connective tissue diseases combined with chronic myelomonocytic leukemia and myelofibrosis: a case report and literature review (PMID 42220537).
    source: https://pubmed.ncbi.nlm.nih.gov/42220537/  (ACCOUNTABLE_RELAY)
    verbatim: "Connective tissue disease (CTD) is one of the common autoimmune diseases (AIDs). Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disease characterized by peripheral blood monocytosis and bone marrow dysplasia, and it is frequently associated with autoimmune complications a..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-94] A 2026 paper in British journal of haematology reports that interpretable machine learning model using peripheral blood for non-invasive detection of moderate-to-severe myelofibrosis in JAK2 V617F-positive MPNs: A multicentre pilot proof-of-concept study (PMID 42203504).
    source: https://pubmed.ncbi.nlm.nih.gov/42203504/  (ACCOUNTABLE_RELAY)
    verbatim: "Progression to moderate-to-severe myelofibrosis (MF) in JAK2 V617F-positive myeloproliferative neoplasms (MPNs) is often clinically silent, and bone marrow biopsy is invasive and unsuitable for regular monitoring. In this multicentre pilot proof-of-concept study, we aimed to develop an interpretable..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-95] A 2026 paper in The oncologist reports that add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study (PMID 42179186).
    source: https://pubmed.ncbi.nlm.nih.gov/42179186/  (ACCOUNTABLE_RELAY)
    verbatim: "Ruxolitinib (JAK1/JAK2 inhibitor) is indicated for adults with intermediate or high-risk myelofibrosis; however, a subset of patients may exhibit a suboptimal response due to persistent PI3K/AKT activation. The phase 3, randomized, double-blind, placebo-controlled LIMBER-304 study (NCT04551053) inve..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-96] A 2026 paper in Cancers reports that the Path Forward in MF: Small Molecules in the Limelight (PMID 42122166).
    source: https://pubmed.ncbi.nlm.nih.gov/42122166/  (ACCOUNTABLE_RELAY)
    verbatim: "Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, extramedullary hematopoiesis (particularly symptomatic splenomegaly), constitutional symptoms, progressive cytopenias, and, in a subset of patients, leukemic transformation. The advent of t..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-97] A 2026 paper in Cancer reports that clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study (PMID 42118670).
    source: https://pubmed.ncbi.nlm.nih.gov/42118670/  (ACCOUNTABLE_RELAY)
    verbatim: "Momelotinib, a JAK1/JAK2/ACVR1 inhibitor, is approved for treating myelofibrosis with splenomegaly, symptoms, and moderate-to-severe anemia. Evidence on its real-world effectiveness after ruxolitinib failure is limited.
This study retrospectively analyzed 221 patients who received momelotinib after..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-98] A 2026 paper in CPT: pharmacometrics & systems pharmacology reports that semi-Mechanistic PK/PD Modeling of Platelets and Spleen Volume With Navitoclax in Combination With Ruxolitinib in Patients With Myelofibrosis (PMID 42107011).
    source: https://pubmed.ncbi.nlm.nih.gov/42107011/  (ACCOUNTABLE_RELAY)
    verbatim: "Navitoclax, an oral small molecule BCL-XL/BCL-2 inhibitor evaluated in myelofibrosis, was assessed through integrated PK/PD modeling to guide starting dose and dose-reduction decisions when combined with ruxolitinib. An integrated sequential PK/PD model was developed to describe the relationships be..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-99] A 2026 paper in PloS one reports that real-world patient characteristics and clinical outcomes in patients with myelofibrosis in Japan (PMID 42102170).
    source: https://pubmed.ncbi.nlm.nih.gov/42102170/  (ACCOUNTABLE_RELAY)
    verbatim: "Anemia is associated with increased morbidity, mortality, healthcare resource utilization, and costs in myelofibrosis. This longitudinal, retrospective, and descriptive cohort study used a Japanese health administrative database (Medical Data Vision) to examine treatment patterns, transfusion burden..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-100] A 2026 paper in Case reports in cardiology reports that cardiac Tamponade-A Rare Manifestation of Ruxolitinib Discontinuation Syndrome: A Case Report (PMID 42088844).
    source: https://pubmed.ncbi.nlm.nih.gov/42088844/  (ACCOUNTABLE_RELAY)
    verbatim: "A 52-year-old gentleman presenting with tachycardia was found to have a large pericardial effusion and cardiac tamponade. This case was on a background of long-standing myelofibrosis managed with ruxolitinib, which was recently withheld for an orthopaedic procedure. He was diagnosed with presumed ru..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-101] A 2026 paper in Annals of hematology reports that high-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort (PMID 42081119).
    source: https://pubmed.ncbi.nlm.nih.gov/42081119/  (ACCOUNTABLE_RELAY)
    verbatim: "Ruxolitinib is standard first-line therapy for symptomatic myelofibrosis (MF). In real-world practice, dose reductions are common, and the impact of maintaining higher dose intensity over time remains incompletely characterized-particularly for patients escalated to 25 mg twice daily (50 mg/day; ful..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-102] A 2026 paper in Mikrobiyoloji bulteni reports that [Cutaneous Cryptococcus neoformans Infection Mimicking Necrotizing Fasciitis in a Myelofibrosis Patient Receiving Ruxolitinib: A Case Report] (PMID 42043354).
    source: https://pubmed.ncbi.nlm.nih.gov/42043354/  (ACCOUNTABLE_RELAY)
    verbatim: "Cryptococcus neoformans is an encapsulated opportunistic yeast widely distributed in the environment and classified as critical-priority fungal pathogen by the World Health Organisation due to its high mortality and limited access to timely diagnosis and effective treatment. Infection is typically a..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-103] A 2026 paper in Clinical epidemiology reports that validity of The Danish National Chronic Myeloid Neoplasia Registry (PMID 42016069).
    source: https://pubmed.ncbi.nlm.nih.gov/42016069/  (ACCOUNTABLE_RELAY)
    verbatim: "Myeloproliferative neoplasms (MPN) are rare hematological malignancies with long survival, making real-world evidence essential to complement clinical trial data. The Danish National Chronic Myeloid Neoplasia Registry (DMR) captures nearly all MPN patients nationwide, but its validity has not been s..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-104] A 2026 paper in Blood neoplasia reports that comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis (PMID 42007252).
    source: https://pubmed.ncbi.nlm.nih.gov/42007252/  (ACCOUNTABLE_RELAY)
    verbatim: "Four Janus kinase inhibitors (JAKinibs), ruxolitinib, fedratinib, pacritinib, and momelotinib, are indicated for myelofibrosis. All inhibit JAK2, but effects on additional kinases vary markedly, shaping their specific clinical pharmacology. Published comparative inhibitory profiles and cellular phar..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-105] A 2026 paper in Annals of hematology reports that modern and multidisciplinary care in polycythemia vera (PMID 41999414).
    source: https://pubmed.ncbi.nlm.nih.gov/41999414/  (ACCOUNTABLE_RELAY)
    verbatim: "Polycythemia Vera (PV) is a chronic, BCR::ABL1-negative, myeloproliferative neoplasm characterized by increased hematocrit and platelet/leukocyte counts, as well as by a high risk of thrombosis and progression to myelofibrosis and acute leukemia. The initial discovery of the JAK2V617F driver mutatio..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-106] A 2026 paper in Leukemia & lymphoma reports that managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors (PMID 41982071).
    source: https://pubmed.ncbi.nlm.nih.gov/41982071/  (ACCOUNTABLE_RELAY)
    verbatim: "Myelofibrosis (MF) is a clonal myeloproliferative neoplasm that predominantly affects older adults and is frequently complicated by anemia, thrombocytopenia, and multimorbidity. In this setting, therapeutic goals extend beyond disease control to include symptom relief, preservation of functional sta..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-107] A 2026 paper in Diagnostics (Basel, Switzerland) reports that pseudotumoral Pulmonary Mycobacterium avium Disease in a Patient on Ruxolitinib Therapy (PMID 41975780).
    source: https://pubmed.ncbi.nlm.nih.gov/41975780/  (ACCOUNTABLE_RELAY)
    verbatim: "Pulmonary disease caused by nontuberculous mycobacteria represents an important diagnostic challenge, particularly in immunocompromised patients, in whom clinical and radiologic findings may mimic malignancy. We report the case of a 70-year-old woman with myelofibrosis treated with ruxolitinib who d..."
    as of: 2026-06-11T19:18:14.124Z

[INCY-108] A 2024 paper in Pharmacology research & perspectives reports that evaluation of the cardiac safety of parsaclisib, a selective PI3K inhibitor, in patients with previously treated B-cell malignancies: Results from the CITADEL-101 study (PMID 38407508).
    source: https://pubmed.ncbi.nlm.nih.gov/38407508/  (ACCOUNTABLE_RELAY)
    verbatim: "Parsaclisib, a potent and selective phosphatidylinositol 3 kinase  inhibitor, has been investigated for the treatment of B-cell malignancies and studied in patients with autoimmune diseases and myelofibrosis. The CITADEL-101 study (NCT02018861) assessed safety, tolerability, and preliminary efficac..."
    as of: 2026-06-11T19:18:14.945Z

[INCY-109] A 2024 paper in Blood advances reports that phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results (PMID 38290135).
    source: https://pubmed.ncbi.nlm.nih.gov/38290135/  (ACCOUNTABLE_RELAY)
    verbatim: "Ruxolitinib reduces spleen volume, improves symptoms, and increases survival in patients with intermediate- or high-risk myelofibrosis. However, suboptimal response may occur, potentially because of signaling via the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway. This phase 2 study evalu..."
    as of: 2026-06-11T19:18:14.945Z

[INCY-110] A 2023 paper in Clinical lymphoma, myeloma & leukemia reports that sOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis (PMID 36797153).
    source: https://pubmed.ncbi.nlm.nih.gov/36797153/  (ACCOUNTABLE_RELAY)
    verbatim: "Development of myelofibrosis (MF) therapeutics has reached fruition as the transformative impact of JAK2 inhibitors in the MPN landscape is complemented/expanded by a profusion of novel monotherapies and rational combinations in the frontline and second line settings. Agents in advanced clinical dev..."
    as of: 2026-06-11T19:18:14.945Z

[INCY-111] A 2022 paper in Expert review of anticancer therapy reports that targeting the PI3K pathway in myeloproliferative neoplasms (PMID 35763287).
    source: https://pubmed.ncbi.nlm.nih.gov/35763287/  (ACCOUNTABLE_RELAY)
    verbatim: "Decreasing efficacy over time and initial suboptimal response to Janus kinase (JAK) inhibitors such as ruxolitinib in a subset of patients are critical clinical challenges associated with myeloproliferative neoplasms (MPNs), primarily myelofibrosis.
The role of phosphatidylinositol-3 kinase (PI3K) i..."
    as of: 2026-06-11T19:18:14.945Z

[INCY-112] A 2021 paper in Journal of immunotherapy and precision oncology reports that jAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis (PMID 35663107).
    source: https://pubmed.ncbi.nlm.nih.gov/35663107/  (ACCOUNTABLE_RELAY)
    verbatim: "Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by uncontrolled blood counts, constitutional symptoms, extramedullary hematopoiesis, and an increased risk of developing acute myeloid leukemia. Janus kinase (JAK) inhibitors are the most common treatment for MF due to their ability to r..."
    as of: 2026-06-11T19:18:14.945Z

[INCY-113] A 2022 paper in Cancer reports that the clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes (PMID 35385124).
    source: https://pubmed.ncbi.nlm.nih.gov/35385124/  (ACCOUNTABLE_RELAY)
    verbatim: "Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, an..."
    as of: 2026-06-11T19:18:14.945Z

[INCY-114] A 2022 paper in International journal of hematology reports that novel treatments for myelofibrosis: beyond JAK inhibitors (PMID 35182376).
    source: https://pubmed.ncbi.nlm.nih.gov/35182376/  (ACCOUNTABLE_RELAY)
    verbatim: "Myelofibrosis is a chronic hematologic malignancy characterized by constitutional symptoms, bone marrow fibrosis, extramedullary hematopoiesis resulting in splenomegaly and a propensity toward leukemic progression. Given the central role of the JAK-STAT pathway in the pathobiology of myelofibrosis,..."
    as of: 2026-06-11T19:18:14.945Z

[INCY-115] A 2021 paper in Expert opinion on emerging drugs reports that emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials (PMID 34875179).
    source: https://pubmed.ncbi.nlm.nih.gov/34875179/  (ACCOUNTABLE_RELAY)
    verbatim: "Myelofibrosis is a clonal hematologic malignancy with clinical manifestations that include cytopenias, debilitating constitutional symptoms, splenomegaly, bone marrow fibrosis and a propensity toward leukemic progression. While allogeneic hematopoietic stem cell transplantation can be curative, this..."
    as of: 2026-06-11T19:18:14.945Z

[INCY-116] A 2022 paper in Clinical lymphoma, myeloma & leukemia reports that sOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis (PMID 34840087).
    source: https://pubmed.ncbi.nlm.nih.gov/34840087/  (ACCOUNTABLE_RELAY)
    verbatim: "Myeloproliferative neoplasms research has entered a dynamic and exciting era as we witness exponential growth of novel agents in advanced/early phase clinical trials for myelofibrosis (MF). Building on the success and pivotal role of ruxolitinib, many novel agents, spanning a wide range of mechanism..."
    as of: 2026-06-11T19:18:14.945Z

[INCY-117] A 2021 paper in Cells reports that next Generation Therapeutics for the Treatment of Myelofibrosis (PMID 33925695).
    source: https://pubmed.ncbi.nlm.nih.gov/33925695/  (ACCOUNTABLE_RELAY)
    verbatim: "Myelofibrosis is a myeloproliferative neoplasm characterized by splenomegaly, constitutional symptoms, bone marrow fibrosis, and a propensity towards transformation to acute leukemia. JAK inhibitors are the only approved therapy for myelofibrosis and have been successful in reducing spleen and sympt..."
    as of: 2026-06-11T19:18:14.945Z

[INCY-118] OpenTargets catalogs JAK1 (Janus kinase 1) under Ensembl identifier ENSG00000162434.
    source: https://platform.opentargets.org/target/ENSG00000162434  (ACCOUNTABLE_RELAY)
    verbatim: "OpenTargets target search for 'JAK1': id=ENSG00000162434, name='JAK1', description='Janus kinase 1'"
    as of: 2026-06-11T19:21:11.414Z

[INCY-119] OpenTargets catalogs JAK2 (Janus kinase 2) under Ensembl identifier ENSG00000096968.
    source: https://platform.opentargets.org/target/ENSG00000096968  (ACCOUNTABLE_RELAY)
    verbatim: "OpenTargets target search for 'JAK2': id=ENSG00000096968, name='JAK2', description='Janus kinase 2'"
    as of: 2026-06-11T19:21:12.243Z

[GMAB-1] Genmab is testing epcoritamab in Leukemia, Chronic Lymphocytic: a Phase 1 trial (NCT06676033), active not recruiting at 5 patients, est. primary completion 2027-07-01.
    source: https://clinicaltrials.gov/study/NCT06676033  (ORIGIN)
    verbatim: "NCT identifier NCT06676033: 'Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome' - Phase: Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 5"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-2] Genmab is testing epcoritamab in Follicular Lymphoma: a Phase 2 trial (NCT06563596), recruiting toward 45 patients, est. primary completion 2030-03-01.
    source: https://clinicaltrials.gov/study/NCT06563596  (ORIGIN)
    verbatim: "NCT identifier NCT06563596: 'Epco, Zanu, Ritux for R/R FL or MZL' - Phase: Phase 2, Status: RECRUITING, Enrollment: 45"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-3] Genmab is testing epcoritamab in Follicular Lymphoma (FL): a Phase 3 trial (NCT06191744), recruiting toward 1095 patients, est. primary completion 2037-11.
    source: https://clinicaltrials.gov/study/NCT06191744  (ORIGIN)
    verbatim: "NCT identifier NCT06191744: 'Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma' - Phase: Phase 3, Status: RECRUITING, Enrollment: 1095"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-4] Genmab is testing epcoritamab in DLBCL: a Phase 1/Phase 2 trial (NCT03625037), active not recruiting at 666 patients, est. primary completion 2029-01.
    source: https://clinicaltrials.gov/study/NCT03625037  (ORIGIN)
    verbatim: "NCT identifier NCT03625037: 'First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma' - Phase: Phase 1/Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 666"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-5] Genmab is testing epcoritamab in CLL/SLL: a Phase 1/Phase 2 trial (NCT05791409), recruiting toward 112 patients, est. primary completion 2032-11.
    source: https://clinicaltrials.gov/study/NCT05791409  (ORIGIN)
    verbatim: "NCT identifier NCT05791409: 'Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL' - Phase: Phase 1/Phase 2, Status: RECRUITING, Enrollment: 112"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-6] Genmab is testing epcoritamab in B-Cell Non-Hodgkin Lymphoma: a Phase 2 trial (NCT07097363), recruiting toward 18 patients, est. primary completion 2030-05-31.
    source: https://clinicaltrials.gov/study/NCT07097363  (ORIGIN)
    verbatim: "NCT identifier NCT07097363: 'Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma' - Phase: Phase 2, Status: RECRUITING, Enrollment: 18"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-7] Genmab is testing epcoritamab in Follicular Lymphoma: a Phase 2 trial (NCT05783609), recruiting toward 100 patients, est. primary completion 2030-02.
    source: https://clinicaltrials.gov/study/NCT05783609  (ORIGIN)
    verbatim: "NCT identifier NCT05783609: 'Epcoritamab and Rituximab for First-line Follicular Lymphoma' - Phase: Phase 2, Status: RECRUITING, Enrollment: 100"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-8] Genmab is testing epcoritamab in DLBCL - Diffuse Large B Cell Lymphoma: a Phase 2 trial (NCT06287398), recruiting toward 39 patients, est. primary completion 2031-11.
    source: https://clinicaltrials.gov/study/NCT06287398  (ORIGIN)
    verbatim: "NCT identifier NCT06287398: 'Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL' - Phase: Phase 2, Status: RECRUITING, Enrollment: 39"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-9] Genmab is testing epcoritamab in Primary CNS Lymphoma (PCNSL): a Phase 2 trial (NCT06931652), recruiting toward 60 patients, est. primary completion 2030-01.
    source: https://clinicaltrials.gov/study/NCT06931652  (ORIGIN)
    verbatim: "NCT identifier NCT06931652: 'Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab' - Phase: Phase 2, Status: RECRUITING, Enrollment: 60"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-10] Genmab is testing epcoritamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: a Phase 2 trial (NCT07451652), recruiting toward 10 patients, est. primary completion 2027-09.
    source: https://clinicaltrials.gov/study/NCT07451652  (ORIGIN)
    verbatim: "NCT identifier NCT07451652: 'Low Dose Epcoritamab Plus GemOx in R/R DLBCL' - Phase: Phase 2, Status: RECRUITING, Enrollment: 10"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-11] Genmab is testing epcoritamab in Large B Cell Lymphoma: a Phase 2 trial (NCT07126236), recruiting toward 80 patients, est. primary completion 2031-12.
    source: https://clinicaltrials.gov/study/NCT07126236  (ORIGIN)
    verbatim: "NCT identifier NCT07126236: 'Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma' - Phase: Phase 2, Status: RECRUITING, Enrollment: 80"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-12] Genmab is testing epcoritamab in Large B-cell Lymphoma: a N/A trial (NCT05733650), approved for marketing.
    source: https://clinicaltrials.gov/study/NCT05733650  (ORIGIN)
    verbatim: "NCT identifier NCT05733650: 'Expanded Access Program for Epcoritamab' - Phase: N/A, Status: APPROVED_FOR_MARKETING, Enrollment: None"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-13] Genmab is testing epcoritamab in Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder: a Phase 1 trial (NCT06672705), recruiting toward 26 patients, est. primary completion 2026-12-31.
    source: https://clinicaltrials.gov/study/NCT06672705  (ORIGIN)
    verbatim: "NCT identifier NCT06672705: 'Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders' - Phase: Phase 1, Status: RECRUITING, Enrollment: 26"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-14] Genmab is testing epcoritamab in Lymphoma, Non-Hodgkin: a Phase 2 trial (NCT06458439), recruiting toward 31 patients, est. primary completion 2027-12.
    source: https://clinicaltrials.gov/study/NCT06458439  (ORIGIN)
    verbatim: "NCT identifier NCT06458439: 'Epcoritamab-CAR T Cells for Large B-cell Lymphomas' - Phase: Phase 2, Status: RECRUITING, Enrollment: 31"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-15] Genmab is testing epcoritamab in Non-hodgkin Lymphoma: a Phase 1 trial (NCT05206357), active not recruiting at 17 patients, est. primary completion 2028-11.
    source: https://clinicaltrials.gov/study/NCT05206357  (ORIGIN)
    verbatim: "NCT identifier NCT05206357: 'Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab' - Phase: Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 17"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-16] Genmab is testing epcoritamab in Diffuse Large B-Cell Lymphoma: a Phase 2 trial (NCT05660967), active not recruiting at 111 patients, est. primary completion 2026-06-28.
    source: https://clinicaltrials.gov/study/NCT05660967  (ORIGIN)
    verbatim: "NCT identifier NCT05660967: 'Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 111"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-17] Genmab is testing epcoritamab in Diffuse Large B-Cell Lymphoma: a Phase 1/Phase 2 trial (NCT04663347), active not recruiting at 543 patients, est. primary completion 2027-09-30.
    source: https://clinicaltrials.gov/study/NCT04663347  (ORIGIN)
    verbatim: "NCT identifier NCT04663347: 'Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)' - Phase: Phase 1/Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 543"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-18] Genmab is testing epcoritamab in Follicular Lymphoma (FL): a Phase 3 trial (NCT05409066), active not recruiting at 549 patients, est. primary completion 2029-12.
    source: https://clinicaltrials.gov/study/NCT05409066  (ORIGIN)
    verbatim: "NCT identifier NCT05409066: 'Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma' - Phase: Phase 3, Status: ACTIVE_NOT_RECRUITING, Enrollment: 549"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-19] Genmab is testing epcoritamab in Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified: a Phase 2 trial (NCT07365306), recruiting toward 43 patients, est. primary completion 2029-10-15.
    source: https://clinicaltrials.gov/study/NCT07365306  (ORIGIN)
    verbatim: "NCT identifier NCT07365306: 'Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma' - Phase: Phase 2, Status: RECRUITING, Enrollment: 43"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-20] Genmab is testing epcoritamab in Diffuse Large B Cell Lymphoma: a Phase 1 trial (NCT07528352), recruiting toward 12 patients, est. primary completion 2031-06.
    source: https://clinicaltrials.gov/study/NCT07528352  (ORIGIN)
    verbatim: "NCT identifier NCT07528352: 'External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL' - Phase: Phase 1, Status: RECRUITING, Enrollment: 12"
    as of: 2026-06-11T19:18:17.144Z

[GMAB-21] Genmab is testing daratumumab in Neuromyelitis Optica: a Phase 2/Phase 3 trial (NCT05403138), active not recruiting at 135 patients, est. primary completion 2025-12-01.
    source: https://clinicaltrials.gov/study/NCT05403138  (ORIGIN)
    verbatim: "NCT identifier NCT05403138: 'Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders' - Phase: Phase 2/Phase 3, Status: ACTIVE_NOT_RECRUITING, Enrollment: 135"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-22] Genmab is testing daratumumab in Multiple Myeloma: a Phase 2 trial (NCT03695744), unknown at 27 patients, est. primary completion 2024-04.
    source: https://clinicaltrials.gov/study/NCT03695744  (ORIGIN)
    verbatim: "NCT identifier NCT03695744: 'Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma' - Phase: Phase 2, Status: UNKNOWN, Enrollment: 27"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-23] Genmab is testing daratumumab in Multiple Myeloma: a Phase 3 trial (NCT07452198), recruiting toward 358 patients, est. primary completion 2030-03.
    source: https://clinicaltrials.gov/study/NCT07452198  (ORIGIN)
    verbatim: "NCT identifier NCT07452198: 'A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma' - Phase: Phase 3, Status: RECRUITING, Enrollment: 358"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-24] Genmab is testing teclistamab in Multiple Myeloma: a Phase 2 trial (NCT05695508), recruiting toward 160 patients, est. primary completion 2029-09-15.
    source: https://clinicaltrials.gov/study/NCT05695508  (ORIGIN)
    verbatim: "NCT identifier NCT05695508: 'GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5' - Phase: Phase 2, Status: RECRUITING, Enrollment: 160"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-25] Genmab is testing daratumumab in Multiple Myeloma: a Phase 2 trial (NCT03490344), completed at 10 patients, primary completion (registry) 2023-03-23.
    source: https://clinicaltrials.gov/study/NCT03490344  (ORIGIN)
    verbatim: "NCT identifier NCT03490344: 'Short Course Daratumumab in Patients With Multiple Myeloma' - Phase: Phase 2, Status: COMPLETED, Enrollment: 10"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-26] Genmab is testing daratumumab in Lupus Nephritis: a Phase 2 trial (NCT04868838), active not recruiting at 12 patients, est. primary completion 2026-09.
    source: https://clinicaltrials.gov/study/NCT04868838  (ORIGIN)
    verbatim: "NCT identifier NCT04868838: 'Daratumumab to Treat Active Lupus Nephritis' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 12"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-27] Genmab is testing daratumumab in T-cell Acute Lymphoblastic Leukemia: a Phase 2 trial (NCT05289687), recruiting toward 20 patients, est. primary completion 2027-06-30.
    source: https://clinicaltrials.gov/study/NCT05289687  (ORIGIN)
    verbatim: "NCT identifier NCT05289687: 'Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL' - Phase: Phase 2, Status: RECRUITING, Enrollment: 20"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-28] Genmab is testing daratumumab in Multiple Myeloma: a Phase 1 trial (NCT07400744), not yet recruiting at 102 patients, est. primary completion 2026-10.
    source: https://clinicaltrials.gov/study/NCT07400744  (ORIGIN)
    verbatim: "NCT identifier NCT07400744: 'A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects' - Phase: Phase 1, Status: NOT_YET_RECRUITING, Enrollment: 102"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-29] Genmab is testing daratumumab in Multiple Myeloma: a Phase 3 trial (NCT02076009), completed at 569 patients, primary completion (registry) 2024-11-21.
    source: https://clinicaltrials.gov/study/NCT02076009  (ORIGIN)
    verbatim: "NCT identifier NCT02076009: 'A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma' - Phase: Phase 3, Status: COMPLETED, Enrollment: 569"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-30] Genmab is testing daratumumab in Multiple Myeloma: a Phase 2 trial (NCT04933539), active not recruiting at 14 patients, est. primary completion 2032-10-31.
    source: https://clinicaltrials.gov/study/NCT04933539  (ORIGIN)
    verbatim: "NCT identifier NCT04933539: 'Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 14"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-31] Genmab is testing daratumumab in Systemic Lupus Erythematosus: a Phase 2 trial (NCT04810754), unknown at 10 patients, est. primary completion 2023-12-31.
    source: https://clinicaltrials.gov/study/NCT04810754  (ORIGIN)
    verbatim: "NCT identifier NCT04810754: 'An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus' - Phase: Phase 2, Status: UNKNOWN, Enrollment: 10"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-32] Genmab is testing daratumumab in Multiple Myeloma: a Phase 2 trial (NCT03215524), completed at 120 patients, primary completion (registry) 2022-06-24.
    source: https://clinicaltrials.gov/study/NCT03215524  (ORIGIN)
    verbatim: "NCT identifier NCT03215524: 'A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide' - Phase: Phase 2, Status: COMPLETED, Enrollment: 120"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-33] Genmab is testing daratumumab in Plasma Cell Disorder: a Phase 1/Phase 2 trial (NCT07075510), recruiting toward 30 patients, est. primary completion 2032-10-01.
    source: https://clinicaltrials.gov/study/NCT07075510  (ORIGIN)
    verbatim: "NCT identifier NCT07075510: 'Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders' - Phase: Phase 1/Phase 2, Status: RECRUITING, Enrollment: 30"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-34] Genmab is testing teclistamab in Multiple Myeloma: a Phase 2 trial (NCT07638683), recruiting toward 30 patients, est. primary completion 2028-12-30.
    source: https://clinicaltrials.gov/study/NCT07638683  (ORIGIN)
    verbatim: "NCT identifier NCT07638683: 'A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).' - Phase: Phase 2, Status: RECRUITING, Enrollment: 30"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-35] Genmab is testing daratumumab in Relapsed/Refractory Multiple Myeloma: a Phase 1 trial (NCT05259839), active not recruiting at 283 patients, est. primary completion 2033-09.
    source: https://clinicaltrials.gov/study/NCT05259839  (ORIGIN)
    verbatim: "NCT identifier NCT05259839: 'A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma' - Phase: Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 283"
    as of: 2026-06-11T19:18:18.560Z

[GMAB-36] Teclistamab appears in 2787 FDA adverse-event reports (FAERS); the most frequent are cytokine release syndrome (313), immune effector cell-associated neurotoxicity syndrome (122), plasma cell myeloma (118).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"teclistamab"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='teclistamab': total=2787, top_reactions=[{"term": "CYTOKINE RELEASE SYNDROME", "count": 313}, {"term": "IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME", "count": 122}, {"term": "PLASMA CELL MYELOMA", "count": 118}]"
    as of: 2026-06-11T19:18:18.382Z

[GMAB-37] Epcoritamab appears in 4694 FDA adverse-event reports (FAERS); the most frequent are cytokine release syndrome (615), pyrexia (268), off label use (247).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"epcoritamab"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='epcoritamab': total=4694, top_reactions=[{"term": "CYTOKINE RELEASE SYNDROME", "count": 615}, {"term": "PYREXIA", "count": 268}, {"term": "OFF LABEL USE", "count": 247}]"
    as of: 2026-06-11T19:18:17.457Z

[GMAB-38] Genmab is testing teclistamab in Recurrent Multiple Myeloma: a Phase 1 trial (NCT06588660), terminated at 1 patients, primary completion on record 2025-02-14.
    source: https://clinicaltrials.gov/study/NCT06588660  (ORIGIN)
    verbatim: "NCT identifier NCT06588660: 'ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma' - Phase: Phase 1, Status: TERMINATED, Enrollment: 1"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-39] Genmab is testing teclistamab in Multiple Myeloma: a Phase 1 trial (NCT04108195), active not recruiting at 290 patients, est. primary completion 2027-04-07.
    source: https://clinicaltrials.gov/study/NCT04108195  (ORIGIN)
    verbatim: "NCT identifier NCT04108195: 'A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma' - Phase: Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 290"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-40] Genmab is testing teclistamab in Multiple Myeloma: a Phase 1/Phase 2 trial (NCT04586426), active not recruiting at 228 patients, est. primary completion 2026-10-27.
    source: https://clinicaltrials.gov/study/NCT04586426  (ORIGIN)
    verbatim: "NCT identifier NCT04586426: 'A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma' - Phase: Phase 1/Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 228"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-41] Genmab is testing teclistamab in AL Amyloidosis: a NA trial (NCT06699394), recruiting toward 20 patients, est. primary completion 2026-12-31.
    source: https://clinicaltrials.gov/study/NCT06699394  (ORIGIN)
    verbatim: "NCT identifier NCT06699394: 'Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis' - Phase: NA, Status: RECRUITING, Enrollment: 20"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-42] Genmab is testing teclistamab in Multiple Myeloma: a Phase 1 trial (NCT07581704), recruiting toward 10 patients, est. primary completion 2029-10-01.
    source: https://clinicaltrials.gov/study/NCT07581704  (ORIGIN)
    verbatim: "NCT identifier NCT07581704: 'Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma' - Phase: Phase 1, Status: RECRUITING, Enrollment: 10"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-43] Genmab is testing teclistamab in Multiple Myeloma: a Phase 1 trial (NCT04722146), active not recruiting at 140 patients, est. primary completion 2027-10-13.
    source: https://clinicaltrials.gov/study/NCT04722146  (ORIGIN)
    verbatim: "NCT identifier NCT04722146: 'A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma' - Phase: Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 140"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-44] Genmab is testing teclistamab in Hematological Malignancies: a Phase 2 trial (NCT04557098), active not recruiting at 194 patients, est. primary completion 2027-05-28.
    source: https://clinicaltrials.gov/study/NCT04557098  (ORIGIN)
    verbatim: "NCT identifier NCT04557098: 'A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 194"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-45] Genmab is testing teclistamab in Multiple Myeloma, Newly Diagnosed: a Phase 2 trial (NCT06758375), recruiting toward 10 patients, est. primary completion 2026-12-01.
    source: https://clinicaltrials.gov/study/NCT06758375  (ORIGIN)
    verbatim: "NCT identifier NCT06758375: 'Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients' - Phase: Phase 2, Status: RECRUITING, Enrollment: 10"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-46] Genmab is testing teclistamab in Multiple Myeloma: a N/A trial (NCT06359067), completed at 600 patients, primary completion (registry) 2023-12-31.
    source: https://clinicaltrials.gov/study/NCT06359067  (ORIGIN)
    verbatim: "NCT identifier NCT06359067: 'A Real-World Study of Bispecific Antibodies in Multiple Myeloma' - Phase: N/A, Status: COMPLETED, Enrollment: 600"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-47] Genmab is testing teclistamab in Multiple Myeloma: a Phase 3 trial (NCT06208150), recruiting toward 795 patients, est. primary completion 2028-12-31.
    source: https://clinicaltrials.gov/study/NCT06208150  (ORIGIN)
    verbatim: "NCT identifier NCT06208150: 'A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide' - Phase: Phase 3, Status: RECRUITING, Enrollment: 795"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-48] Genmab is testing teclistamab in Multiple Myeloma: a Phase 2 trial (NCT05972135), recruiting toward 100 patients, est. primary completion 2027-10.
    source: https://clinicaltrials.gov/study/NCT05972135  (ORIGIN)
    verbatim: "NCT identifier NCT05972135: 'Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma' - Phase: Phase 2, Status: RECRUITING, Enrollment: 100"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-49] Genmab is testing teclistamab in Multiple Myeloma: a Phase 4 trial (NCT06251076), recruiting toward 15 patients, est. primary completion 2026-10.
    source: https://clinicaltrials.gov/study/NCT06251076  (ORIGIN)
    verbatim: "NCT identifier NCT06251076: 'Plan Development for Giving Teclistamab in the Outpatient Setting' - Phase: Phase 4, Status: RECRUITING, Enrollment: 15"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-50] Genmab is testing teclistamab in Multiple Myeloma: a Phase 3 trial (NCT05243797), recruiting toward 1594 patients, est. primary completion 2032-04.
    source: https://clinicaltrials.gov/study/NCT05243797  (ORIGIN)
    verbatim: "NCT identifier NCT05243797: 'Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation' - Phase: Phase 3, Status: RECRUITING, Enrollment: 1594"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-51] Genmab is testing teclistamab in High-Risk de Novo Multiple Myeloma: a Phase 2 trial (NCT05849610), active not recruiting at 30 patients, est. primary completion 2029-07.
    source: https://clinicaltrials.gov/study/NCT05849610  (ORIGIN)
    verbatim: "NCT identifier NCT05849610: 'Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 30"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-52] Genmab is testing teclistamab in Recurrent Multiple Myeloma: a Phase 2 trial (NCT06948084), not yet recruiting at 80 patients, est. primary completion 2028-02-28.
    source: https://clinicaltrials.gov/study/NCT06948084  (ORIGIN)
    verbatim: "NCT identifier NCT06948084: 'Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse' - Phase: Phase 2, Status: NOT_YET_RECRUITING, Enrollment: 80"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-53] Genmab is testing teclistamab in Hematologic Malignancies: a Phase 1/Phase 2 trial (NCT04696809), completed at 40 patients, primary completion (registry) 2026-04-13.
    source: https://clinicaltrials.gov/study/NCT04696809  (ORIGIN)
    verbatim: "NCT identifier NCT04696809: 'A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma' - Phase: Phase 1/Phase 2, Status: COMPLETED, Enrollment: 40"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-54] Genmab is testing teclistamab in Amyloid Light-chain Amyloidosis: a Phase 2 trial (NCT07110844), recruiting toward 25 patients, est. primary completion 2033-10.
    source: https://clinicaltrials.gov/study/NCT07110844  (ORIGIN)
    verbatim: "NCT identifier NCT07110844: 'Teclistamab-Daratumumab in AL Amyloidosis' - Phase: Phase 2, Status: RECRUITING, Enrollment: 25"
    as of: 2026-06-11T19:18:17.717Z

[GMAB-55] Genmab is testing its candidate in Malignant Solid Tumor: a Phase 1/Phase 2 trial (NCT04083599), active not recruiting at 350 patients, est. primary completion 2026-11.
    source: https://clinicaltrials.gov/study/NCT04083599  (ORIGIN)
    verbatim: "NCT identifier NCT04083599: 'GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors' - Phase: Phase 1/Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 350"
    as of: 2026-06-11T19:18:16.963Z

[GMAB-56] Genmab is testing its candidate in Platinum-resistant Ovarian Cancer: a Phase 3 trial (NCT07604766), not yet recruiting at 82 patients, est. primary completion 2028-12.
    source: https://clinicaltrials.gov/study/NCT07604766  (ORIGIN)
    verbatim: "NCT identifier NCT07604766: 'An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China' - Phase: Phase 3, Status: NOT_YET_RECRUITING, Enrollment: 82"
    as of: 2026-06-11T19:18:16.963Z

[GMAB-57] Genmab is testing its candidate in Head and Neck Cancer: a Phase 2 trial (NCT00542308), completed at 90 patients, primary completion (registry) 2011-08.
    source: https://clinicaltrials.gov/study/NCT00542308  (ORIGIN)
    verbatim: "NCT identifier NCT00542308: 'Zalutumumab in Non-curable Patients With SCCHN' - Phase: Phase 2, Status: COMPLETED, Enrollment: 90"
    as of: 2026-06-11T19:18:16.963Z

[GMAB-58] Genmab is testing its candidate in Platinum-Sensitive Ovarian Cancer: a Phase 3 trial (NCT07564141), not yet recruiting at 688 patients, est. primary completion 2031-11.
    source: https://clinicaltrials.gov/study/NCT07564141  (ORIGIN)
    verbatim: "NCT identifier NCT07564141: 'Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer' - Phase: Phase 3, Status: NOT_YET_RECRUITING, Enrollment: 688"
    as of: 2026-06-11T19:18:16.963Z

[GMAB-59] Genmab is testing its candidate in Gastrointestinal Cancers: a Phase 2 trial (NCT07539311), recruiting toward 160 patients, est. primary completion 2028-11.
    source: https://clinicaltrials.gov/study/NCT07539311  (ORIGIN)
    verbatim: "NCT identifier NCT07539311: 'Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers' - Phase: Phase 2, Status: RECRUITING, Enrollment: 160"
    as of: 2026-06-11T19:18:16.963Z

[GMAB-60] Genmab is testing its candidate in Malignant Solid Tumor: a Phase 1 trial (NCT06057038), active not recruiting at 42 patients, est. primary completion 2026-11-28.
    source: https://clinicaltrials.gov/study/NCT06057038  (ORIGIN)
    verbatim: "NCT identifier NCT06057038: 'A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors' - Phase: Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 42"
    as of: 2026-06-11T19:18:16.963Z

[GMAB-61] Genmab is testing its candidate in Head and Neck Cancer: a Phase 1/Phase 2 trial (NCT00401401), terminated at 30 patients, primary completion on record 2010-10.
    source: https://clinicaltrials.gov/study/NCT00401401  (ORIGIN)
    verbatim: "NCT identifier NCT00401401: 'Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer' - Phase: Phase 1/Phase 2, Status: TERMINATED, Enrollment: 30"
    as of: 2026-06-11T19:18:16.963Z

[GMAB-62] Genmab is testing its candidate in Malignant Solid Tumor: a Phase 1/Phase 2 trial (NCT06771921), terminated at 3 patients, primary completion on record 2025-06-11.
    source: https://clinicaltrials.gov/study/NCT06771921  (ORIGIN)
    verbatim: "NCT identifier NCT06771921: 'A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors' - Phase: Phase 1/Phase 2, Status: TERMINATED, Enrollment: 3"
    as of: 2026-06-11T19:18:16.963Z

[GMAB-63] Genmab is testing its candidate in Ovarian Cancer: a Phase 1/Phase 2 trial (NCT02988817), completed at 306 patients, primary completion (registry) 2021-11-12.
    source: https://clinicaltrials.gov/study/NCT02988817  (ORIGIN)
    verbatim: "NCT identifier NCT02988817: 'Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors' - Phase: Phase 1/Phase 2, Status: COMPLETED, Enrollment: 306"
    as of: 2026-06-11T19:18:16.963Z

[GMAB-64] Genmab is testing its candidate in Advanced Endometrial Cancer: a Phase 2 trial (NCT06046274), withdrawn, primary completion on record 2028-06-01.
    source: https://clinicaltrials.gov/study/NCT06046274  (ORIGIN)
    verbatim: "NCT identifier NCT06046274: 'GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer' - Phase: Phase 2, Status: WITHDRAWN, Enrollment: 0"
    as of: 2026-06-11T19:18:16.963Z

[GMAB-65] Daratumumab appears in 28995 FDA adverse-event reports (FAERS); the most frequent are plasma cell myeloma (1691), off label use (1545), pneumonia (1140).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"daratumumab"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='daratumumab': total=28995, top_reactions=[{"term": "PLASMA CELL MYELOMA", "count": 1691}, {"term": "OFF LABEL USE", "count": 1545}, {"term": "PNEUMONIA", "count": 1140}]"
    as of: 2026-06-11T19:18:19.059Z

[GMAB-66] A 2026 paper in Journal of the National Comprehensive Cancer Network : JNCCN reports that targeting BCMA in Plasmablastic Lymphoma With Teclistamab: A Case Study of Three Patients (PMID 41771248).
    source: https://pubmed.ncbi.nlm.nih.gov/41771248/  (ACCOUNTABLE_RELAY)
    verbatim: "Plasmablastic lymphoma (PBL) is a rare subtype of non-Hodgkin lymphoma (NHL) with limited standard therapeutic options and poor outcomes. PBL typically lacks expression of the B-cell antigens CD20 or CD19 and, accordingly, has not benefited from the incorporation of B-cell-targeted antibodies. Howev..."
    as of: 2026-06-11T19:18:17.875Z

[GMAB-67] A 2025 paper in International journal of molecular sciences reports that from Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies (PMID 40508128).
    source: https://pubmed.ncbi.nlm.nih.gov/40508128/  (ACCOUNTABLE_RELAY)
    verbatim: "Multispecific antibodies have redefined the immunotherapeutic landscape in hematologic malignancies. Bispecific antibodies (BsAbs), which redirect cytotoxic T cells toward malignant targets via dual antigen engagement, are now established components of treatment for diseases such as acute lymphoblas..."
    as of: 2026-06-11T19:18:17.875Z

[GMAB-68] A 2024 paper in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists reports that pharmacist perspectives on emerging T cell-engaging bispecific therapies in cancer therapeutics (PMID 38394329).
    source: https://pubmed.ncbi.nlm.nih.gov/38394329/  (ACCOUNTABLE_RELAY)
    verbatim: "To summarize the pharmacology, efficacy, safety, dosing, administration, and pharmacist perspectives related to operationalization of new and emerging bispecific therapies indicated for the treatment of various cancers.
In recent years, there have been significant advancements in the expansion of im..."
    as of: 2026-06-11T19:18:17.875Z

[GMAB-69] A 2023 paper in Expert opinion on biological therapy reports that bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting (PMID 37852928).
    source: https://pubmed.ncbi.nlm.nih.gov/37852928/  (ACCOUNTABLE_RELAY)
    verbatim: "According to recent research, bispecific antibodies (BsAbs) are a promising new immunotherapy method. Various BsAb forms are constantly being developed. In the year 2022 alone, four BsAbs (tebentafusp, faricimab, mosunetuzumab, and teclistamab) were approved for clinical applications. BsAbs includin..."
    as of: 2026-06-11T19:18:17.875Z

[GMAB-70] A 2023 paper in Current opinion in oncology reports that update on bi-specific monoclonal antibodies for blood cancers (PMID 37551951).
    source: https://pubmed.ncbi.nlm.nih.gov/37551951/  (ACCOUNTABLE_RELAY)
    verbatim: "The purpose of this review is to present updates in the field of bispecific antibodies focusing on those agents that have been recently approved for multiple myeloma, follicular lymphoma and diffuse large B cell lymphoma.
Teclistamab, the -cell maturation antigen -targeted bispecific antibody has s..."
    as of: 2026-06-11T19:18:17.875Z

[GMAB-71] A 2022 paper in Cancer research communications reports that redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas (PMID 36875718).
    source: https://pubmed.ncbi.nlm.nih.gov/36875718/  (ACCOUNTABLE_RELAY)
    verbatim: "T-cell redirecting bispecific antibodies hold high promise for treatment of B-cell malignancies. B-cell maturation antigen (BCMA) exhibits high expression on normal and malignant mature B cells including plasma cells, which can be enhanced by inhibition of -secretase. BCMA is considered a validated..."
    as of: 2026-06-11T19:18:17.875Z

[GMAB-72] A 2026 paper in American journal of hematology reports that plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management (PMID 42138287).
    source: https://pubmed.ncbi.nlm.nih.gov/42138287/  (ACCOUNTABLE_RELAY)
    verbatim: "Plasmablastic lymphoma (PBL) is a rare CD20-negative aggressive lymphoma with poor prognosis when treated with standard treatment options. Although PBL is associated with HIV infection and other immunosuppressed states, it can also affect immunocompetent individuals.
The diagnosis of PBL requires a..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-73] A 2025 paper in Hematology. American Society of Hematology. Education Program reports that what to know about rare B-cell malignancies in 2025 (PMID 41348048).
    source: https://pubmed.ncbi.nlm.nih.gov/41348048/  (ACCOUNTABLE_RELAY)
    verbatim: "Rare B-cell malignancies pose a unique management challenge because of their rarity and aggressiveness. Given their low incidence, they require a high index of suspicion for diagnosis and necessitate specialized therapeutic approaches. Herein, we discuss 3 of those rare lymphomas: plasmablastic lymp..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-74] A 2025 paper in Frontiers in immunology reports that case Report: CD19 and CD22 CAR-T therapy induced durable complete remission in a patient with refractory plasmablastic lymphoma (PMID 41235228).
    source: https://pubmed.ncbi.nlm.nih.gov/41235228/  (ACCOUNTABLE_RELAY)
    verbatim: "Plasmablastic lymphoma (PBL) is a rare and highly aggressive form of non-Hodgkin lymphoma that is associated with a poor prognosis. Traditional chemotherapy has demonstrated limited efficacy for PBL. There is currently no standard treatment for patients with refractory or relapsing PBL. While CAR-T..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-75] A 2025 paper in Journal of cellular and molecular medicine reports that daratumumab for CD20(-)CD38(+) Relapsed/Refractory Diffuse Large B-Cell Lymphoma (PMID 41102901).
    source: https://pubmed.ncbi.nlm.nih.gov/41102901/  (ACCOUNTABLE_RELAY)
    verbatim: "Patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma) treated with rituximab-based regimens often have a reduction in the expression level of CD20. Replacement of target proteins for new targeted chemotherapy has become a popular direction for the treatment of R/R DLBCL. To inv..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-76] A 2025 paper in BMC nephrology reports that a case of renal diffuse large B-cell lymphoma concurrent with disseminated muscle involvement (PMID 41057983).
    source: https://pubmed.ncbi.nlm.nih.gov/41057983/  (ACCOUNTABLE_RELAY)
    verbatim: "Renal involvement in the diffuse large B-cell lymphoma (DLBCL) is rare and usually occurs as part of systemic disease. Muscle infiltration is even less common and can mimic inflammatory or obstructive conditions.
We present a 58-year-old male with right flank pain, myalgia, oliguria, and weight loss..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-77] A 2025 paper in Immunotherapy reports that gamma heavy chain disease treated with daratumumab-based regimen: a first case report and review of literature (PMID 40838430).
    source: https://pubmed.ncbi.nlm.nih.gov/40838430/  (ACCOUNTABLE_RELAY)
    verbatim: "We report on the use of a daratumumab-CHOP regimen for treatment of gamma heavy chain disease (HCD) in a 79-year-old woman. HCD is a very rare hematological disease, often associated with an underlying lymphoproliferative disorder. Only a few cases are reported in the literature, and, therefore, s..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-78] A 2025 paper in Journal of controlled release : official journal of the Controlled Release Society reports that antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas (PMID 40409372).
    source: https://pubmed.ncbi.nlm.nih.gov/40409372/  (ACCOUNTABLE_RELAY)
    verbatim: "The current frontline therapy for B-cell non-Hodgkin lymphomas (B-NHL), the most frequent hematologic malignancy in the Western hemisphere, is based on immunochemotherapy (ICT), i.e., a combination of genotoxic cytostatics and the anti-CD20 monoclonal antibody (mAb) rituximab. The treatment of relap..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-79] A 2025 paper in Cancer reports (Hoboken, N.J.) reports that two Cases of Plasmablastic Myeloma Mimicking Plasmablastic Lymphoma With In-Depth Review of Literature (PMID 39907148).
    source: https://pubmed.ncbi.nlm.nih.gov/39907148/  (ACCOUNTABLE_RELAY)
    verbatim: "Plasmablastic myeloma (PBM) is a rare, aggressive subtype of multiple myeloma (MM) with poor prognosis. On the other hand, plasmablastic lymphoma (PBL) is an aggressive B-cell lymphoma with a plasmacytic phenotype. Importantly, PBM is difficult to distinguish from PBL, because clinical features of b..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-80] A 2025 paper in Cureus reports that complete Remission of Plasmablastic Lymphoma With Daratumumab and a Mild Regimen of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (Mini-CHOP) (PMID 39897241).
    source: https://pubmed.ncbi.nlm.nih.gov/39897241/  (ACCOUNTABLE_RELAY)
    verbatim: "Plasmablastic lymphoma (PBL) is a rare and highly aggressive subtype of diffuse large B-cell lymphoma, characterized by a dismal prognosis. Due to its rarity and aggressive nature, no established standard of care exists for PBL. Treatment is primarily based on large B-cell lymphoma- or multiple myel..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-81] A 2024 paper in American journal of hematology reports that plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management (PMID 38767403).
    source: https://pubmed.ncbi.nlm.nih.gov/38767403/  (ACCOUNTABLE_RELAY)
    verbatim: "Plasmablastic lymphoma (PBL) is a rare CD20-negative aggressive lymphoma with a poor prognosis under standard treatment options. Though PBL is associated with human immunodeficiency virus infection and other immunosuppressed states, it can also affect immunocompetent individuals.
The diagnosis requi..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-82] A 2025 paper in Recent patents on anti-cancer drug discovery reports that treatment of Refractory p53 Mutation Large B-cell Lymphoma with Daratumumab and Venetoclax Followed by CAR-T Cell Therapy: Case Report and Animal Study (PMID 38265376).
    source: https://pubmed.ncbi.nlm.nih.gov/38265376/  (ACCOUNTABLE_RELAY)
    verbatim: "The tumor burden before chimeric antigen receptor T (CAR-T) cell therapy was one of the critical factors affecting the prognosis of lymphoma. It was a challenge to effectively reduce the tumor burden of relapsed/refractory large B-cell lymphoma with p53 mutation.
Here, we have presented a case of re..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-83] A 2023 paper in Journal for immunotherapy of cancer reports that bCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma (PMID 37137553).
    source: https://pubmed.ncbi.nlm.nih.gov/37137553/  (ACCOUNTABLE_RELAY)
    verbatim: "Plasmablastic lymphoma (PBL) is a rare subtype of aggressive large B-cell lymphoma, with a dismal prognosis despite aggressive therapies. New approaches are needed for those with refractory disease. PBL expresses antigens similar to multiple myeloma (MM), including B-cell maturation antigen (BCMA)...."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-84] A 2023 paper in Blood cells, molecules & diseases reports that daratumumab as a novel treatment option in refractory ITP (PMID 36669360).
    source: https://pubmed.ncbi.nlm.nih.gov/36669360/  (ACCOUNTABLE_RELAY)
    verbatim: "Primary immune thrombocytopenia (ITP) in adult patients typically presents as a repeatedly relapsing disease in need of multiple lines of therapy. Here we report the clinical courses of two patients, an 82-year-old female and a 54-year-old male, with primary ITP after multiple relapses and exhausted..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-85] A 2023 paper in Journal of clinical oncology : official journal of the American Society of Clinical Oncology reports that epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial (PMID 36548927).
    source: https://pubmed.ncbi.nlm.nih.gov/36548927/  (ACCOUNTABLE_RELAY)
    verbatim: "Epcoritamab is a subcutaneously administered CD3xCD20 T-cell-engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20+ B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-86] A 2023 paper in Leukemia reports that inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma (PMID 36539557).
    source: https://pubmed.ncbi.nlm.nih.gov/36539557/  (ACCOUNTABLE_RELAY)
    verbatim: "Redirection of tumor-associated macrophages to eliminate tumor cells holds great promise for overcoming therapeutic resistance to rituximab and other antibody drugs. Here, we determined the expression of ectonucleotidases CD39 and CD73 in diffuse large B-cell lymphoma (DLBCL), and examined the impac..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-87] A 2022 paper in Blood advances reports that venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis (PMID 35820018).
    source: https://pubmed.ncbi.nlm.nih.gov/35820018/  (ACCOUNTABLE_RELAY)
    verbatim: "Immunotherapy has evolved as a powerful tool for the treatment of B-cell malignancies, and patient outcomes have improved by combining therapeutic antibodies with conventional chemotherapy. Overexpression of antiapoptotic B-cell lymphoma 2 (Bcl-2) is associated with a poor prognosis, and increased l..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-88] A 2022 paper in Case reports in hematology reports that daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: Review of the Literature (PMID 35795542).
    source: https://pubmed.ncbi.nlm.nih.gov/35795542/  (ACCOUNTABLE_RELAY)
    verbatim: "Characterized by an aggressive course with a poor overall survival due to treatment refractoriness, plasmablastic lymphoma (PBL) is a rare variant of diffuse large cell B cell lymphoma. Gorham's lymphangiomatosis or Gorham-Stout disease (GSD) is a rare skeletal condition of unknown etiology characte..."
    as of: 2026-06-11T19:18:18.714Z

[GMAB-89] A 2026 paper in [Rinsho ketsueki] The Japanese journal of clinical hematology reports that [Long-term remission in refractory diffuse large B-cell lymphoma with concurrent epcoritamab and radiotherapy] (PMID 42236241).
    source: https://pubmed.ncbi.nlm.nih.gov/42236241/  (ACCOUNTABLE_RELAY)
    verbatim: "Epcoritamab, a subcutaneous CD3CD20 bispecific antibody, has shown high efficacy in relapsed or refractory large B-cell lymphoma (R/R LBCL). However, treatment options are limited for patients who fail to achieve durable remission after immune-based therapy. Here, we describe a case of refractory d..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-90] A 2026 paper in The oncologist reports that patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma (PMID 42166746).
    source: https://pubmed.ncbi.nlm.nih.gov/42166746/  (ACCOUNTABLE_RELAY)
    verbatim: "Several bispecific antibodies (BsAbs), including mosunetuzumab, glofitamab, and epcoritamab, are approved for non-Hodgkin lymphoma (NHL). However, real-world patient-centered data evaluating treatment-related time burden and preferences are lacking.
We conducted an online survey of 120 patients with..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-91] A 2026 paper in Journal of comparative effectiveness research reports that health care resource use in the management of patients with relapsed/refractory diffuse large B-cell lymphoma - Canadian perspective (PMID 42003701).
    source: https://pubmed.ncbi.nlm.nih.gov/42003701/  (ACCOUNTABLE_RELAY)
    verbatim: "Aim: Epcoritamab, the first subcutaneous (SC) bispecific approved for relapsed/refractory diffuse large B-cell lymphoma (R/R-DLBCL), offers potential advantages in terms of healthcare resource utilization (HCRU) associated with its SC administration. This study aimed to estimate HCRU and associated..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-92] A 2026 paper in Cureus reports that bruton Tyrosine Kinase Inhibition in Combination With Bispecific Antibodies for Richter's Syndrome: A Report of Two Cases and Mini Review (PMID 41930040).
    source: https://pubmed.ncbi.nlm.nih.gov/41930040/  (ACCOUNTABLE_RELAY)
    verbatim: "Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the United States. One feared complication of CLL is Richter's syndrome (RS), where the leukemia transforms into a more aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). The current standard of care aims..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-93] A 2026 paper in Frontiers in oncology reports that case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy (PMID 41907623).
    source: https://pubmed.ncbi.nlm.nih.gov/41907623/  (ACCOUNTABLE_RELAY)
    verbatim: "Neurolymphomatosis frequently impairs physical function, rendering patients unable to tolerate chimeric antigen receptor T-cell therapy (CAR-T). An alternative treatment strategy which can cross the blood-nerve barrier is warranted.
A 64-year-old woman had a history of MYD88L265P mutated diffuse lar..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-94] A 2026 paper in Journal of pharmaceutical health care and sciences reports that cytokine release syndrome-compatible fever after initiation of local radiotherapy during late-phase epcoritamab therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report (PMID 41896935).
    source: https://pubmed.ncbi.nlm.nih.gov/41896935/  (ACCOUNTABLE_RELAY)
    verbatim: "Epcoritamab, a subcutaneous CD3CD20 bispecific antibody, has demonstrated promising activity in relapsed or refractory diffuse large Bcell lymphoma. Cytokine release syndrome (CRS) is a key adverse event associated with Tcell-engaging therapies; however, it typically occurs early after treatment..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-95] A 2026 paper in Clinical lymphoma, myeloma & leukemia reports that epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6 (PMID 41881714).
    source: https://pubmed.ncbi.nlm.nih.gov/41881714/  (ACCOUNTABLE_RELAY)
    verbatim: "Epcoritamab, a CD3  CD20 bispecific antibody approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), is administered subcutaneously with recommended 24 hours inpatient monitoring after the first full dose (FFD). EPCORE NHL-6 (NCT05451810) investigated feasibility of outpatient monit..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-96] A 2026 paper in Case reports in oncology reports that successful Use of Epcoritamab in Refractory Diffuse Large B-Cell Lymphoma with Central Nervous System Involvement: A Case Report (PMID 41867647).
    source: https://pubmed.ncbi.nlm.nih.gov/41867647/  (ACCOUNTABLE_RELAY)
    verbatim: "Diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) involvement carries an extremely poor prognosis, particularly in patients' refractory to standard immunochemotherapy. Although bispecific antibodies are generally considered to have limited efficacy in CNS disease, this case sug..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-97] A 2026 paper in Haematologica reports that epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial (PMID 41784015).
    source: https://pubmed.ncbi.nlm.nih.gov/41784015/  (ACCOUNTABLE_RELAY)
    verbatim: "The treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains challenging, with inadequate responses to salvage chemoimmunotherapy limiting patients' ability to receive potentially curative treatments like autologous stem cell transplantation (ASCT). Epcoritamab, a subcuta..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-98] A 2026 paper in [Rinsho ketsueki] The Japanese journal of clinical hematology reports that [Tumor flare reaction during epcoritamab treatment in refractory diffuse large B-cell lymphoma] (PMID 41780953).
    source: https://pubmed.ncbi.nlm.nih.gov/41780953/  (ACCOUNTABLE_RELAY)
    verbatim: "An 87-year-old man was diagnosed with diffuse large B-cell lymphoma in 2020. The disease relapsed repeatedly and remained poorly controlled despite multiple salvage chemotherapy regimens. In February 2024, inguinal lymphadenopathy reappeared and epcoritamab was administered as the sixth line of chem..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-99] A 2026 paper in Medicina (Kaunas, Lithuania) reports that bispecific Antibodies in B-Cell Lymphomas: Mechanisms, Efficacy, Toxicity, and Management (PMID 41752741).
    source: https://pubmed.ncbi.nlm.nih.gov/41752741/  (ACCOUNTABLE_RELAY)
    verbatim: "Bispecific antibodies represent a pivotal advancement in treating relapsed/refractory B-cell lymphomas, addressing unmet needs for patients with limited conventional options. This review examines CD20  CD3 bispecific antibodies (BsAbs) like mosunetuzumab, epcoritamab, odronextamab, and glofitamab,..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-100] A 2026 paper in Frontiers in oncology reports that a rare case report of relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type, treated with Epcoritamab: results obtained and lesson learned (PMID 41743953).
    source: https://pubmed.ncbi.nlm.nih.gov/41743953/  (ACCOUNTABLE_RELAY)
    verbatim: "Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type (PCDLBCL-LT), is a rare and aggressive subtype of primary cutaneous B-cell lymphoma, predominantly affecting elderly individuals. The disease presents with nodular or tumorous skin lesions, mainly on the legs, and follows a highly aggressive..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-101] A 2026 paper in Journal of medical economics reports that health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general population (PMID 41705966).
    source: https://pubmed.ncbi.nlm.nih.gov/41705966/  (ACCOUNTABLE_RELAY)
    verbatim: "Conventional therapies in Japan for relapsed or refractory large B-cell lymphoma (r/r LBCL) require intravenous infusion (IV), while epcoritamab is administered subcutaneously. Despite the expected quality of life (QOL) improvement from reduced drug administration burden, limited data exists on QOL..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-102] A 2026 paper in Annals of hematology reports that efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial (PMID 41634395).
    source: https://pubmed.ncbi.nlm.nih.gov/41634395/  (ACCOUNTABLE_RELAY)
    verbatim: "Epcoritamab, a CD3xCD20 bispecific antibody, resulted in deep, durable responses with a manageable safety profile in patients with relapsed/refractory large B-cell lymphoma (LBCL) in EPCORE NHL-1 (NCT03625037). We report results from a 3-year follow-up. Adults with relapsed/refractory LBCL received..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-103] A 2025 paper in Seminars in hematology reports that t-cell engaging antibodies for B-cell lymphomas (PMID 41539896).
    source: https://pubmed.ncbi.nlm.nih.gov/41539896/  (ACCOUNTABLE_RELAY)
    verbatim: "T-cell engaging bispecific antibodies (BsAbs) have transformed the treatment paradigms for B-cell non-Hodgkin lymphomas. This review focused on 4 CD20  CD3 BsAbs, as well as surovatamig, a CD19  CD3 BsAb currently under investigation that has demonstrated promising efficacy against relapsed/refrac..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-104] A 2025 paper in Journal of clinical and experimental hematopathology : JCEH reports that development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma (PMID 41443882).
    source: https://pubmed.ncbi.nlm.nih.gov/41443882/  (ACCOUNTABLE_RELAY)
    verbatim: "The efficacy of chemotherapy for relapsed/refractory diffuse large B-cell lymphoma remains inadequate. Recent advances in T-cell engaging therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies (BsAbs), aim to overcome chemotherapy resistance. BsAbs targeting CD20/CD3..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-105] A 2026 paper in The Lancet. Haematology reports that epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial (PMID 41380698).
    source: https://pubmed.ncbi.nlm.nih.gov/41380698/  (ACCOUNTABLE_RELAY)
    verbatim: "Richter transformation is one of the most challenging B-cell lymphomas to treat, particularly in patients with high-risk chronic lymphocytic leukaemia features or who have had previous therapy for chronic lymphocytic leukaemia. Median survival remains 6-12 months across various therapeutic approache..."
    as of: 2026-06-11T19:18:17.177Z

[GMAB-106] OpenTargets catalogs MS4A1 (membrane spanning 4-domains A1) under Ensembl identifier ENSG00000156738.
    source: https://platform.opentargets.org/target/ENSG00000156738  (ACCOUNTABLE_RELAY)
    verbatim: "OpenTargets target search for 'MS4A1': id=ENSG00000156738, name='MS4A1', description='membrane spanning 4-domains A1'"
    as of: 2026-06-11T19:21:13.093Z

[GMAB-107] OpenTargets catalogs CD3E (CD3 epsilon subunit of T-cell receptor complex) under Ensembl identifier ENSG00000198851.
    source: https://platform.opentargets.org/target/ENSG00000198851  (ACCOUNTABLE_RELAY)
    verbatim: "OpenTargets target search for 'CD3E': id=ENSG00000198851, name='CD3E', description='CD3 epsilon subunit of T-cell receptor complex'"
    as of: 2026-06-11T19:21:13.806Z

[GILD-1] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): a Phase 3 trial (NCT03391466), completed at 359 patients, primary completion (registry) 2024-11-25.
    source: https://clinicaltrials.gov/study/NCT03391466  (ORIGIN)
    verbatim: "NCT identifier NCT03391466: 'Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma' - Phase: Phase 3, Status: COMPLETED, Enrollment: 359"
    as of: 2026-06-11T19:18:19.309Z

[GILD-2] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Follicular Lymphoma: a Phase 2 trial (NCT06043323), recruiting toward 20 patients, est. primary completion 2028-09-01.
    source: https://clinicaltrials.gov/study/NCT06043323  (ORIGIN)
    verbatim: "NCT identifier NCT06043323: 'A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma' - Phase: Phase 2, Status: RECRUITING, Enrollment: 20"
    as of: 2026-06-11T19:18:19.309Z

[GILD-3] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Non Hodgkin Lymphoma: a Phase 2 trial (NCT04150913), completed at 15 patients, primary completion (registry) 2024-10-31.
    source: https://clinicaltrials.gov/study/NCT04150913  (ORIGIN)
    verbatim: "NCT identifier NCT04150913: 'A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity' - Phase: Phase 2, Status: COMPLETED, Enrollment: 15"
    as of: 2026-06-11T19:18:19.309Z

[GILD-4] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Lymphoma: a Phase 2 trial (NCT06218602), recruiting toward 40 patients, est. primary completion 2026-08-01.
    source: https://clinicaltrials.gov/study/NCT06218602  (ORIGIN)
    verbatim: "NCT identifier NCT06218602: 'Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.' - Phase: Phase 2, Status: RECRUITING, Enrollment: 40"
    as of: 2026-06-11T19:18:19.309Z

[GILD-5] Gilead / Kite Pharma is testing Yescarta in Cytokine Release Syndrome: a Phase 2 trial (NCT04071366), completed at 112 patients, primary completion (registry) 2023-08-22.
    source: https://clinicaltrials.gov/study/NCT04071366  (ORIGIN)
    verbatim: "NCT identifier NCT04071366: 'A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy' - Phase: Phase 2, Status: COMPLETED, Enrollment: 112"
    as of: 2026-06-11T19:18:19.309Z

[GILD-6] Gilead / Kite Pharma is testing axicabtagene ciloleucel in B-Cell Non-Hodgkin Lymphoma: a Phase 1/Phase 2 trial (NCT04257578), active not recruiting at 23 patients, est. primary completion 2031-03-01.
    source: https://clinicaltrials.gov/study/NCT04257578  (ORIGIN)
    verbatim: "NCT identifier NCT04257578: 'Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma' - Phase: Phase 1/Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 23"
    as of: 2026-06-11T19:18:19.309Z

[GILD-7] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Lymphoma: a Phase 2 trial (NCT06826118), recruiting toward 30 patients, est. primary completion 2026-12-31.
    source: https://clinicaltrials.gov/study/NCT06826118  (ORIGIN)
    verbatim: "NCT identifier NCT06826118: 'Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma' - Phase: Phase 2, Status: RECRUITING, Enrollment: 30"
    as of: 2026-06-11T19:18:19.309Z

[GILD-8] Gilead / Kite Pharma is testing axi-cel in NHL: a Phase 2 trial (NCT05641428), recruiting toward 300 patients, est. primary completion 2027-12.
    source: https://clinicaltrials.gov/study/NCT05641428  (ORIGIN)
    verbatim: "NCT identifier NCT05641428: 'Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL' - Phase: Phase 2, Status: RECRUITING, Enrollment: 300"
    as of: 2026-06-11T19:18:19.309Z

[GILD-9] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Solid and Hematological Malignancies: a N/A trial (NCT05041309), enrolling by invitation at 1000 patients, est. primary completion 2040-12.
    source: https://clinicaltrials.gov/study/NCT05041309  (ORIGIN)
    verbatim: "NCT identifier NCT05041309: 'Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells' - Phase: N/A, Status: ENROLLING_BY_INVITATION, Enrollment: 1000"
    as of: 2026-06-11T19:18:19.309Z

[GILD-10] Gilead / Kite Pharma is testing Yescarta in Diffuse Large B-Cell Lymphoma (DLBCL): a N/A trial (NCT05349201), completed at 273 patients, primary completion (registry) 2021-05-28.
    source: https://clinicaltrials.gov/study/NCT05349201  (ORIGIN)
    verbatim: "NCT identifier NCT05349201: 'CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)' - Phase: N/A, Status: COMPLETED, Enrollment: 273"
    as of: 2026-06-11T19:18:19.309Z

[GILD-11] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Lymphoma, B-Cell: a Phase 4 trial (NCT06609304), recruiting toward 20 patients, est. primary completion 2027-08-31.
    source: https://clinicaltrials.gov/study/NCT06609304  (ORIGIN)
    verbatim: "NCT identifier NCT06609304: 'Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma' - Phase: Phase 4, Status: RECRUITING, Enrollment: 20"
    as of: 2026-06-11T19:18:19.309Z

[GILD-12] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Large B-cell Lymphoma: a Phase 4 trial (NCT05108805), completed at 25 patients, primary completion (registry) 2023-12-08.
    source: https://clinicaltrials.gov/study/NCT05108805  (ORIGIN)
    verbatim: "NCT identifier NCT05108805: 'Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting' - Phase: Phase 4, Status: COMPLETED, Enrollment: 25"
    as of: 2026-06-11T19:18:19.309Z

[GILD-13] Gilead / Kite Pharma is testing axicabtagene ciloleucel in DIFFUSE LARGE B-CELL LYMPHOMA: a Phase 2 trial (NCT07254754), recruiting toward 45 patients, est. primary completion 2031-12-31.
    source: https://clinicaltrials.gov/study/NCT07254754  (ORIGIN)
    verbatim: "NCT identifier NCT07254754: 'Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma' - Phase: Phase 2, Status: RECRUITING, Enrollment: 45"
    as of: 2026-06-11T19:18:19.309Z

[GILD-14] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Hematopoietic and Lymphoid Cell Neoplasm: a Phase 2 trial (NCT04432506), completed at 22 patients, primary completion (registry) 2024-05-28.
    source: https://clinicaltrials.gov/study/NCT04432506  (ORIGIN)
    verbatim: "NCT identifier NCT04432506: 'Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma' - Phase: Phase 2, Status: COMPLETED, Enrollment: 22"
    as of: 2026-06-11T19:18:19.309Z

[GILD-15] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Large B-cell Lymphoma: a Phase 2 trial (NCT06550141), recruiting toward 28 patients, est. primary completion 2027-08-01.
    source: https://clinicaltrials.gov/study/NCT06550141  (ORIGIN)
    verbatim: "NCT identifier NCT06550141: 'Emapalumab Prevention of CAR-T Cell Associated Toxicities' - Phase: Phase 2, Status: RECRUITING, Enrollment: 28"
    as of: 2026-06-11T19:18:19.309Z

[GILD-16] Gilead / Kite Pharma is testing axicabtagene ciloleucel in DLBCL - Diffuse Large B Cell Lymphoma: a Phase 2 trial (NCT07326371), not yet recruiting at 24 patients, est. primary completion 2029-03.
    source: https://clinicaltrials.gov/study/NCT07326371  (ORIGIN)
    verbatim: "NCT identifier NCT07326371: 'Glofitamab Combined With CAR-T Therapy in R/R DLBCL' - Phase: Phase 2, Status: NOT_YET_RECRUITING, Enrollment: 24"
    as of: 2026-06-11T19:18:19.309Z

[GILD-17] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Diffuse Large B Cell Lymphoma: a N/A trial (NCT04319237), completed at 60 patients, primary completion (registry) 2023-07-31.
    source: https://clinicaltrials.gov/study/NCT04319237  (ORIGIN)
    verbatim: "NCT identifier NCT04319237: 'Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes' - Phase: N/A, Status: COMPLETED, Enrollment: 60"
    as of: 2026-06-11T19:18:19.851Z

[GILD-18] Gilead / Kite Pharma is testing axi-cel in CAR-T Retreatment: a NA trial (NCT05800067), unknown at 32 patients, est. primary completion 2024-12-31.
    source: https://clinicaltrials.gov/study/NCT05800067  (ORIGIN)
    verbatim: "NCT identifier NCT05800067: 'Axi-cel Retreatment in Relapsed/Refractory LBCL' - Phase: NA, Status: UNKNOWN, Enrollment: 32"
    as of: 2026-06-11T19:18:19.851Z

[GILD-19] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Relapsed or Refractory Large B-cell Lymphoma: a Phase 3 trial (NCT07479797), recruiting toward 550 patients, est. primary completion 2031-05.
    source: https://clinicaltrials.gov/study/NCT07479797  (ORIGIN)
    verbatim: "NCT identifier NCT07479797: 'Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy' - Phase: Phase 3, Status: RECRUITING, Enrollment: 550"
    as of: 2026-06-11T19:18:19.851Z

[GILD-20] Gilead / Kite Pharma is testing axicabtagene ciloleucel in CAR-T Cell Therapy: a NA trial (NCT06935136), not yet recruiting at 60 patients, est. primary completion 2028-04-09.
    source: https://clinicaltrials.gov/study/NCT06935136  (ORIGIN)
    verbatim: "NCT identifier NCT06935136: 'Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma' - Phase: NA, Status: NOT_YET_RECRUITING, Enrollment: 60"
    as of: 2026-06-11T19:18:19.851Z

[GILD-21] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Recurrent Diffuse Large B-Cell Lymphoma: a Phase 2 trial (NCT07042438), recruiting toward 56 patients, est. primary completion 2029-01-23.
    source: https://clinicaltrials.gov/study/NCT07042438  (ORIGIN)
    verbatim: "NCT identifier NCT07042438: 'Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells' - Phase: Phase 2, Status: RECRUITING, Enrollment: 56"
    as of: 2026-06-11T19:18:19.851Z

[GILD-22] Gilead / Kite Pharma is testing axi-cel in Diffuse Large B-cell Lymphoma: a N/A trial (NCT06271369), completed at 613 patients, primary completion (registry) 2023-02-15.
    source: https://clinicaltrials.gov/study/NCT06271369  (ORIGIN)
    verbatim: "NCT identifier NCT06271369: 'Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.' - Phase: N/A, Status: COMPLETED, Enrollment: 613"
    as of: 2026-06-11T19:18:19.851Z

[GILD-23] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Large B-cell Lymphoma: a Phase 1 trial (NCT07052305), recruiting toward 24 patients, est. primary completion 2028-08-31.
    source: https://clinicaltrials.gov/study/NCT07052305  (ORIGIN)
    verbatim: "NCT identifier NCT07052305: 'NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma' - Phase: Phase 1, Status: RECRUITING, Enrollment: 24"
    as of: 2026-06-11T19:18:19.851Z

[GILD-24] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Large B-cell Lymphoma: a Phase 3 trial (NCT07188558), recruiting toward 400 patients, est. primary completion 2032-01.
    source: https://clinicaltrials.gov/study/NCT07188558  (ORIGIN)
    verbatim: "NCT identifier NCT07188558: 'A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy' - Phase: Phase 3, Status: RECRUITING, Enrollment: 400"
    as of: 2026-06-11T19:18:19.851Z

[GILD-25] Gilead / Kite Pharma is testing axicabtagene ciloleucel in B-Cell Lymphoma Refractory: a Phase 2 trial (NCT04531046), active not recruiting at 62 patients, est. primary completion 2026-06.
    source: https://clinicaltrials.gov/study/NCT04531046  (ORIGIN)
    verbatim: "NCT identifier NCT04531046: 'Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 62"
    as of: 2026-06-11T19:18:19.851Z

[GILD-26] Axi-cel appears in 139 FDA adverse-event reports (FAERS); the most frequent are anaemia (11), lymphopenia (11), neutropenia (11).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"axi-cel"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='axi-cel': total=139, top_reactions=[{"term": "ANAEMIA", "count": 11}, {"term": "LYMPHOPENIA", "count": 11}, {"term": "NEUTROPENIA", "count": 11}]"
    as of: 2026-06-11T19:18:20.495Z

[GILD-27] Yescarta appears in 15389 FDA adverse-event reports (FAERS); the most frequent are cytokine release syndrome (3387), immune effector cell-associated neurotoxicity syndrome (1534), neurotoxicity (1138).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"Yescarta"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='Yescarta': total=15389, top_reactions=[{"term": "CYTOKINE RELEASE SYNDROME", "count": 3387}, {"term": "IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME", "count": 1534}, {"term": "NEUROTOXICITY", "count": 1138}]"
    as of: 2026-06-11T19:18:21.807Z

[GILD-28] Axicabtagene ciloleucel appears in 7323 FDA adverse-event reports (FAERS); the most frequent are cytokine release syndrome (997), immune effector cell-associated neurotoxicity syndrome (452), pyrexia (284).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"axicabtagene ciloleucel"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='axicabtagene ciloleucel': total=7323, top_reactions=[{"term": "CYTOKINE RELEASE SYNDROME", "count": 997}, {"term": "IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME", "count": 452}, {"term": "PYREXIA", "count": 284}]"
    as of: 2026-06-11T19:18:19.792Z

[GILD-29] Brexucabtagene autoleucel appears in 1496 FDA adverse-event reports (FAERS); the most frequent are cytokine release syndrome (204), immune effector cell-associated neurotoxicity syndrome (122), squamous cell carcinoma of skin (57).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"brexucabtagene autoleucel"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='brexucabtagene autoleucel': total=1496, top_reactions=[{"term": "CYTOKINE RELEASE SYNDROME", "count": 204}, {"term": "IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME", "count": 122}, {"term": "SQUAMOUS CELL CARCINOMA OF SKIN", "count": 57}]"
    as of: 2026-06-11T19:18:22.702Z

[GILD-30] Gilead / Kite Pharma is testing brexucabtagene autoleucel in Mantle Cell Lymphoma: a N/A trial (NCT05776134), available.
    source: https://clinicaltrials.gov/study/NCT05776134  (ORIGIN)
    verbatim: "NCT identifier NCT05776134: 'Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel' - Phase: N/A, Status: AVAILABLE, Enrollment: None"
    as of: 2026-06-11T19:18:21.951Z

[GILD-31] Gilead / Kite Pharma is testing brexucabtagene autoleucel in Mantle Cell Lymphoma: a Phase 2 trial (NCT06553872), recruiting toward 60 patients, est. primary completion 2029-08.
    source: https://clinicaltrials.gov/study/NCT06553872  (ORIGIN)
    verbatim: "NCT identifier NCT06553872: 'Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL' - Phase: Phase 2, Status: RECRUITING, Enrollment: 60"
    as of: 2026-06-11T19:18:21.951Z

[GILD-32] Gilead / Kite Pharma is testing brexucabtagene autoleucel in Relapsed/Refractory Mantle Cell Lymphoma: a Phase 2 trial (NCT04880434), completed at 95 patients, primary completion (registry) 2025-06-17.
    source: https://clinicaltrials.gov/study/NCT04880434  (ORIGIN)
    verbatim: "NCT identifier NCT04880434: 'Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)' - Phase: Phase 2, Status: COMPLETED, Enrollment: 95"
    as of: 2026-06-11T19:18:21.951Z

[GILD-33] Gilead / Kite Pharma is testing brexucabtagene autoleucel in Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma: a Phase 1 trial (NCT03624036), terminated at 16 patients, primary completion on record 2022-11-18.
    source: https://clinicaltrials.gov/study/NCT03624036  (ORIGIN)
    verbatim: "NCT identifier NCT03624036: 'Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma' - Phase: Phase 1, Status: TERMINATED, Enrollment: 16"
    as of: 2026-06-11T19:18:21.951Z

[GILD-34] Gilead / Kite Pharma is testing brexucabtagene autoleucel in Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia: a Phase 1/Phase 2 trial (NCT02625480), completed at 95 patients, primary completion (registry) 2026-03-25.
    source: https://clinicaltrials.gov/study/NCT02625480  (ORIGIN)
    verbatim: "NCT identifier NCT02625480: 'Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma' - Phase: Phase 1/Phase 2, Status: COMPLETED, Enrollment: 95"
    as of: 2026-06-11T19:18:21.951Z

[GILD-35] Gilead / Kite Pharma is testing brexucabtagene autoleucel in Relapsed/Refractory Waldenstrom Macroglobulinemia: a Phase 2 trial (NCT05537766), terminated at 19 patients, primary completion on record 2025-01-27.
    source: https://clinicaltrials.gov/study/NCT05537766  (ORIGIN)
    verbatim: "NCT identifier NCT05537766: 'Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies' - Phase: Phase 2, Status: TERMINATED, Enrollment: 19"
    as of: 2026-06-11T19:18:21.951Z

[GILD-36] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Relapsed/Refractory Mantle Cell Lymphoma: a Phase 2 trial (NCT02601313), completed at 105 patients, primary completion (registry) 2023-09-22.
    source: https://clinicaltrials.gov/study/NCT02601313  (ORIGIN)
    verbatim: "NCT identifier NCT02601313: 'Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)' - Phase: Phase 2, Status: COMPLETED, Enrollment: 105"
    as of: 2026-06-11T19:18:21.951Z

[GILD-37] Gilead / Kite Pharma is testing brexucabtagene autoleucel in Lymphoblastic Leukemia: a Phase 1 trial (NCT05993949), active not recruiting at 8 patients, est. primary completion 2027-06.
    source: https://clinicaltrials.gov/study/NCT05993949  (ORIGIN)
    verbatim: "NCT identifier NCT05993949: 'Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia' - Phase: Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 8"
    as of: 2026-06-11T19:18:21.951Z

[GILD-38] Gilead / Kite Pharma is testing Yescarta in Acute Lymphoblastic Leukemia: a Phase 2 trial (NCT03642626), active not recruiting at 150 patients, est. primary completion 2028-06-01.
    source: https://clinicaltrials.gov/study/NCT03642626  (ORIGIN)
    verbatim: "NCT identifier NCT03642626: 'MT2017-45: CAR-T Cell Therapy for Heme Malignancies' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 150"
    as of: 2026-06-11T19:18:21.951Z

[GILD-39] Gilead / Kite Pharma is testing axicabtagene ciloleucel in B Cell Lymphoma: a Phase 2 trial (NCT06213311), recruiting toward 40 patients, est. primary completion 2027-01-31.
    source: https://clinicaltrials.gov/study/NCT06213311  (ORIGIN)
    verbatim: "NCT identifier NCT06213311: 'A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma' - Phase: Phase 2, Status: RECRUITING, Enrollment: 40"
    as of: 2026-06-11T19:18:21.951Z

[GILD-40] Gilead / Kite Pharma is testing brexucabtagene autoleucel in Relapsed/Refractory: a Phase 1/Phase 2 trial (NCT06287229), recruiting toward 40 patients, est. primary completion 2030-12-31.
    source: https://clinicaltrials.gov/study/NCT06287229  (ORIGIN)
    verbatim: "NCT identifier NCT06287229: 'Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab' - Phase: Phase 1/Phase 2, Status: RECRUITING, Enrollment: 40"
    as of: 2026-06-11T19:18:21.951Z

[GILD-41] Gilead / Kite Pharma is testing brexucabtagene autoleucel in Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia: a Phase 1/Phase 2 trial (NCT02614066), completed at 125 patients, primary completion (registry) 2023-11-03.
    source: https://clinicaltrials.gov/study/NCT02614066  (ORIGIN)
    verbatim: "NCT identifier NCT02614066: 'A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)' - Phase: Phase 1/Phase 2, Status: COMPLETED, Enrollment: 125"
    as of: 2026-06-11T19:18:21.951Z

[GILD-42] Gilead / Kite Pharma is testing brexucabtagene autoleucel in Relapse/Refractory Mantle Cell Lymphoma: a N/A trial (NCT04162756), approved for marketing.
    source: https://clinicaltrials.gov/study/NCT04162756  (ORIGIN)
    verbatim: "NCT identifier NCT04162756: 'Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies' - Phase: N/A, Status: APPROVED_FOR_MARKETING, Enrollment: None"
    as of: 2026-06-11T19:18:21.951Z

[GILD-43] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Relapsed or Refractory Large B-cell Lymphoma: a Phase 2 trial (NCT05459571), completed at 35 patients, primary completion (registry) 2025-11-24.
    source: https://clinicaltrials.gov/study/NCT05459571  (ORIGIN)
    verbatim: "NCT identifier NCT05459571: 'Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma' - Phase: Phase 2, Status: COMPLETED, Enrollment: 35"
    as of: 2026-06-11T19:18:20.910Z

[GILD-44] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Relapsed/Refractory Diffuse Large B Cell Lymphoma: a N/A trial (NCT03153462), approved for marketing.
    source: https://clinicaltrials.gov/study/NCT03153462  (ORIGIN)
    verbatim: "NCT identifier NCT03153462: 'Axicabtagene Ciloleucel Expanded Access Study' - Phase: N/A, Status: APPROVED_FOR_MARKETING, Enrollment: None"
    as of: 2026-06-11T19:18:20.910Z

[GILD-45] Gilead / Kite Pharma is testing axicabtagene ciloleucel in DLBCL: a Phase 1/Phase 2 trial (NCT04855253), suspended at 30 patients, est. primary completion 2026-12.
    source: https://clinicaltrials.gov/study/NCT04855253  (ORIGIN)
    verbatim: "NCT identifier NCT04855253: 'Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL' - Phase: Phase 1/Phase 2, Status: SUSPENDED, Enrollment: 30"
    as of: 2026-06-11T19:18:20.910Z

[GILD-46] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Diffuse Large B-Cell Lymphoma, Not Otherwise Specified: a Phase 2 trial (NCT04205838), terminated at 23 patients, primary completion on record 2026-02-19.
    source: https://clinicaltrials.gov/study/NCT04205838  (ORIGIN)
    verbatim: "NCT identifier NCT04205838: 'Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma' - Phase: Phase 2, Status: TERMINATED, Enrollment: 23"
    as of: 2026-06-11T19:18:20.910Z

[GILD-47] Gilead / Kite Pharma is testing lisocabtagene maraleucel in Leukemia, Lymphocytic, Chronic, B-Cell: a Phase 1/Phase 2 trial (NCT03331198), recruiting toward 320 patients, est. primary completion 2027-11-26.
    source: https://clinicaltrials.gov/study/NCT03331198  (ORIGIN)
    verbatim: "NCT identifier NCT03331198: 'Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)' - Phase: Phase 1/Phase 2, Status: RECRUITING, Enrollment: 320"
    as of: 2026-06-11T19:18:22.930Z

[GILD-48] Gilead / Kite Pharma is testing lisocabtagene maraleucel in Recurrent Diffuse Large B-Cell Lymphoma: a Phase 1 trial (NCT05359211), active not recruiting at 27 patients, est. primary completion 2026-09-04.
    source: https://clinicaltrials.gov/study/NCT05359211  (ORIGIN)
    verbatim: "NCT identifier NCT05359211: 'NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma' - Phase: Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 27"
    as of: 2026-06-11T19:18:22.930Z

[GILD-49] Gilead / Kite Pharma is testing lisocabtagene maraleucel in Recurrent Transformed Chronic Lymphocytic Leukemia: a Phase 2 trial (NCT05672173), active not recruiting at 9 patients, est. primary completion 2026-09-10.
    source: https://clinicaltrials.gov/study/NCT05672173  (ORIGIN)
    verbatim: "NCT identifier NCT05672173: 'Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 9"
    as of: 2026-06-11T19:18:22.930Z

[GILD-50] Gilead / Kite Pharma is testing lisocabtagene maraleucel in Refractory Aggressive B-cell Lymphomas: a Phase 2 trial (NCT05583149), active not recruiting at 28 patients, est. primary completion 2029-03-01.
    source: https://clinicaltrials.gov/study/NCT05583149  (ORIGIN)
    verbatim: "NCT identifier NCT05583149: 'Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 28"
    as of: 2026-06-11T19:18:22.930Z

[GILD-51] Gilead / Kite Pharma is testing lisocabtagene maraleucel in Recurrent Transformed Chronic Lymphocytic Leukemia: a Phase 2 trial (NCT05873712), recruiting toward 24 patients, est. primary completion 2026-12-31.
    source: https://clinicaltrials.gov/study/NCT05873712  (ORIGIN)
    verbatim: "NCT identifier NCT05873712: 'Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome' - Phase: Phase 2, Status: RECRUITING, Enrollment: 24"
    as of: 2026-06-11T19:18:22.930Z

[GILD-52] Gilead / Kite Pharma is testing lisocabtagene maraleucel in Lymphoma, Non-Hodgkin: a Phase 2 trial (NCT03483103), completed at 74 patients, primary completion (registry) 2022-12-01.
    source: https://clinicaltrials.gov/study/NCT03483103  (ORIGIN)
    verbatim: "NCT identifier NCT03483103: 'Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)' - Phase: Phase 2, Status: COMPLETED, Enrollment: 74"
    as of: 2026-06-11T19:18:22.930Z

[GILD-53] Gilead / Kite Pharma is testing lisocabtagene maraleucel in Follicular Lymphoma: a N/A trial (NCT06794268), recruiting toward 300 patients, est. primary completion 2044-08-31.
    source: https://clinicaltrials.gov/study/NCT06794268  (ORIGIN)
    verbatim: "NCT identifier NCT06794268: 'A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting' - Phase: N/A, Status: RECRUITING, Enrollment: 300"
    as of: 2026-06-11T19:18:22.930Z

[GILD-54] Gilead / Kite Pharma is testing lisocabtagene maraleucel in Large B-cell Lymphoma: a Phase 2 trial (NCT07316010), active not recruiting at 50 patients, est. primary completion 2031-03-21.
    source: https://clinicaltrials.gov/study/NCT07316010  (ORIGIN)
    verbatim: "NCT identifier NCT07316010: 'Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 50"
    as of: 2026-06-11T19:18:22.930Z

[GILD-55] Gilead / Kite Pharma is testing lisocabtagene maraleucel in Leukemia, Lymphocytic, Chronic, B-Cell: a Phase 3 trial (NCT06205290), withdrawn, primary completion on record 2031-10-13.
    source: https://clinicaltrials.gov/study/NCT06205290  (ORIGIN)
    verbatim: "NCT identifier NCT06205290: 'A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies' - Phase: Phase 3, Status: WITHDRAWN, Enrollment: 0"
    as of: 2026-06-11T19:18:22.930Z

[GILD-56] Gilead / Kite Pharma is testing lisocabtagene maraleucel in Lymphoma, Large B-Cell, Diffuse: a N/A trial (NCT04400591), available.
    source: https://clinicaltrials.gov/study/NCT04400591  (ORIGIN)
    verbatim: "NCT identifier NCT04400591: 'Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol' - Phase: N/A, Status: AVAILABLE, Enrollment: None"
    as of: 2026-06-11T19:18:22.930Z

[GILD-57] Gilead / Kite Pharma is testing axicabtagene ciloleucel in Non-Hodgkin Lymphoma: a Phase 1 trial (NCT05794958), recruiting toward 20 patients, est. primary completion 2038-04-01.
    source: https://clinicaltrials.gov/study/NCT05794958  (ORIGIN)
    verbatim: "NCT identifier NCT05794958: 'Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel' - Phase: Phase 1, Status: RECRUITING, Enrollment: 20"
    as of: 2026-06-11T19:18:19.194Z

[GILD-58] Gilead / Kite Pharma is testing brexucabtagene autoleucel in Lymphoma: a EARLY_Phase 1 trial (NCT05495464), active not recruiting at 22 patients, est. primary completion 2027-03-31.
    source: https://clinicaltrials.gov/study/NCT05495464  (ORIGIN)
    verbatim: "NCT identifier NCT05495464: 'A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma' - Phase: EARLY_Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 22"
    as of: 2026-06-11T19:18:19.194Z

[GILD-59] Lisocabtagene maraleucel appears in 501 FDA adverse-event reports (FAERS); the most frequent are cytokine release syndrome (88), immune effector cell-associated neurotoxicity syndrome (32), neurotoxicity (23).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"lisocabtagene maraleucel"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='lisocabtagene maraleucel': total=501, top_reactions=[{"term": "CYTOKINE RELEASE SYNDROME", "count": 88}, {"term": "IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME", "count": 32}, {"term": "NEUROTOXICITY", "count": 23}]"
    as of: 2026-06-11T19:18:23.423Z

[GILD-60] A 2026 paper in Transplantation and cellular therapy reports that prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in Adult Patients with Relapsed/Refractory Lymphoma (PMID 42173255).
    source: https://pubmed.ncbi.nlm.nih.gov/42173255/  (ACCOUNTABLE_RELAY)
    verbatim: "CD19-directed chimeric antigen receptor (CAR) T-cell therapy has markedly improved outcomes for patients with relapsed or refractory B-cell malignancies, although coagulopathy characterized by hypofibrinogenemia has increasingly been recognized as a complication after CAR T-cell therapy. Nevertheles..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-61] A 2026 paper in Nature communications reports that naive CD4(+) T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy (PMID 42140929).
    source: https://pubmed.ncbi.nlm.nih.gov/42140929/  (ACCOUNTABLE_RELAY)
    verbatim: "Axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are standard-of-care second-line therapies for relapsed or refractory large B-cell lymphomas, yet clinical and immunological predictors of durable benefit remain poorly defined. Here, we retrospectively analyze 64 patients tre..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-62] A 2026 paper in HemaSphere reports that outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group (PMID 42099680).
    source: https://pubmed.ncbi.nlm.nih.gov/42099680/  (ACCOUNTABLE_RELAY)
    verbatim: "Relapse after chimeric antigen receptor (CAR) T-cell therapy in large B-cell lymphoma (LBCL) is associated with a dismal prognosis. Although Phase 3 trials have established CAR T-cells as standard second-line (2L) therapy, outcomes and optimal management after relapse in this setting remain unknown..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-63] A 2026 paper in Leukemia & lymphoma reports that unraveling the care pathway for CAR T-cell therapy in large B-cell lymphoma: insights from a nationwide study in France (2018-2023) (PMID 42052989).
    source: https://pubmed.ncbi.nlm.nih.gov/42052989/  (ACCOUNTABLE_RELAY)
    verbatim: "This study describes the inpatient care pathway for 1914 Large B-cell Lymphoma (LBCL) patients treated with CAR T-cell therapy in France between 2018 and 2023 and identifies factors influencing their management. Based on a retrospective analysis of the French national hospital database, we found the..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-64] A 2026 paper in Journal of clinical oncology : official journal of the American Society of Clinical Oncology reports that circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy (PMID 42044466).
    source: https://pubmed.ncbi.nlm.nih.gov/42044466/  (ACCOUNTABLE_RELAY)
    verbatim: "We report correlative circulating tumor DNA (ctDNA) analyses from TRANSFORM (ClinicalTrials.gov identifier: NCT03575351) evaluating lisocabtagene maraleucel (liso-cel) versus standard of care (salvage immunochemotherapy, high-dose chemotherapy, autologous stem cell transplantation [ASCT]) in second-..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-65] A 2026 paper in Blood advances reports that drivers of Temporal Improvement in CAR T-Cell Therapy for Large B-Cell Lymphoma: A Japanese Nationwide Registry Analysis (PMID 42018609).
    source: https://pubmed.ncbi.nlm.nih.gov/42018609/  (ACCOUNTABLE_RELAY)
    verbatim: "Real-world CD19 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is characterized by expanded eligibility and evolving management practices. However, the prognostic impact of these changes remains inconsistent, and the specific drivers of the outcomes remain unclear. T..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-66] A 2026 paper in International journal of clinical oncology reports that real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma (PMID 41968224).
    source: https://pubmed.ncbi.nlm.nih.gov/41968224/  (ACCOUNTABLE_RELAY)
    verbatim: "Clinical data on chimeric antigen receptor (CAR) T-cell therapy in Japanese patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBCL) are limited. This study evaluated the safety and long-term outcomes of CAR T-cell therapy in R/R PMBCL, including the impact of pembroli..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-67] A 2026 paper in Transplantation and cellular therapy reports that neurotoxicity in Older Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Study (PMID 41935576).
    source: https://pubmed.ncbi.nlm.nih.gov/41935576/  (ACCOUNTABLE_RELAY)
    verbatim: "Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy is a standard treatment option in relapsed or refractory (RR) large B-cell lymphoma (LBCL), including older patients. However, immune effector cell-associated neurotoxicity syndrome (ICANS)/neurotoxicity is frequent and can be debilitating,..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-68] A 2026 paper in Cureus reports that successful Use of Chimeric Antigen Receptor T-cell (CAR-T) Therapy With Lisocabtagene Maraleucel in a Renal Transplant Recipient With Refractory/Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) (PMID 41853416).
    source: https://pubmed.ncbi.nlm.nih.gov/41853416/  (ACCOUNTABLE_RELAY)
    verbatim: "This case describes a 53-year-old male with end-stage renal disease who developed monomorphic post-transplant lymphoproliferative disorder (PTLD) in the form of diffuse large B-cell lymphoma (DLBCL) after kidney transplantation. Despite initial treatment with rituximab, cyclophosphamide, doxorubicin..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-69] A 2026 paper in Frontiers in oncology reports that case Report: CAR-T therapy for relapsed diffuse large B-cell lymphoma in a patient with pre-existing Parkinson's disease-unfolding clinical challenges (PMID 41836222).
    source: https://pubmed.ncbi.nlm.nih.gov/41836222/  (ACCOUNTABLE_RELAY)
    verbatim: "Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the outcomes for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, immune effector cell-associated neurotoxicity syndrome (ICANS) remains a concern. Pre-existing neurological disorders such as Parkinson's disease (PD)..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-70] A 2026 paper in Journal of the National Comprehensive Cancer Network : JNCCN reports that nCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026 (PMID 41825137).
    source: https://pubmed.ncbi.nlm.nih.gov/41825137/  (ACCOUNTABLE_RELAY)
    verbatim: "Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)-containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Results from randomized clinical trials have demonstrated that time-limited treatment w..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-71] A 2026 paper in Blood reports that real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma (PMID 41774517).
    source: https://pubmed.ncbi.nlm.nih.gov/41774517/  (ACCOUNTABLE_RELAY)
    verbatim: "This study assessed real-world effectiveness and safety of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including those with high-risk disease, secondary central nervous system (sCNS) involvement, comorbidities, and poor fitness, using..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-72] A 2026 paper in Leukemia & lymphoma reports that a new era for transplant-ineligible R/R LBCL patients: what's changing? (PMID 41774434).
    source: https://pubmed.ncbi.nlm.nih.gov/41774434/  (ACCOUNTABLE_RELAY)
    verbatim: "Most patients with large B-cell lymphoma (LBCL) are cured with frontline chemoimmunotherapy; however, 30-40% experience relapsed or refractory (R/R) disease. Historically, salvage chemotherapy followed by autologous stem cell transplantation (ASCT) represented the standard second-line treatment. Sev..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-73] A 2026 paper in Journal of clinical and experimental hematopathology : JCEH reports that cD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma in a nonagenarian patient (PMID 41765468).
    source: https://pubmed.ncbi.nlm.nih.gov/41765468/  (ACCOUNTABLE_RELAY)
    verbatim: "Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the management of relapsed/refractory large B-cell lymphoma. However, evidence in the ultra-elderly population remains scarce. We report a 90-year-old woman with relapsed/refractory diffuse large B-cell lymphoma transformed from folli..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-74] A 2026 paper in Transplantation and cellular therapy reports that landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma (PMID 41765136).
    source: https://pubmed.ncbi.nlm.nih.gov/41765136/  (ACCOUNTABLE_RELAY)
    verbatim: "CAR T-cell therapy has transformed relapsed/refractory large B-cell lymphoma (LBCL) treatment, yet durable remissions remain challenging. In this retrospective multicenter study, 479 LBCL patients treated with commercial CD19 CAR-T products, axicabtagene ciloleucel (axi-cel, n = 262), tisagenlecleuc..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-75] A 2026 paper in European journal of haematology reports that cost-Effectiveness Analysis of Second-Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B-Cell Lymphoma (PMID 41651792).
    source: https://pubmed.ncbi.nlm.nih.gov/41651792/  (ACCOUNTABLE_RELAY)
    verbatim: "CAR-T cell therapies such as lisocabtagene maraleucel (liso-cel) have transformed the treatment of patients with second line primary refractory or early relapsed  12 months (R/R) large B-cell lymphoma (LBCL). The objective of this study was to assess the cost-effectiveness of liso-cel compared to s..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-76] A 2026 paper in Cytotherapy reports that impact of CD5 expression on outcomes for chimeric antigen receptor-T cell therapy in relapsed and refractory diffuse large B-cell lymphoma (PMID 41529329).
    source: https://pubmed.ncbi.nlm.nih.gov/41529329/  (ACCOUNTABLE_RELAY)
    verbatim: "Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has become the standard of care for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). However, CD5 expression is known to be associated with an aggressive phenotype in DLBCL, and its impact on outcomes after CAR-T cell therapy rem..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-77] A 2026 paper in International journal of clinical oncology reports that real-world effectiveness and safety of lisocabtagene maraleucel for relapsed/refractory large B cell lymphoma in Japan (PMID 41504990).
    source: https://pubmed.ncbi.nlm.nih.gov/41504990/  (ACCOUNTABLE_RELAY)
    verbatim: "Lisocabtagene maraleucel (liso-cel), an anti-CD19 CAR T cell therapy, has demonstrated efficacy in relapsed/refractory (R/R) large B cell lymphoma (LBCL). However, real-world data from commercial settings outside the United States remain limited.
To evaluate the safety and effectiveness of commercia..."
    as of: 2026-06-11T19:18:23.003Z

[GILD-78] A 2026 paper in Blood advances reports that impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma (PMID 42269079).
    source: https://pubmed.ncbi.nlm.nih.gov/42269079/  (ACCOUNTABLE_RELAY)
    verbatim: "The impact of fludarabine pharmacokinetics (PK) on chimeric antigen receptor (CAR) T-cell outcomes is not fully elucidated. We hypothesized that, in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients, measured fludarabine exposure during lymphodepletion would correlate with CAR T-cell r..."
    as of: 2026-06-11T19:18:20.010Z

[GILD-79] A 2026 paper in Bone marrow transplantation reports that impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT (PMID 42251173).
    source: https://pubmed.ncbi.nlm.nih.gov/42251173/  (ACCOUNTABLE_RELAY)
    verbatim: "Lymphodepleting conditioning (LD) with fludarabine and cyclophosphamide is critical to ensure optimal expansion and persistence of CD19 CAR T-cells. We conducted a retrospective EBMT registry study to assess the impact of fludarabine dosing in LD on outcomes in large B-cell lymphoma (LBCL). Among 14..."
    as of: 2026-06-11T19:18:20.010Z

[GILD-80] A 2026 paper in Molecular therapy. Advances reports that comparative pharmacokinetic derivations for axicabtagene ciloleucel and brexucabtagene autoleucel in the treatment of B cell malignancies (PMID 42137294).
    source: https://pubmed.ncbi.nlm.nih.gov/42137294/  (ACCOUNTABLE_RELAY)
    verbatim: "Axicabtagene ciloleucel (axi-cel) and brexucabtagene autoleucel (brexu-cel) are autologous anti-CD19 chimeric antigen receptor (CAR) T cell products originally approved in the pivotal ZUMA-1 and ZUMA-2 clinical studies for the treatment of relapsed/refractory (r/r) large B cell lymphoma (r/r LBCL) a..."
    as of: 2026-06-11T19:18:20.010Z

[GILD-81] A 2026 paper in Cytotherapy reports that real-world outcomes of Axicabtagene Ciloleucel CAR-T therapy in large B-cell lymphoma: a single-center observational study (PMID 42134094).
    source: https://pubmed.ncbi.nlm.nih.gov/42134094/  (ACCOUNTABLE_RELAY)
    verbatim: "Axicabtagene Ciloleucel (Axi-cel) has recently transformed the treatment landscape for relapsed or refractory large B-cell lymphoma (R/R LBCL). Despite promising results in pivotal trials like ZUMA-1 and ZUMA-7, there is limited data on its outcomes in the Middle East and North Africa (MENA) region...."
    as of: 2026-06-11T19:18:20.010Z

[GILD-82] A 2026 paper in European journal of haematology reports that real-World Experience With a ZUMA-1 Cohort 4 Adopted Approach to CRS and ICANS in CAR-T Recipients (PMID 42119568).
    source: https://pubmed.ncbi.nlm.nih.gov/42119568/  (ACCOUNTABLE_RELAY)
    verbatim: "Axicabtagene ciloleucel (Axi-cel) is a chimeric antigen receptor T-cell (CAR-T) therapy approved for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The registrational phase 1/2 ZUMA-1 study cohorts 1 and 4 addressed toxicity management in terms of cytokine release syndrome..."
    as of: 2026-06-11T19:18:20.010Z

[GILD-83] A 2026 paper in International journal of hematology reports that t-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel (PMID 42118449).
    source: https://pubmed.ncbi.nlm.nih.gov/42118449/  (ACCOUNTABLE_RELAY)
    verbatim: "Axicabtagene ciloleucel (axi-cel) has demonstrated efficacy and safety in relapsed/refractory large B cell lymphoma (r/r LBCL). However, evidence from Asian populations remains limited.This study evaluated patients with r/r LBCL who underwent leukapheresis for axi-cel between April 2023 and December..."
    as of: 2026-06-11T19:18:20.010Z

[GILD-84] A 2026 paper in Cancer immunology research reports that low-Strength Type I Interferon Signaling Promotes CAR T Cell Treatment Efficacy (PMID 42112708).
    source: https://pubmed.ncbi.nlm.nih.gov/42112708/  (ACCOUNTABLE_RELAY)
    verbatim: "CD19-directed chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). However, up to 60% of patients do not achieve a complete response. To uncover determinants of therapeutic efficacy, we an..."
    as of: 2026-06-11T19:18:20.010Z

[GILD-85] A 2026 paper in Clinical drug investigation reports that economic Evaluation of Axicabtagene Ciloleucel as a Second-Line Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in South Korea: A Cost-Utility Analysis Based on the ZUMA-7 Trial (PMID 42101810).
    source: https://pubmed.ncbi.nlm.nih.gov/42101810/  (ACCOUNTABLE_RELAY)
    verbatim: "Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in South Korea, with 30-40% of patients relapsing or becoming refractory after first-line therapy. Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy over standard-of-care (SoC) salvage chemotherap..."
    as of: 2026-06-11T19:18:20.010Z

[GILD-86] A 2026 paper in American journal of hematology reports that hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis (PMID 42086512).
    source: https://pubmed.ncbi.nlm.nih.gov/42086512/  (ACCOUNTABLE_RELAY)
    verbatim: "Chimeric Antigen Receptor T-cell Immunotherapy represents a breakthrough in treating relapsed/refractory hematologic malignancies, yet immune-related adverse events, particularly hemophagocytic lymphohistiocytosis (HLH), also known as immune effector cell-associated HLH-like syndrome (IEC-HS), are r..."
    as of: 2026-06-11T19:18:20.010Z

[GILD-87] A 2026 paper in Annals of hematology reports that distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity (PMID 41979680).
    source: https://pubmed.ncbi.nlm.nih.gov/41979680/  (ACCOUNTABLE_RELAY)
    verbatim: "Bone marrow toxicity, or immune effector cell-associated hematotoxicity (ICAHT), is a notable complication of CAR T-cell therapy, characterized by persistent cytopenia's and typically classified into three phenotypes: transient, intermittent and aplastic. This study aimed to characterize the bone ma..."
    as of: 2026-06-11T19:18:20.010Z

[GILD-88] A 2026 paper in Blood advances reports that early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma (PMID 41894687).
    source: https://pubmed.ncbi.nlm.nih.gov/41894687/  (ACCOUNTABLE_RELAY)
    verbatim: "Patients with large B-cell lymphoma who progress after second-line (2L) chimeric antigen receptor T cell (CAR T) therapy have an increasing number of post-CAR T treatment options available and should be considered for timely intervention if at high risk of CAR T failure. In this national cohort of 3..."
    as of: 2026-06-11T19:18:20.010Z

[GILD-89] A 2026 paper in medRxiv : the preprint server for health sciences reports that cell-free RNA Signatures Derived from the Tumor Microenvironment Predict Outcomes of CAR-T Therapy in Large B Cell Lymphoma (PMID 41891043).
    source: https://pubmed.ncbi.nlm.nih.gov/41891043/  (ACCOUNTABLE_RELAY)
    verbatim: "Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions in patients with large B-cell lymphoma (LBCL), yet outcomes remain variable. Reliable pre-treatment predictors of durable response remain limited, leaving a critical gap in patient management. To address this, we..."
    as of: 2026-06-11T19:18:20.010Z

[GILD-90] A 2026 paper in Blood neoplasia reports that impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas (PMID 41867486).
    source: https://pubmed.ncbi.nlm.nih.gov/41867486/  (ACCOUNTABLE_RELAY)
    verbatim: "Age may influence clinical outcomes after CD19-directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapy. Real-world data on the survival and toxicity outcomes of older patients receiving CAR-T therapy are limited. We used data from the Center for International Blood and Marrow Transplant Rese..."
    as of: 2026-06-11T19:18:20.010Z

[GILD-91] A 2026 paper in Critical reviews in oncology/hematology reports that chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis (PMID 41448297).
    source: https://pubmed.ncbi.nlm.nih.gov/41448297/  (ACCOUNTABLE_RELAY)
    verbatim: "Chimeric antigen receptor (CAR) T-cell therapy, a form of adoptive immunotherapy, has expanded treatment options for various hematologic malignancies. However, CAR T therapy is associated with a range of side effects, including immune effector cell-associated neurotoxicity syndrome (ICANS), with var..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-92] A 2026 paper in Blood advances reports that cAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia (PMID 41052404).
    source: https://pubmed.ncbi.nlm.nih.gov/41052404/  (ACCOUNTABLE_RELAY)
    verbatim: "Chimeric antigen receptor (CAR) T-cell (CAR-T) treatment for B-cell acute lymphoblastic leukemia (ALL) induces high initial response rates, but most patients relapse. Low disease burden (often defined as <5% blasts in the bone marrow) is associated with better outcomes. CAR HEMATOTOX (HT) is a score..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-93] A 2025 paper in Blood advances reports that bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study (PMID 40203192).
    source: https://pubmed.ncbi.nlm.nih.gov/40203192/  (ACCOUNTABLE_RELAY)
    verbatim: "Despite the increasing utilization of bridging radiotherapy (Br-RT), its impact on chimeric antigen receptor T-cell therapy (CAR-T) efficacy and toxicity remains poorly characterized. We retrospectively reviewed patients with relapsed/refractory B-cell lymphomas (BCLs) who received Br-RT followed by..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-94] A 2025 paper in Nature medicine reports that t cell malignancies after CAR T cell therapy in the DESCAR-T registry (PMID 39779930).
    source: https://pubmed.ncbi.nlm.nih.gov/39779930/  (ACCOUNTABLE_RELAY)
    verbatim: "The risk of T cell malignancies after chimeric antigen receptor (CAR) T cell therapy is a concern, although the true incidence remains unclear. Here we analyzed the DESCAR-T registry database, encompassing all pediatric and adult patients with hematologic malignancies who received CAR T cell therapy..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-95] A 2025 paper in Blood advances reports that access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network (PMID 39418599).
    source: https://pubmed.ncbi.nlm.nih.gov/39418599/  (ACCOUNTABLE_RELAY)
    verbatim: "We analyzed access barriers to anti-CD19+ chimeric antigen receptor T cells (CARTs) for non-Hodgkin lymphoma (NHL) within a community-based transplant and cell therapy network registry. A total of 357 intended recipients for approved anti-CD19+ CARTs were identified between 2018 to 2022. The median..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-96] A 2024 paper in Blood advances reports that cAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity (PMID 38498731).
    source: https://pubmed.ncbi.nlm.nih.gov/38498731/  (ACCOUNTABLE_RELAY)
    verbatim: "Chimeric antigen receptor (CAR) T cells directed against CD19 (CAR19) are a revolutionary treatment for B-cell lymphomas (BCLs). CAR19 cell expansion is necessary for CAR19 function but is also associated with toxicity. To define the impact of CAR19 expansion on patient outcomes, we prospectively fo..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-97] A 2023 paper in HemaSphere reports that clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients (PMID 37799345).
    source: https://pubmed.ncbi.nlm.nih.gov/37799345/  (ACCOUNTABLE_RELAY)
    verbatim: "Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-98] A 2023 paper in Journal for immunotherapy of cancer reports that impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 (PMID 37648261).
    source: https://pubmed.ncbi.nlm.nih.gov/37648261/  (ACCOUNTABLE_RELAY)
    verbatim: "Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the USA for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and in the European Union for patients 26 years with R/R B-ALL. After 2 years..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-99] A 2023 paper in Journal of clinical oncology : official journal of the American Society of Clinical Oncology reports that brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium (PMID 36753699).
    source: https://pubmed.ncbi.nlm.nih.gov/36753699/  (ACCOUNTABLE_RELAY)
    verbatim: "Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the single-arm phase II ZUMA-2 trial, which showed best overall and complete resp..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-100] A 2022 paper in Hematology/oncology and stem cell therapy reports that chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement (PMID 36537908).
    source: https://pubmed.ncbi.nlm.nih.gov/36537908/  (ACCOUNTABLE_RELAY)
    verbatim: "CAR T-cell therapy has significantly improved the outcomes of patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). However, most clinical trials excluded patients with central nervous system (CNS) involvement due to uncertain efficacy and safety.
On January 1, 2022, we sea..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-101] A 2022 paper in Hematology/oncology and stem cell therapy reports that next-Generation Chimeric Antigen Receptor T-cells (PMID 36537905).
    source: https://pubmed.ncbi.nlm.nih.gov/36537905/  (ACCOUNTABLE_RELAY)
    verbatim: "The U.S. Food and Drug Administration (FDA) approved 6 CAR T cell (CAR-T) products, including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), lisocabtagene maraleucel (liso-cel), idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (c..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-102] A 2022 paper in Current treatment options in oncology reports that the Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL) (PMID 35258793).
    source: https://pubmed.ncbi.nlm.nih.gov/35258793/  (ACCOUNTABLE_RELAY)
    verbatim: "Natural killer (NK) cells have played a critical-if largely unrecognized or ignored-role in the treatment of B cell non-Hodgkin lymphoma (NHL) since the introduction of CD20-directed immunotherapy with rituximab as a cornerstone of therapy over 25 years ago. Engagement with NK cells leading to lysis..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-103] A 2022 paper in Current oncology reports reports that engineered T Cells: CAR T Cell Therapy and Beyond (PMID 35059997).
    source: https://pubmed.ncbi.nlm.nih.gov/35059997/  (ACCOUNTABLE_RELAY)
    verbatim: "This article reviews the current data and future directions of engineered T cell therapies in non-Hodgkin lymphomas.
Currently, four chimeric antigen receptor (CAR) T cell products are approved: axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, and brexucabtagene autoleucel. These..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-104] A 2021 paper in Current hematologic malignancy reports reports that selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies (PMID 33630232).
    source: https://pubmed.ncbi.nlm.nih.gov/33630232/  (ACCOUNTABLE_RELAY)
    verbatim: "Chimeric antigen receptor T-cell (CAR-T) therapy is a form of adoptive cellular therapy that has revolutionized the treatment landscape in hematologic malignancies, especially B-cell lymphomas. In this review, we will discuss some of the landmark data behind these therapies and then lay out our appr..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-105] A 2021 paper in Expert opinion on biological therapy reports that brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma (PMID 33566715).
    source: https://pubmed.ncbi.nlm.nih.gov/33566715/  (ACCOUNTABLE_RELAY)
    verbatim: "Introduction: The therapeutic options for mantle cell lymphoma (MCL) include traditional chemo-immunotherapy for newly diagnosed cases, and targeted treatments including the bruton tyrosine kinase inhibitors in the relapsed/refractory (R/R) disease setting. The advent of commercially available chime..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-106] A 2021 paper in Future oncology (London, England) reports that axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas (PMID 33448873).
    source: https://pubmed.ncbi.nlm.nih.gov/33448873/  (ACCOUNTABLE_RELAY)
    verbatim: "Axicabtagene ciloleucel and brexucabtagene autoleucel are anti-CD19 T-cell therapies that utilize the same second-generation chimeric antigen receptor with a CD28 costimulatory subunit. They have demonstrated high rates of response in high-risk patients with relapsed and refractory B-cell malignanci..."
    as of: 2026-06-11T19:18:22.111Z

[GILD-107] OpenTargets catalogs MS4A1 (membrane spanning 4-domains A1) under Ensembl identifier ENSG00000156738.
    source: https://platform.opentargets.org/target/ENSG00000156738  (ACCOUNTABLE_RELAY)
    verbatim: "OpenTargets target search for 'MS4A1': id=ENSG00000156738, name='MS4A1', description='membrane spanning 4-domains A1'"
    as of: 2026-06-11T19:21:14.453Z

[LLY-1] Eli Lilly is testing its candidate in Healthy: a Phase 1 trial (NCT04991766), completed at 16 patients, primary completion (registry) 2022-04-02.
    source: https://clinicaltrials.gov/study/NCT04991766  (ORIGIN)
    verbatim: "NCT identifier NCT04991766: 'A Study of [14C]-LY3484356 in Healthy Female Participants' - Phase: Phase 1, Status: COMPLETED, Enrollment: 16"
    as of: 2026-06-11T19:18:23.574Z

[LLY-2] Eli Lilly is testing imlunestrant in Breast Cancer: a Phase 1 trial (NCT05307705), active not recruiting at 193 patients, est. primary completion 2026-12.
    source: https://clinicaltrials.gov/study/NCT05307705  (ORIGIN)
    verbatim: "NCT identifier NCT05307705: 'A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors' - Phase: Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 193"
    as of: 2026-06-11T19:18:23.574Z

[LLY-3] Eli Lilly is testing imlunestrant in Hepatic Insufficiency: a Phase 1 trial (NCT05440344), completed at 27 patients, primary completion (registry) 2024-02-28.
    source: https://clinicaltrials.gov/study/NCT05440344  (ORIGIN)
    verbatim: "NCT identifier NCT05440344: 'A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function' - Phase: Phase 1, Status: COMPLETED, Enrollment: 27"
    as of: 2026-06-11T19:18:23.574Z

[LLY-4] Eli Lilly is testing imlunestrant in Anatomic Stage I Breast Cancer AJCC v8: a Phase 2 trial (NCT07191717), not yet recruiting at 42 patients, est. primary completion 2031-04-30.
    source: https://clinicaltrials.gov/study/NCT07191717  (ORIGIN)
    verbatim: "NCT identifier NCT07191717: 'Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial' - Phase: Phase 2, Status: NOT_YET_RECRUITING, Enrollment: 42"
    as of: 2026-06-11T19:18:23.574Z

[LLY-5] Eli Lilly is testing its candidate in Healthy: a Phase 1 trial (NCT04840888), completed at 82 patients, primary completion (registry) 2022-04-12.
    source: https://clinicaltrials.gov/study/NCT04840888  (ORIGIN)
    verbatim: "NCT identifier NCT04840888: 'A Study of LY3484356 in Healthy Female Participants' - Phase: Phase 1, Status: COMPLETED, Enrollment: 82"
    as of: 2026-06-11T19:18:23.574Z

[LLY-6] Eli Lilly is testing its candidate in Breast Cancer: a Phase 1 trial (NCT04188548), active not recruiting at 500 patients, est. primary completion 2027-12.
    source: https://clinicaltrials.gov/study/NCT04188548  (ORIGIN)
    verbatim: "NCT identifier NCT04188548: 'A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer' - Phase: Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 500"
    as of: 2026-06-11T19:18:23.574Z

[LLY-7] Eli Lilly is testing imlunestrant in Breast Cancer: a Phase 2 trial (NCT07410559), not yet recruiting at 189 patients, est. primary completion 2031-07-01.
    source: https://clinicaltrials.gov/study/NCT07410559  (ORIGIN)
    verbatim: "NCT identifier NCT07410559: 'Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer' - Phase: Phase 2, Status: NOT_YET_RECRUITING, Enrollment: 189"
    as of: 2026-06-11T19:18:23.574Z

[LLY-8] Eli Lilly is testing its candidate in Breast Neoplasms: a Phase 1 trial (NCT05509790), active not recruiting at 17 patients, est. primary completion 2026-12.
    source: https://clinicaltrials.gov/study/NCT05509790  (ORIGIN)
    verbatim: "NCT identifier NCT05509790: 'A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer' - Phase: Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 17"
    as of: 2026-06-11T19:18:23.574Z

[LLY-9] Eli Lilly is testing imlunestrant in Breast Neoplasms: a Phase 3 trial (NCT04975308), active not recruiting at 874 patients, est. primary completion 2027-08.
    source: https://clinicaltrials.gov/study/NCT04975308  (ORIGIN)
    verbatim: "NCT identifier NCT04975308: 'A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer' - Phase: Phase 3, Status: ACTIVE_NOT_RECRUITING, Enrollment: 874"
    as of: 2026-06-11T19:18:23.574Z

[LLY-10] Eli Lilly is testing imlunestrant in Breast Neoplasms: a Phase 3 trial (NCT05514054), active not recruiting at 8000 patients, est. primary completion 2032-03.
    source: https://clinicaltrials.gov/study/NCT05514054  (ORIGIN)
    verbatim: "NCT identifier NCT05514054: 'A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer' - Phase: Phase 3, Status: ACTIVE_NOT_RECRUITING, Enrollment: 8000"
    as of: 2026-06-11T19:18:23.574Z

[LLY-11] Eli Lilly is testing its candidate in Breast Cancer: a Phase 1 trial (NCT04647487), completed at 87 patients, primary completion (registry) 2022-11-11.
    source: https://clinicaltrials.gov/study/NCT04647487  (ORIGIN)
    verbatim: "NCT identifier NCT04647487: 'A Study of LY3484356 in Women With Breast Cancer Before Having Surgery' - Phase: Phase 1, Status: COMPLETED, Enrollment: 87"
    as of: 2026-06-11T19:18:23.574Z

[LLY-12] Eli Lilly is testing its candidate in Breast Cancer: a Phase 1/Phase 2 trial (NCT05768139), recruiting toward 880 patients, est. primary completion 2030-07.
    source: https://clinicaltrials.gov/study/NCT05768139  (ORIGIN)
    verbatim: "NCT identifier NCT05768139: 'First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors' - Phase: Phase 1/Phase 2, Status: RECRUITING, Enrollment: 880"
    as of: 2026-06-11T19:18:23.574Z

[LLY-13] Eli Lilly is testing its candidate in Breast Neoplasms: a Phase 1 trial (NCT07114601), recruiting toward 421 patients, est. primary completion 2035-04.
    source: https://clinicaltrials.gov/study/NCT07114601  (ORIGIN)
    verbatim: "NCT identifier NCT07114601: 'A Study of LY4257496 in Participants With Cancer (OMNIRAY)' - Phase: Phase 1, Status: RECRUITING, Enrollment: 421"
    as of: 2026-06-11T19:18:23.574Z

[LLY-14] Eli Lilly is testing imlunestrant in Breast Neoplasms: a Phase 2 trial (NCT07287098), not yet recruiting at 600 patients, est. primary completion 2029-12.
    source: https://clinicaltrials.gov/study/NCT07287098  (ORIGIN)
    verbatim: "NCT identifier NCT07287098: 'A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer' - Phase: Phase 2, Status: NOT_YET_RECRUITING, Enrollment: 600"
    as of: 2026-06-11T19:18:23.574Z

[LLY-15] Eli Lilly is testing imlunestrant in Healthy: a Phase 1 trial (NCT05444556), completed at 113 patients, primary completion (registry) 2022-11-02.
    source: https://clinicaltrials.gov/study/NCT05444556  (ORIGIN)
    verbatim: "NCT identifier NCT05444556: 'A Study of Imlunestrant (LY3484356) in Female Healthy Participants' - Phase: Phase 1, Status: COMPLETED, Enrollment: 113"
    as of: 2026-06-11T19:18:23.574Z

[LLY-16] Eli Lilly is testing imlunestrant in Healthy: a Phase 1 trial (NCT05509816), completed at 20 patients, primary completion (registry) 2022-11-30.
    source: https://clinicaltrials.gov/study/NCT05509816  (ORIGIN)
    verbatim: "NCT identifier NCT05509816: 'A Study of Imlunestrant (LY3484356) in Healthy Women' - Phase: Phase 1, Status: COMPLETED, Enrollment: 20"
    as of: 2026-06-11T19:18:23.574Z

[LLY-17] Eli Lilly is testing olaratumab in Sarcoma, Soft Tissue: a Phase 1 trial (NCT03985722), unknown at 28 patients, est. primary completion 2024-05-05.
    source: https://clinicaltrials.gov/study/NCT03985722  (ORIGIN)
    verbatim: "NCT identifier NCT03985722: 'Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients' - Phase: Phase 1, Status: UNKNOWN, Enrollment: 28"
    as of: 2026-06-11T19:18:24.093Z

[LLY-18] Eli Lilly is testing olaratumab in Leiomyosarcoma: a Phase 1 trial (NCT03437070), withdrawn, primary completion on record 2023-06.
    source: https://clinicaltrials.gov/study/NCT03437070  (ORIGIN)
    verbatim: "NCT identifier NCT03437070: 'Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma' - Phase: Phase 1, Status: WITHDRAWN, Enrollment: 0"
    as of: 2026-06-11T19:18:24.093Z

[LLY-19] Eli Lilly is testing olaratumab in Gastrointestinal Stromal Tumor (GIST): a Phase 2 trial (NCT01316263), terminated at 21 patients, primary completion on record 2012-11.
    source: https://clinicaltrials.gov/study/NCT01316263  (ORIGIN)
    verbatim: "NCT identifier NCT01316263: 'A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors' - Phase: Phase 2, Status: TERMINATED, Enrollment: 21"
    as of: 2026-06-11T19:18:24.093Z

[LLY-20] Eli Lilly is testing olaratumab in Adult Glioblastoma Multiforme: a Phase 2 trial (NCT00895180), completed at 80 patients, primary completion (registry) 2014-03-04.
    source: https://clinicaltrials.gov/study/NCT00895180  (ORIGIN)
    verbatim: "NCT identifier NCT00895180: 'Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme' - Phase: Phase 2, Status: COMPLETED, Enrollment: 80"
    as of: 2026-06-11T19:18:24.093Z

[LLY-21] Eli Lilly is testing its candidate in Solid Tumors: a Phase 1 trial (NCT00768391), completed at 20 patients, primary completion (registry) 2010-01.
    source: https://clinicaltrials.gov/study/NCT00768391  (ORIGIN)
    verbatim: "NCT identifier NCT00768391: 'Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available' - Phase: Phase 1, Status: COMPLETED, Enrollment: 20"
    as of: 2026-06-11T19:18:24.093Z

[LLY-22] Eli Lilly is testing olaratumab in Soft Tissue Sarcoma: a Phase 3 trial (NCT02451943), completed at 509 patients, primary completion (registry) 2024-06-27.
    source: https://clinicaltrials.gov/study/NCT02451943  (ORIGIN)
    verbatim: "NCT identifier NCT02451943: 'A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma' - Phase: Phase 3, Status: COMPLETED, Enrollment: 509"
    as of: 2026-06-11T19:18:24.093Z

[LLY-23] Eli Lilly is testing olaratumab in Malignancy: a Phase 1 trial (NCT01199822), completed at 16 patients, primary completion (registry) 2012-01.
    source: https://clinicaltrials.gov/study/NCT01199822  (ORIGIN)
    verbatim: "NCT identifier NCT01199822: 'Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors' - Phase: Phase 1, Status: COMPLETED, Enrollment: 16"
    as of: 2026-06-11T19:18:24.093Z

[LLY-24] Eli Lilly is testing olaratumab in Neoplasm: a Phase 1 trial (NCT02377752), completed at 25 patients, primary completion (registry) 2020-01-14.
    source: https://clinicaltrials.gov/study/NCT02377752  (ORIGIN)
    verbatim: "NCT identifier NCT02377752: 'A Study of Olaratumab in Japanese Participants With Advanced Cancer' - Phase: Phase 1, Status: COMPLETED, Enrollment: 25"
    as of: 2026-06-11T19:18:24.093Z

[LLY-25] Eli Lilly is testing olaratumab in Metastatic Pancreatic Cancer: a Phase 1/Phase 2 trial (NCT03086369), completed at 184 patients, primary completion (registry) 2021-06-17.
    source: https://clinicaltrials.gov/study/NCT03086369  (ORIGIN)
    verbatim: "NCT identifier NCT03086369: 'A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer' - Phase: Phase 1/Phase 2, Status: COMPLETED, Enrollment: 184"
    as of: 2026-06-11T19:18:24.093Z

[LLY-26] Eli Lilly is testing olaratumab in Soft Tissue Sarcoma: a Phase 1 trial (NCT03126591), completed at 41 patients, primary completion (registry) 2023-02-21.
    source: https://clinicaltrials.gov/study/NCT03126591  (ORIGIN)
    verbatim: "NCT identifier NCT03126591: 'A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma' - Phase: Phase 1, Status: COMPLETED, Enrollment: 41"
    as of: 2026-06-11T19:18:24.093Z

[LLY-27] Eli Lilly is testing olaratumab in Ovarian Neoplasms: a Phase 2 trial (NCT00913835), completed at 125 patients, primary completion (registry) 2014-02.
    source: https://clinicaltrials.gov/study/NCT00913835  (ORIGIN)
    verbatim: "NCT identifier NCT00913835: 'A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer' - Phase: Phase 2, Status: COMPLETED, Enrollment: 125"
    as of: 2026-06-11T19:18:24.093Z

[LLY-28] Eli Lilly is testing olaratumab in Sarcoma, Soft Tissue: a Phase 1 trial (NCT02326025), completed at 49 patients, primary completion (registry) 2018-11-02.
    source: https://clinicaltrials.gov/study/NCT02326025  (ORIGIN)
    verbatim: "NCT identifier NCT02326025: 'A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma' - Phase: Phase 1, Status: COMPLETED, Enrollment: 49"
    as of: 2026-06-11T19:18:24.093Z

[LLY-29] Eli Lilly is testing olaratumab in Soft Tissue Sarcoma: a Phase 1 trial (NCT06537596), recruiting toward 50 patients, est. primary completion 2026-08.
    source: https://clinicaltrials.gov/study/NCT06537596  (ORIGIN)
    verbatim: "NCT identifier NCT06537596: '89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma' - Phase: Phase 1, Status: RECRUITING, Enrollment: 50"
    as of: 2026-06-11T19:18:24.093Z

[LLY-30] Eli Lilly is testing olaratumab in Soft Tissue Sarcoma: a Phase 1/Phase 2 trial (NCT02659020), completed at 310 patients, primary completion (registry) 2021-04-27.
    source: https://clinicaltrials.gov/study/NCT02659020  (ORIGIN)
    verbatim: "NCT identifier NCT02659020: 'A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma' - Phase: Phase 1/Phase 2, Status: COMPLETED, Enrollment: 310"
    as of: 2026-06-11T19:18:24.093Z

[LLY-31] Eli Lilly is testing olaratumab in Advanced Soft Tissue Sarcoma: a Phase 2 trial (NCT03698227), terminated at 2 patients, primary completion on record 2020-06-25.
    source: https://clinicaltrials.gov/study/NCT03698227  (ORIGIN)
    verbatim: "NCT identifier NCT03698227: 'OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients' - Phase: Phase 2, Status: TERMINATED, Enrollment: 2"
    as of: 2026-06-11T19:18:24.093Z

[LLY-32] Eli Lilly is testing olaratumab in Sarcoma, Soft Tissue: a Phase 1/Phase 2 trial (NCT01185964), completed at 148 patients, primary completion (registry) 2016-04.
    source: https://clinicaltrials.gov/study/NCT01185964  (ORIGIN)
    verbatim: "NCT identifier NCT01185964: 'A Study of Olaratumab in Soft Tissue Sarcoma' - Phase: Phase 1/Phase 2, Status: COMPLETED, Enrollment: 148"
    as of: 2026-06-11T19:18:24.093Z

[LLY-33] Eli Lilly is testing olaratumab in Non-Small Cell Lung Cancer: a Phase 2 trial (NCT00918203), completed at 137 patients, primary completion (registry) 2017-11-17.
    source: https://clinicaltrials.gov/study/NCT00918203  (ORIGIN)
    verbatim: "NCT identifier NCT00918203: 'A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)' - Phase: Phase 2, Status: COMPLETED, Enrollment: 137"
    as of: 2026-06-11T19:18:24.093Z

[LLY-34] Eli Lilly is testing olaratumab in Neoplasm Metastasis: a Phase 1 trial (NCT02677116), completed at 68 patients, primary completion (registry) 2019-04-03.
    source: https://clinicaltrials.gov/study/NCT02677116  (ORIGIN)
    verbatim: "NCT identifier NCT02677116: 'A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer' - Phase: Phase 1, Status: COMPLETED, Enrollment: 68"
    as of: 2026-06-11T19:18:24.093Z

[LLY-35] Olaratumab appears in 728 FDA adverse-event reports (FAERS); the most frequent are off label use (51), febrile neutropenia (47), drug ineffective (44).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"olaratumab"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='olaratumab': total=728, top_reactions=[{"term": "OFF LABEL USE", "count": 51}, {"term": "FEBRILE NEUTROPENIA", "count": 47}, {"term": "DRUG INEFFECTIVE", "count": 44}]"
    as of: 2026-06-11T19:18:25.026Z

[LLY-36] Eli Lilly is testing its candidate in Diabetes Mellitus, Type 1: a Phase 1 trial (NCT03449433), completed at 80 patients, primary completion (registry) 2018-08-14.
    source: https://clinicaltrials.gov/study/NCT03449433  (ORIGIN)
    verbatim: "NCT identifier NCT03449433: 'A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus' - Phase: Phase 1, Status: COMPLETED, Enrollment: 80"
    as of: 2026-06-11T19:18:23.517Z

[LLY-37] Eli Lilly is testing its candidate in Fibromyalgia: a Phase 4 trial (NCT00673452), completed at 530 patients, primary completion (registry) 2009-07.
    source: https://clinicaltrials.gov/study/NCT00673452  (ORIGIN)
    verbatim: "NCT identifier NCT00673452: 'A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia' - Phase: Phase 4, Status: COMPLETED, Enrollment: 530"
    as of: 2026-06-11T19:18:23.517Z

[LLY-38] Eli Lilly is testing its candidate in Non-Small-Cell Lung Cancer: a Phase 1/Phase 2 trial (NCT00482014), completed at 120 patients, primary completion (registry) 2011-10.
    source: https://clinicaltrials.gov/study/NCT00482014  (ORIGIN)
    verbatim: "NCT identifier NCT00482014: 'A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer' - Phase: Phase 1/Phase 2, Status: COMPLETED, Enrollment: 120"
    as of: 2026-06-11T19:18:23.517Z

[LLY-39] Eli Lilly is testing its candidate in Breast Cancer: a Phase 3 trial (NCT00191152), completed at 475 patients, primary completion (registry) 2008-11.
    source: https://clinicaltrials.gov/study/NCT00191152  (ORIGIN)
    verbatim: "NCT identifier NCT00191152: 'A Phase III Trial For Patients With Metastatic Breast Cancer' - Phase: Phase 3, Status: COMPLETED, Enrollment: 475"
    as of: 2026-06-11T19:18:23.517Z

[LLY-40] Eli Lilly is testing its candidate in Diabetes Mellitus, Type 2: a Phase 1 trial (NCT01247363), completed at 20 patients, primary completion (registry) 2011-03.
    source: https://clinicaltrials.gov/study/NCT01247363  (ORIGIN)
    verbatim: "NCT identifier NCT01247363: 'A Study of LY2608204 in Patients With Type 2 Diabetes' - Phase: Phase 1, Status: COMPLETED, Enrollment: 20"
    as of: 2026-06-11T19:18:23.517Z

[LLY-41] Eli Lilly is testing its candidate in Healthy Volunteers: a Phase 1 trial (NCT01618916), completed at 51 patients, primary completion (registry) 2013-02.
    source: https://clinicaltrials.gov/study/NCT01618916  (ORIGIN)
    verbatim: "NCT identifier NCT01618916: 'A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol' - Phase: Phase 1, Status: COMPLETED, Enrollment: 51"
    as of: 2026-06-11T19:18:23.517Z

[LLY-42] Eli Lilly is testing its candidate in Nonsquamous Non-Small Cell Neoplasm of Lung: a Phase 2 trial (NCT01473563), completed at 52 patients, primary completion (registry) 2013-09.
    source: https://clinicaltrials.gov/study/NCT01473563  (ORIGIN)
    verbatim: "NCT identifier NCT01473563: 'A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)' - Phase: Phase 2, Status: COMPLETED, Enrollment: 52"
    as of: 2026-06-11T19:18:23.517Z

[LLY-43] Eli Lilly is testing its candidate in Acute Coronary Syndromes: a Phase 3 trial (NCT01015287), completed at 4033 patients, primary completion (registry) 2013-02.
    source: https://clinicaltrials.gov/study/NCT01015287  (ORIGIN)
    verbatim: "NCT identifier NCT01015287: 'A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction' - Phase: Phase 3, Status: COMPLETED, Enrollment: 4033"
    as of: 2026-06-11T19:18:23.517Z

[LLY-44] Eli Lilly is testing its candidate in Urologic Neoplasms: a Phase 2 trial (NCT00191971), completed at 40 patients, primary completion (registry) 2006-09.
    source: https://clinicaltrials.gov/study/NCT00191971  (ORIGIN)
    verbatim: "NCT identifier NCT00191971: '2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen' - Phase: Phase 2, Status: COMPLETED, Enrollment: 40"
    as of: 2026-06-11T19:18:23.517Z

[LLY-45] Eli Lilly is testing its candidate in Diabetes Mellitus, Type 2: a Phase 4 trial (NCT01215955), completed at 1117 patients, primary completion (registry) 2013-01.
    source: https://clinicaltrials.gov/study/NCT01215955  (ORIGIN)
    verbatim: "NCT identifier NCT01215955: 'Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes' - Phase: Phase 4, Status: COMPLETED, Enrollment: 1117"
    as of: 2026-06-11T19:18:23.517Z

[LLY-46] Eli Lilly is testing its candidate in Systemic Lupus Erythematosus: a Phase 3 trial (NCT01488708), terminated at 1518 patients, primary completion on record 2015-10.
    source: https://clinicaltrials.gov/study/NCT01488708  (ORIGIN)
    verbatim: "NCT identifier NCT01488708: 'On Open-Label Study in Participants With Systemic Lupus Erythematosus' - Phase: Phase 3, Status: TERMINATED, Enrollment: 1518"
    as of: 2026-06-11T19:18:23.517Z

[LLY-47] Eli Lilly is testing its candidate in Breast Cancer: a Phase 2 trial (NCT00192062), completed at 80 patients, primary completion (registry) 2007-06.
    source: https://clinicaltrials.gov/study/NCT00192062  (ORIGIN)
    verbatim: "NCT identifier NCT00192062: 'A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer' - Phase: Phase 2, Status: COMPLETED, Enrollment: 80"
    as of: 2026-06-11T19:18:23.517Z

[LLY-48] Eli Lilly is testing its candidate in Breast Cancer: a Phase 3 trial (NCT02763566), active not recruiting at 463 patients, est. primary completion 2028-03.
    source: https://clinicaltrials.gov/study/NCT02763566  (ORIGIN)
    verbatim: "NCT identifier NCT02763566: 'A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer' - Phase: Phase 3, Status: ACTIVE_NOT_RECRUITING, Enrollment: 463"
    as of: 2026-06-11T19:18:23.517Z

[LLY-49] Eli Lilly is testing its candidate in Lipoprotein Disorder: a Phase 2 trial (NCT05565742), completed at 320 patients, primary completion (registry) 2024-10-17.
    source: https://clinicaltrials.gov/study/NCT05565742  (ORIGIN)
    verbatim: "NCT identifier NCT05565742: 'A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]' - Phase: Phase 2, Status: COMPLETED, Enrollment: 320"
    as of: 2026-06-11T19:18:23.517Z

[LLY-50] Eli Lilly is testing its candidate in Chronic Low-back Pain: a Phase 2 trial (NCT04529096), completed at 149 patients, primary completion (registry) 2021-10-04.
    source: https://clinicaltrials.gov/study/NCT04529096  (ORIGIN)
    verbatim: "NCT identifier NCT04529096: 'Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain' - Phase: Phase 2, Status: COMPLETED, Enrollment: 149"
    as of: 2026-06-11T19:18:23.517Z

[LLY-51] Eli Lilly is testing its candidate in Type 2 Diabetes: a Phase 3 trial (NCT06297603), active not recruiting at 320 patients, est. primary completion 2026-11.
    source: https://clinicaltrials.gov/study/NCT06297603  (ORIGIN)
    verbatim: "NCT identifier NCT06297603: 'Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)' - Phase: Phase 3, Status: ACTIVE_NOT_RECRUITING, Enrollment: 320"
    as of: 2026-06-11T19:18:23.517Z

[LLY-52] Eli Lilly is testing its candidate in Schizophrenia: a Phase 1/Phase 2 trial (NCT00485810), completed at 31 patients, primary completion (registry) 2004-11.
    source: https://clinicaltrials.gov/study/NCT00485810  (ORIGIN)
    verbatim: "NCT identifier NCT00485810: 'Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia' - Phase: Phase 1/Phase 2, Status: COMPLETED, Enrollment: 31"
    as of: 2026-06-11T19:18:23.517Z

[LLY-53] Eli Lilly is testing selpercatinib in Non-Small Cell Lung Cancer: a Phase 1/Phase 2 trial (NCT03157128), active not recruiting at 857 patients, est. primary completion 2027-02.
    source: https://clinicaltrials.gov/study/NCT03157128  (ORIGIN)
    verbatim: "NCT identifier NCT03157128: 'A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)' - Phase: Phase 1/Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 857"
    as of: 2026-06-11T19:18:25.511Z

[LLY-54] Eli Lilly is testing selpercatinib in Non-Small Cell Lung Cancer: a Phase 3 trial (NCT04194944), active not recruiting at 261 patients, est. primary completion 2030-06.
    source: https://clinicaltrials.gov/study/NCT04194944  (ORIGIN)
    verbatim: "NCT identifier NCT04194944: 'A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer' - Phase: Phase 3, Status: ACTIVE_NOT_RECRUITING, Enrollment: 261"
    as of: 2026-06-11T19:18:25.511Z

[LLY-55] Eli Lilly is testing selpercatinib in Cachexia-Anorexia Syndrome: a EARLY_Phase 1 trial (NCT07146893), not yet recruiting at 7 patients, est. primary completion 2028-02-23.
    source: https://clinicaltrials.gov/study/NCT07146893  (ORIGIN)
    verbatim: "NCT identifier NCT07146893: 'Feasibility Study for Repurposing RET Inhibitors' - Phase: EARLY_Phase 1, Status: NOT_YET_RECRUITING, Enrollment: 7"
    as of: 2026-06-11T19:18:25.511Z

[LLY-56] Eli Lilly is testing selpercatinib in Solid Tumor: a Phase 2 trial (NCT04280081), active not recruiting at 77 patients, est. primary completion 2027-11.
    source: https://clinicaltrials.gov/study/NCT04280081  (ORIGIN)
    verbatim: "NCT identifier NCT04280081: 'A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 77"
    as of: 2026-06-11T19:18:25.511Z

[LLY-57] Eli Lilly is testing selpercatinib in Non Small Cell Lung Cancer: a N/A trial (NCT03906331), approved for marketing.
    source: https://clinicaltrials.gov/study/NCT03906331  (ORIGIN)
    verbatim: "NCT identifier NCT03906331: 'Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation' - Phase: N/A, Status: APPROVED_FOR_MARKETING, Enrollment: None"
    as of: 2026-06-11T19:18:25.511Z

[LLY-58] Eli Lilly is testing selpercatinib in Healthy: a Phase 1 trial (NCT05338515), completed at 18 patients, primary completion (registry) 2019-03-26.
    source: https://clinicaltrials.gov/study/NCT05338515  (ORIGIN)
    verbatim: "NCT identifier NCT05338515: 'A Study of Selpercatinib (LY3527723) in Healthy Participants' - Phase: Phase 1, Status: COMPLETED, Enrollment: 18"
    as of: 2026-06-11T19:18:25.511Z

[LLY-59] Eli Lilly is testing selpercatinib in Recurrent Lung Non-Small Cell Carcinoma: a Phase 2 trial (NCT04268550), active not recruiting at 124 patients, est. primary completion 2026-12-01.
    source: https://clinicaltrials.gov/study/NCT04268550  (ORIGIN)
    verbatim: "NCT identifier NCT04268550: 'Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 124"
    as of: 2026-06-11T19:18:25.511Z

[LLY-60] Eli Lilly is testing selpercatinib in Healthy: a Phase 1 trial (NCT05324124), completed at 46 patients, primary completion (registry) 2022-06-22.
    source: https://clinicaltrials.gov/study/NCT05324124  (ORIGIN)
    verbatim: "NCT identifier NCT05324124: 'A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants' - Phase: Phase 1, Status: COMPLETED, Enrollment: 46"
    as of: 2026-06-11T19:18:25.511Z

[LLY-61] Eli Lilly is testing selpercatinib in Healthy: a Phase 1 trial (NCT04782076), completed at 36 patients, primary completion (registry) 2021-05-17.
    source: https://clinicaltrials.gov/study/NCT04782076  (ORIGIN)
    verbatim: "NCT identifier NCT04782076: 'A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants' - Phase: Phase 1, Status: COMPLETED, Enrollment: 36"
    as of: 2026-06-11T19:18:25.511Z

[LLY-62] Eli Lilly is testing selpercatinib in Healthy: a Phase 1 trial (NCT05630287), completed at 12 patients, primary completion (registry) 2018-09-24.
    source: https://clinicaltrials.gov/study/NCT05630287  (ORIGIN)
    verbatim: "NCT identifier NCT05630287: 'A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants' - Phase: Phase 1, Status: COMPLETED, Enrollment: 12"
    as of: 2026-06-11T19:18:25.511Z

[LLY-63] Eli Lilly is testing selpercatinib in Malignant Thyroid Gland Neoplasm: a Phase 2 trial (NCT04759911), active not recruiting at 30 patients, est. primary completion 2027-11-30.
    source: https://clinicaltrials.gov/study/NCT04759911  (ORIGIN)
    verbatim: "NCT identifier NCT04759911: 'Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 30"
    as of: 2026-06-11T19:18:25.511Z

[LLY-64] Eli Lilly is testing selpercatinib in Healthy: a Phase 1 trial (NCT05089019), completed at 224 patients, primary completion (registry) 2022-07-19.
    source: https://clinicaltrials.gov/study/NCT05089019  (ORIGIN)
    verbatim: "NCT identifier NCT05089019: 'A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants' - Phase: Phase 1, Status: COMPLETED, Enrollment: 224"
    as of: 2026-06-11T19:18:25.511Z

[LLY-65] Eli Lilly is testing selpercatinib in Differentiated Thyroid Cancer: a Phase 2 trial (NCT06458036), recruiting toward 13 patients, est. primary completion 2031-11-01.
    source: https://clinicaltrials.gov/study/NCT06458036  (ORIGIN)
    verbatim: "NCT identifier NCT06458036: 'Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)' - Phase: Phase 2, Status: RECRUITING, Enrollment: 13"
    as of: 2026-06-11T19:18:25.511Z

[LLY-66] Eli Lilly is testing selpercatinib in Healthy: a Phase 1 trial (NCT05469100), completed at 37 patients, primary completion (registry) 2019-08-07.
    source: https://clinicaltrials.gov/study/NCT05469100  (ORIGIN)
    verbatim: "NCT identifier NCT05469100: 'A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function' - Phase: Phase 1, Status: COMPLETED, Enrollment: 37"
    as of: 2026-06-11T19:18:25.511Z

[LLY-67] Eli Lilly is testing selpercatinib in Healthy: a Phase 1 trial (NCT05469113), completed at 16 patients, primary completion (registry) 2019-03-05.
    source: https://clinicaltrials.gov/study/NCT05469113  (ORIGIN)
    verbatim: "NCT identifier NCT05469113: 'A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants' - Phase: Phase 1, Status: COMPLETED, Enrollment: 16"
    as of: 2026-06-11T19:18:25.511Z

[LLY-68] Eli Lilly is testing selpercatinib in Medullary Thyroid Cancer: a Phase 1/Phase 2 trial (NCT03899792), active not recruiting at 36 patients, est. primary completion 2029-05.
    source: https://clinicaltrials.gov/study/NCT03899792  (ORIGIN)
    verbatim: "NCT identifier NCT03899792: 'A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors' - Phase: Phase 1/Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 36"
    as of: 2026-06-11T19:18:25.511Z

[LLY-69] Eli Lilly is testing selpercatinib in Healthy: a Phase 1 trial (NCT05468164), completed at 20 patients, primary completion (registry) 2018-09-13.
    source: https://clinicaltrials.gov/study/NCT05468164  (ORIGIN)
    verbatim: "NCT identifier NCT05468164: 'A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants' - Phase: Phase 1, Status: COMPLETED, Enrollment: 20"
    as of: 2026-06-11T19:18:25.511Z

[LLY-70] Eli Lilly is testing selpercatinib in Healthy: a Phase 1 trial (NCT05338476), completed at 16 patients, primary completion (registry) 2018-09-18.
    source: https://clinicaltrials.gov/study/NCT05338476  (ORIGIN)
    verbatim: "NCT identifier NCT05338476: 'A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants' - Phase: Phase 1, Status: COMPLETED, Enrollment: 16"
    as of: 2026-06-11T19:18:25.511Z

[LLY-71] Imlunestrant appears in 59 FDA adverse-event reports (FAERS); the most frequent are hyponatraemia (3), diarrhoea (2), headache (2).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"imlunestrant"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='imlunestrant': total=59, top_reactions=[{"term": "HYPONATRAEMIA", "count": 3}, {"term": "DIARRHOEA", "count": 2}, {"term": "HEADACHE", "count": 2}]"
    as of: 2026-06-11T19:18:23.879Z

[LLY-72] Selpercatinib appears in 915 FDA adverse-event reports (FAERS); the most frequent are malignant neoplasm progression (59), diarrhoea (31), blood creatinine increased (24).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"selpercatinib"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='selpercatinib': total=915, top_reactions=[{"term": "MALIGNANT NEOPLASM PROGRESSION", "count": 59}, {"term": "DIARRHOEA", "count": 31}, {"term": "BLOOD CREATININE INCREASED", "count": 24}]"
    as of: 2026-06-11T19:18:26.099Z

[LLY-73] A 2025 paper in Med (New York, N.Y.) reports that if it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide (PMID 39689708).
    source: https://pubmed.ncbi.nlm.nih.gov/39689708/  (ACCOUNTABLE_RELAY)
    verbatim: "Tumor-agnostic US Food and Drug Administration approvals are transforming oncology. They include larotrectinib/entrectinib/repotrectinib (NTRK fusions), selpercatinib (RET fusions), dabrafenib/trametinib (BRAFV600E mutations), pembrolizumab/dostarlimab (microsatellite instability), pembrolizumab (hi..."
    as of: 2026-06-11T19:18:25.694Z

[LLY-74] A 2024 paper in Cancer treatment reviews reports that if it's a target, it's a pan-cancer target: Tissue is not the issue (PMID 38522181).
    source: https://pubmed.ncbi.nlm.nih.gov/38522181/  (ACCOUNTABLE_RELAY)
    verbatim: "Cancer is traditionally diagnosed and treated on the basis of its organ of origin (e.g., lung or colon cancer). However, organ-of-origin diagnostics does not reveal the underlying oncogenic drivers. Fortunately, molecular diagnostics have advanced at a breathtaking pace, and it is increasingly appar..."
    as of: 2026-06-11T19:18:25.694Z

[LLY-75] A 2022 paper in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners reports that a contemporary review of rearranged during transfection-selective inhibitors (PMID 34590525).
    source: https://pubmed.ncbi.nlm.nih.gov/34590525/  (ACCOUNTABLE_RELAY)
    verbatim: "Rearranged during transfection genes are present in 1-2% of patients who have non-small cell lung cancer and 10-30% of patients with papillary thyroid cancer. The objective of this article is to review the current rearranged during transfection inhibitors indicated for patients with rearranged durin..."
    as of: 2026-06-11T19:18:25.694Z

[LLY-76] A 2019 paper in Nature medicine reports that activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms (PMID 31768065).
    source: https://pubmed.ncbi.nlm.nih.gov/31768065/  (ACCOUNTABLE_RELAY)
    verbatim: "Histiocytoses are clonal hematopoietic disorders frequently driven by mutations mapping to the BRAF and MEK1 and MEK2 kinases. Currently, however, the developmental origins of histiocytoses in patients are not well understood, and clinically meaningful therapeutic targets outside of BRAF and MEK are..."
    as of: 2026-06-11T19:18:25.694Z

[LLY-77] OpenTargets catalogs ESR1 (estrogen receptor 1) under Ensembl identifier ENSG00000091831.
    source: https://platform.opentargets.org/target/ENSG00000091831  (ACCOUNTABLE_RELAY)
    verbatim: "OpenTargets target search for 'ESR1': id=ENSG00000091831, name='ESR1', description='estrogen receptor 1'"
    as of: 2026-06-11T19:21:15.109Z

[LLY-78] OpenTargets catalogs RET (ret proto-oncogene) under Ensembl identifier ENSG00000165731.
    source: https://platform.opentargets.org/target/ENSG00000165731  (ACCOUNTABLE_RELAY)
    verbatim: "OpenTargets target search for 'RET': id=ENSG00000165731, name='RET', description='ret proto-oncogene'"
    as of: 2026-06-11T19:21:15.851Z

[LEGN-1] Legend Biotech is testing ciltacabtagene autoleucel in Multiple Myeloma: a Phase 1 trial (NCT06623630), recruiting toward 16 patients, est. primary completion 2028-05-31.
    source: https://clinicaltrials.gov/study/NCT06623630  (ORIGIN)
    verbatim: "NCT identifier NCT06623630: 'Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function' - Phase: Phase 1, Status: RECRUITING, Enrollment: 16"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-2] Legend Biotech is testing cilta-cel in Multiple Myeloma: a Phase 1 trial (NCT07200089), recruiting toward 52 patients, est. primary completion 2028-12-31.
    source: https://clinicaltrials.gov/study/NCT07200089  (ORIGIN)
    verbatim: "NCT identifier NCT07200089: 'Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)' - Phase: Phase 1, Status: RECRUITING, Enrollment: 52"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-3] Legend Biotech is testing cilta-cel in Multiple Myeloma: a Phase 3 trial (NCT04923893), active not recruiting at 743 patients, est. primary completion 2036-09-22.
    source: https://clinicaltrials.gov/study/NCT04923893  (ORIGIN)
    verbatim: "NCT identifier NCT04923893: 'A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy' - Phase: Phase 3, Status: ACTIVE_NOT_RECRUITING, Enrollment: 743"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-4] Legend Biotech is testing cilta-cel in Multiple Myeloma: a Phase 3 trial (NCT04181827), active not recruiting at 419 patients, est. primary completion 2029-04-09.
    source: https://clinicaltrials.gov/study/NCT04181827  (ORIGIN)
    verbatim: "NCT identifier NCT04181827: 'A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma' - Phase: Phase 3, Status: ACTIVE_NOT_RECRUITING, Enrollment: 419"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-5] Legend Biotech is testing its candidate in Multiple Myeloma: a Phase 2 trial (NCT03758417), terminated at 123 patients, primary completion on record 2025-10-20.
    source: https://clinicaltrials.gov/study/NCT03758417  (ORIGIN)
    verbatim: "NCT identifier NCT03758417: 'A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma' - Phase: Phase 2, Status: TERMINATED, Enrollment: 123"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-6] Legend Biotech is testing cilta-cel in Myeloma: a Phase 2 trial (NCT06947083), recruiting toward 39 patients, est. primary completion 2029-04.
    source: https://clinicaltrials.gov/study/NCT06947083  (ORIGIN)
    verbatim: "NCT identifier NCT06947083: 'Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma' - Phase: Phase 2, Status: RECRUITING, Enrollment: 39"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-7] Legend Biotech is testing ciltacabtagene autoleucel in Multiple Myeloma: a Phase 2 trial (NCT06550895), active not recruiting at 11 patients, est. primary completion 2027-08-26.
    source: https://clinicaltrials.gov/study/NCT06550895  (ORIGIN)
    verbatim: "NCT identifier NCT06550895: 'A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 11"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-8] Legend Biotech is testing ciltacabtagene autoleucel in Multiple Myeloma: a Phase 4 trial (NCT05201781), recruiting toward 295 patients, est. primary completion 2042-06-01.
    source: https://clinicaltrials.gov/study/NCT05201781  (ORIGIN)
    verbatim: "NCT identifier NCT05201781: 'A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel' - Phase: Phase 4, Status: RECRUITING, Enrollment: 295"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-9] Legend Biotech is testing ciltacabtagene autoleucel in Myeloma Multiple: a N/A trial (NCT06855121), recruiting toward 400 patients, est. primary completion 2037-12-01.
    source: https://clinicaltrials.gov/study/NCT06855121  (ORIGIN)
    verbatim: "NCT identifier NCT06855121: 'The Norwegian Immunotherapy in Multiple Myeloma Study' - Phase: N/A, Status: RECRUITING, Enrollment: 400"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-10] Legend Biotech is testing ciltacabtagene autoleucel in Multiple Myeloma: a N/A trial (NCT05346835), available.
    source: https://clinicaltrials.gov/study/NCT05346835  (ORIGIN)
    verbatim: "NCT identifier NCT05346835: 'Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma' - Phase: N/A, Status: AVAILABLE, Enrollment: None"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-11] Legend Biotech is testing its candidate in Refractory or Relapsed Multiple Myeloma: a Phase 1/Phase 2 trial (NCT03090659), unknown at 100 patients, est. primary completion 2023-12-31.
    source: https://clinicaltrials.gov/study/NCT03090659  (ORIGIN)
    verbatim: "NCT identifier NCT03090659: 'LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma' - Phase: Phase 1/Phase 2, Status: UNKNOWN, Enrollment: 100"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-12] Legend Biotech is testing ciltacabtagene autoleucel in Multiple Myeloma: a Phase 2 trial (NCT07149857), recruiting toward 60 patients, est. primary completion 2029-04-06.
    source: https://clinicaltrials.gov/study/NCT07149857  (ORIGIN)
    verbatim: "NCT identifier NCT07149857: 'A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel' - Phase: Phase 2, Status: RECRUITING, Enrollment: 60"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-13] Legend Biotech is testing cilta-cel in Multiple Myeloma: a Phase 2 trial (NCT05347485), completed at 86 patients, primary completion (registry) 2023-12-15.
    source: https://clinicaltrials.gov/study/NCT05347485  (ORIGIN)
    verbatim: "NCT identifier NCT05347485: 'A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma' - Phase: Phase 2, Status: COMPLETED, Enrollment: 86"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-14] Legend Biotech is testing ciltacabtagene autoleucel in High Risk Smoldering Multiple Myeloma: a Phase 2 trial (NCT06574126), recruiting toward 20 patients, est. primary completion 2032-09-30.
    source: https://clinicaltrials.gov/study/NCT06574126  (ORIGIN)
    verbatim: "NCT identifier NCT06574126: 'Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma' - Phase: Phase 2, Status: RECRUITING, Enrollment: 20"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-15] Legend Biotech is testing ciltacabtagene autoleucel in Multiple Myeloma: a Phase 3 trial (NCT05257083), active not recruiting at 759 patients, est. primary completion 2040-08.
    source: https://clinicaltrials.gov/study/NCT05257083  (ORIGIN)
    verbatim: "NCT identifier NCT05257083: 'A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma' - Phase: Phase 3, Status: ACTIVE_NOT_RECRUITING, Enrollment: 759"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-16] Legend Biotech is testing ciltacabtagene autoleucel in Recurrent Multiple Myeloma: a Phase 2 trial (NCT06940297), recruiting toward 44 patients, est. primary completion 2031-08-15.
    source: https://clinicaltrials.gov/study/NCT06940297  (ORIGIN)
    verbatim: "NCT identifier NCT06940297: 'Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma' - Phase: Phase 2, Status: RECRUITING, Enrollment: 44"
    as of: 2026-06-11T19:18:08.054Z

[LEGN-17] Cilta-cel appears in 136 FDA adverse-event reports (FAERS); the most frequent are anaemia (11), lymphopenia (11), neutropenia (11).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"cilta-cel"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='cilta-cel': total=136, top_reactions=[{"term": "ANAEMIA", "count": 11}, {"term": "LYMPHOPENIA", "count": 11}, {"term": "NEUTROPENIA", "count": 11}]"
    as of: 2026-06-11T19:18:09.638Z

[LEGN-18] Ciltacabtagene autoleucel appears in 1679 FDA adverse-event reports (FAERS); the most frequent are cytokine release syndrome (153), immune effector cell-associated neurotoxicity syndrome (91), bacterial infection (49).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"ciltacabtagene autoleucel"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='ciltacabtagene autoleucel': total=1679, top_reactions=[{"term": "CYTOKINE RELEASE SYNDROME", "count": 153}, {"term": "IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME", "count": 91}, {"term": "BACTERIAL INFECTION", "count": 49}]"
    as of: 2026-06-11T19:18:08.868Z

[LEGN-19] Legend Biotech is testing its candidate in Gastric Cancer: a Phase 1 trial (NCT05539430), active not recruiting at 56 patients, est. primary completion 2027-12.
    source: https://clinicaltrials.gov/study/NCT05539430  (ORIGIN)
    verbatim: "NCT identifier NCT05539430: 'Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma' - Phase: Phase 1, Status: ACTIVE_NOT_RECRUITING, Enrollment: 56"
    as of: 2026-06-11T19:18:07.885Z

[LEGN-20] Legend Biotech is testing its candidate in Relapsed/Refractory Autoimmune Diseases: a EARLY_Phase 1 trial (NCT07095075), recruiting toward 36 patients, est. primary completion 2029-12-31.
    source: https://clinicaltrials.gov/study/NCT07095075  (ORIGIN)
    verbatim: "NCT identifier NCT07095075: 'A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases' - Phase: EARLY_Phase 1, Status: RECRUITING, Enrollment: 36"
    as of: 2026-06-11T19:18:07.885Z

[LEGN-21] A 2026 paper in Clinical epidemiology reports that real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple Myeloma (PMID 42227005).
    source: https://pubmed.ncbi.nlm.nih.gov/42227005/  (ACCOUNTABLE_RELAY)
    verbatim: "Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell (CAR-T) therapy for relapsed/refractory multiple myeloma (RRMM) approved after 1 prior line of therapy (LOT). Non-immune effector cell-associated neurotoxicity syndrome (ICANS) neurologic events (NEs) may occur following inf..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-22] A 2026 paper in Journal of hematology & oncology reports that standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis (PMID 42163304).
    source: https://pubmed.ncbi.nlm.nih.gov/42163304/  (ACCOUNTABLE_RELAY)
    verbatim: "Ciltacabtagene autoleucel (cilta-cel) is a BCMA-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed or refractory multiple myeloma (RRMM). Following the CARTITUDE-1 results in heavily pretreated patients, the randomized phase 3 CARTITUDE-4 trial demonstrated superior progre..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-23] A 2026 paper in Clinical lymphoma, myeloma & leukemia reports that non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies (PMID 42161729).
    source: https://pubmed.ncbi.nlm.nih.gov/42161729/  (ACCOUNTABLE_RELAY)
    verbatim: "B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). However, emerging non-immune effector cell-associated neurotoxicity syndrome (non-ICANS) neurologic events-including cranial nerv..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-24] A 2026 paper in Transplantation and cellular therapy reports that impact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma (PMID 42144192).
    source: https://pubmed.ncbi.nlm.nih.gov/42144192/  (ACCOUNTABLE_RELAY)
    verbatim: "Chimeric antigen receptor (CAR) T cell therapy revolutionized treatment for relapsed/refractory multiple myeloma (RRMM). The standard lymphodepletion (LDP) regimen is fludarabine and cyclophosphamide (Flu/Cy), but bendamustine has shown comparable efficacy with lower toxicity and is a potentially sa..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-25] A 2026 paper in Bone marrow transplantation reports that patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma (PMID 42115674).
    source: https://pubmed.ncbi.nlm.nih.gov/42115674/  (ACCOUNTABLE_RELAY)
    verbatim: "This was the first study to assess patient-reported outcome (PRO) trajectories among patients with relapsed/refractory multiple myeloma (RRMM) receiving standard of care chimeric antigen receptor T-cell therapy (CAR-T) and to compare PRO trajectories by treatment group, idecabtagene vicleucel (ide-c..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-26] A 2026 paper in American journal of hematology reports that hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis (PMID 42086512).
    source: https://pubmed.ncbi.nlm.nih.gov/42086512/  (ACCOUNTABLE_RELAY)
    verbatim: "Chimeric Antigen Receptor T-cell Immunotherapy represents a breakthrough in treating relapsed/refractory hematologic malignancies, yet immune-related adverse events, particularly hemophagocytic lymphohistiocytosis (HLH), also known as immune effector cell-associated HLH-like syndrome (IEC-HS), are r..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-27] A 2026 paper in JCI insight reports that detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma (PMID 42084945).
    source: https://pubmed.ncbi.nlm.nih.gov/42084945/  (ACCOUNTABLE_RELAY)
    verbatim: "Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized treatment for relapsed/refractory multiple myeloma (RRMM). However, cytokine release syndrome (CRS), a common and potentially severe complication, requires inpatient monitoring, limiting access and increasing costs. Wearable devi..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-28] A 2026 paper in Current medical research and opinion reports that clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptoms (PMID 42057607).
    source: https://pubmed.ncbi.nlm.nih.gov/42057607/  (ACCOUNTABLE_RELAY)
    verbatim: "Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, has shown deep and durable responses in clinical trials for relapsed/refractory multiple myeloma (RRMM). This study aimed to provide a descriptive evaluation of outcomes among patien..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-29] A 2026 paper in Nature medicine reports that ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial (PMID 42010117).
    source: https://pubmed.ncbi.nlm.nih.gov/42010117/  (ACCOUNTABLE_RELAY)
    verbatim: "High-risk smoldering multiple myeloma (HR-SMM) carries an increased risk of progression to multiple myeloma, making it an ideal setting to test whether chimeric antigen receptor (CAR) T cell therapy can achieve curative outcomes. Here in this phase 2 study, patients with HR-SMM received ciltacabtage..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-30] A 2026 paper in Frontiers in immunology reports that reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case report (PMID 42004964).
    source: https://pubmed.ncbi.nlm.nih.gov/42004964/  (ACCOUNTABLE_RELAY)
    verbatim: "Ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T therapy, is approved for relapsed/refractory multiple myeloma (RRMM). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common, but reversible cerebral vasoconstriction syndrome (RCVS) i..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-31] A 2026 paper in Kidney medicine reports that minimal Change Disease Following B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy (PMID 42004656).
    source: https://pubmed.ncbi.nlm.nih.gov/42004656/  (ACCOUNTABLE_RELAY)
    verbatim: "Acute kidney injury (AKI) is a well-recognized complication of chimeric antigen receptor (CAR) T-cell therapy, typically attributed to cytokine release syndrome and acute tubular injury. However, glomerular disease post CAR-T cell is rare. We report a case of minimal change disease presenting with A..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-32] A 2026 paper in Oncology and therapy reports that real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases (PMID 42000954).
    source: https://pubmed.ncbi.nlm.nih.gov/42000954/  (ACCOUNTABLE_RELAY)
    verbatim: "Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved in the USA for relapsed or refractory multiple myeloma (RRMM) as early as following first relapse, based on pivotal CARTITUDE-1 ( 4 prior lines of therapy [LOT]) and CARTI..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-33] A 2026 paper in Blood cancer journal reports that safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study (PMID 41980929).
    source: https://pubmed.ncbi.nlm.nih.gov/41980929/  (ACCOUNTABLE_RELAY)
    verbatim: "Ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, was approved in 2022 for heavily pretreated relapsed/refractory multiple myeloma (RRMM). This study evaluates the safety and efficacy of cilta-cel in RRMM patients report..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-34] A 2026 paper in Blood cancer journal reports that dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy (PMID 41935039).
    source: https://pubmed.ncbi.nlm.nih.gov/41935039/  (ACCOUNTABLE_RELAY)
    verbatim: "There is limited systemic data on the dynamics of BCMA-target antigen expression with BCMA CAR-T at relapse. We analyzed 76 patients receiving standard-of-care BCMA-directed CAR-T who underwent real-time BCMA expression evaluation at baseline (n = 50), relapse (6), or both (20) using flow cytometry..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-35] A 2026 paper in American journal of hematology reports that navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis (PMID 41914448).
    source: https://pubmed.ncbi.nlm.nih.gov/41914448/  (ACCOUNTABLE_RELAY)
    verbatim: "Patients with relapsed/refractory multiple myeloma (RRMM) who are penta-drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T-cell-redirecting therapies. Selinex..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-36] A 2026 paper in Cancers reports that real-World Experience with Approved CAR T-Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in 1272 Relapsed/Refractory Multiple Myeloma Patients (PMID 41899614).
    source: https://pubmed.ncbi.nlm.nih.gov/41899614/  (ACCOUNTABLE_RELAY)
    verbatim: "Background: Ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) have transformed the treatment landscape of relapsed/refractory multiple myeloma (RRMM). Given their recent regulatory approval and limited availability, mainly due to logistical issues, real-world data remain sca..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-37] A 2026 paper in Blood advances reports that dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma (PMID 41894686).
    source: https://pubmed.ncbi.nlm.nih.gov/41894686/  (ACCOUNTABLE_RELAY)
    verbatim: "Increased absolute lymphocyte count (ALC) may predict risk of treatment-related mortality and atypical neurologic events among patients receiving chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory multiple myeloma. In this study, we analyzed the clinical outcomes of patients re..."
    as of: 2026-06-11T19:18:08.136Z

[LEGN-38] A 2026 paper in Blood advances reports that non-ICANS Neurologic Toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients (PMID 41886632).
    source: https://pubmed.ncbi.nlm.nih.gov/41886632/  (ACCOUNTABLE_RELAY)
    verbatim: "B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapies have drastically improved outcomes for patients with relapsed or refractory multiple myeloma. While CAR-T associated cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICAN..."
    as of: 2026-06-11T19:18:09.216Z

[LEGN-39] A 2026 paper in Advances in therapy reports that fREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA (PMID 41874852).
    source: https://pubmed.ncbi.nlm.nih.gov/41874852/  (ACCOUNTABLE_RELAY)
    verbatim: "Ciltacabtagene autoleucel (cilta-cel) was approved in February 2022 for adults with relapsed/refractory multiple myeloma (RRMM). This study evaluated US real-world outcomes among patients with RRMM treated with cilta-cel after  4 prior lines of therapy (4 + pLOT), overall and stratified by receipt..."
    as of: 2026-06-11T19:18:09.216Z

[LEGN-40] A 2026 paper in Annals of hematology reports that predictors of 30-day readmissions post-CAR-T in patients with relapsed/refractory multiple myeloma using the United States nationwide readmission database (PMID 41870621).
    source: https://pubmed.ncbi.nlm.nih.gov/41870621/  (ACCOUNTABLE_RELAY)
    verbatim: "B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy has changed the therapeutic landscape of relapsed/refractory multiple myeloma (RRMM). Despite the efficacy, these products have been associated with an adverse effect profile including cytokine release syndrom..."
    as of: 2026-06-11T19:18:09.216Z

[LEGN-41] A 2026 paper in Journal of medical economics reports that real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings (PMID 41848013).
    source: https://pubmed.ncbi.nlm.nih.gov/41848013/  (ACCOUNTABLE_RELAY)
    verbatim: "Ciltacabtagene autoleucel (cilta-cel) has demonstrated remarkable efficacy in relapsed or refractory multiple myeloma (RRMM). Outpatient (OP) administration of cilta-cel is increasingly used to improve access and reduce healthcare resource utilization (HCRU) compared to inpatient (IP) administration..."
    as of: 2026-06-11T19:18:09.216Z

[LEGN-42] OpenTargets catalogs TNFRSF17 (TNF receptor superfamily member 17) under Ensembl identifier ENSG00000048462.
    source: https://platform.opentargets.org/target/ENSG00000048462  (ACCOUNTABLE_RELAY)
    verbatim: "OpenTargets target search for 'TNFRSF17': id=ENSG00000048462, name='TNFRSF17', description='TNF receptor superfamily member 17'"
    as of: 2026-06-11T19:21:05.340Z

[KURA-1] Kura Oncology is testing ziftomenib in AML: a Phase 1 trial (NCT06001788), recruiting toward 171 patients, est. primary completion 2027-08.
    source: https://clinicaltrials.gov/study/NCT06001788  (ORIGIN)
    verbatim: "NCT identifier NCT06001788: 'Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia' - Phase: Phase 1, Status: RECRUITING, Enrollment: 171"
    as of: 2026-06-11T19:18:06.632Z

[KURA-2] Kura Oncology is testing ziftomenib in Acute Myeloid Leukemia (AML): a Phase 3 trial (NCT07007312), recruiting toward 1300 patients, est. primary completion 2031-11.
    source: https://clinicaltrials.gov/study/NCT07007312  (ORIGIN)
    verbatim: "NCT identifier NCT07007312: 'Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML' - Phase: Phase 3, Status: RECRUITING, Enrollment: 1300"
    as of: 2026-06-11T19:18:06.632Z

[KURA-3] Kura Oncology is testing ziftomenib in Acute Myeloid Leukemia: a Phase 1 trial (NCT06769490), recruiting toward 44 patients, est. primary completion 2030-09-15.
    source: https://clinicaltrials.gov/study/NCT06769490  (ORIGIN)
    verbatim: "NCT identifier NCT06769490: 'Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia' - Phase: Phase 1, Status: RECRUITING, Enrollment: 44"
    as of: 2026-06-11T19:18:06.632Z

[KURA-4] Kura Oncology is testing ziftomenib in Acute Myeloid Leukemia: a Phase 2 trial (NCT06930352), not yet recruiting at 70 patients, est. primary completion 2027-12-31.
    source: https://clinicaltrials.gov/study/NCT06930352  (ORIGIN)
    verbatim: "NCT identifier NCT06930352: 'Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy' - Phase: Phase 2, Status: NOT_YET_RECRUITING, Enrollment: 70"
    as of: 2026-06-11T19:18:06.632Z

[KURA-5] Kura Oncology is testing ziftomenib in Acute Myeloid Leukemia: a Phase 1 trial (NCT05735184), recruiting toward 420 patients, est. primary completion 2030-04.
    source: https://clinicaltrials.gov/study/NCT05735184  (ORIGIN)
    verbatim: "NCT identifier NCT05735184: 'A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML' - Phase: Phase 1, Status: RECRUITING, Enrollment: 420"
    as of: 2026-06-11T19:18:06.632Z

[KURA-6] Kura Oncology is testing ziftomenib in Acute Myeloid Leukemia: a Phase 1 trial (NCT07411586), not yet recruiting at 20 patients, est. primary completion 2029-01-14.
    source: https://clinicaltrials.gov/study/NCT07411586  (ORIGIN)
    verbatim: "NCT identifier NCT07411586: 'Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia' - Phase: Phase 1, Status: NOT_YET_RECRUITING, Enrollment: 20"
    as of: 2026-06-11T19:18:06.632Z

[KURA-7] Kura Oncology is testing ziftomenib in Advanced Malignant Neoplasm: a Phase 1/Phase 2 trial (NCT04067336), active not recruiting at 263 patients, est. primary completion 2028-10-16.
    source: https://clinicaltrials.gov/study/NCT04067336  (ORIGIN)
    verbatim: "NCT identifier NCT04067336: 'First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia' - Phase: Phase 1/Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 263"
    as of: 2026-06-11T19:18:06.632Z

[KURA-8] Kura Oncology is testing ziftomenib in Acute Lymphoblastic Leukemia, With Appropriate Mutations: a N/A trial (NCT05738538), available.
    source: https://clinicaltrials.gov/study/NCT05738538  (ORIGIN)
    verbatim: "NCT identifier NCT05738538: 'Expanded Access to Ziftomenib' - Phase: N/A, Status: AVAILABLE, Enrollment: None"
    as of: 2026-06-11T19:18:06.632Z

[KURA-9] Kura Oncology is testing ziftomenib in Refractory Acute Leukemia: a Phase 1 trial (NCT06397027), recruiting toward 22 patients, est. primary completion 2030-12-31.
    source: https://clinicaltrials.gov/study/NCT06397027  (ORIGIN)
    verbatim: "NCT identifier NCT06397027: 'A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias' - Phase: Phase 1, Status: RECRUITING, Enrollment: 22"
    as of: 2026-06-11T19:18:06.632Z

[KURA-10] Kura Oncology is testing ziftomenib in Acute Myeloid Leukemia: a Phase 1 trial (NCT06440135), recruiting toward 22 patients, est. primary completion 2027-09-01.
    source: https://clinicaltrials.gov/study/NCT06440135  (ORIGIN)
    verbatim: "NCT identifier NCT06440135: 'Ziftomenib Maintenance Post Allo-HCT' - Phase: Phase 1, Status: RECRUITING, Enrollment: 22"
    as of: 2026-06-11T19:18:06.632Z

[KURA-11] Kura Oncology is testing ziftomenib in Relapsed/Refractory KMT2A-r Acute Leukemia: a Phase 1 trial (NCT06376162), recruiting toward 20 patients, est. primary completion 2027-01.
    source: https://clinicaltrials.gov/study/NCT06376162  (ORIGIN)
    verbatim: "NCT identifier NCT06376162: 'Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia' - Phase: Phase 1, Status: RECRUITING, Enrollment: 20"
    as of: 2026-06-11T19:18:06.632Z

[KURA-12] Kura Oncology is testing ziftomenib in KMT2A-rearranged: a Phase 1 trial (NCT07355335), not yet recruiting at 24 patients, est. primary completion 2028-01-01.
    source: https://clinicaltrials.gov/study/NCT07355335  (ORIGIN)
    verbatim: "NCT identifier NCT07355335: 'Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML' - Phase: Phase 1, Status: NOT_YET_RECRUITING, Enrollment: 24"
    as of: 2026-06-11T19:18:06.632Z

[KURA-13] Kura Oncology is testing ziftomenib in Gastrointestinal Stromal Tumor (GIST): a Phase 1 trial (NCT06655246), recruiting toward 157 patients, est. primary completion 2028-12.
    source: https://clinicaltrials.gov/study/NCT06655246  (ORIGIN)
    verbatim: "NCT identifier NCT06655246: 'A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)' - Phase: Phase 1, Status: RECRUITING, Enrollment: 157"
    as of: 2026-06-11T19:18:06.632Z

[KURA-14] Kura Oncology is testing ziftomenib in Acute Myeloid Leukemia (AML): a Phase 2 trial (NCT07623616), recruiting toward 6 patients, est. primary completion 2028-12.
    source: https://clinicaltrials.gov/study/NCT07623616  (ORIGIN)
    verbatim: "NCT identifier NCT07623616: 'A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia' - Phase: Phase 2, Status: RECRUITING, Enrollment: 6"
    as of: 2026-06-11T19:18:06.632Z

[KURA-15] Kura Oncology is testing ziftomenib in Acute Myeloid Leukemia: a Phase 1 trial (NCT06448013), recruiting toward 22 patients, est. primary completion 2030-12-31.
    source: https://clinicaltrials.gov/study/NCT06448013  (ORIGIN)
    verbatim: "NCT identifier NCT06448013: 'A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia' - Phase: Phase 1, Status: RECRUITING, Enrollment: 22"
    as of: 2026-06-11T19:18:06.632Z

[KURA-16] Ziftomenib appears in 22 FDA adverse-event reports (FAERS); the most frequent are off label use (3), death (2), drug ineffective (2).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"ziftomenib"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='ziftomenib': total=22, top_reactions=[{"term": "OFF LABEL USE", "count": 3}, {"term": "DEATH", "count": 2}, {"term": "DRUG INEFFECTIVE", "count": 2}]"
    as of: 2026-06-11T19:18:07.058Z

[KURA-17] Kura Oncology is testing tuspetinib in Leukemia, Myeloid, Acute: a Phase 1/Phase 2 trial (NCT03850574), recruiting toward 240 patients, est. primary completion 2027-04.
    source: https://clinicaltrials.gov/study/NCT03850574  (ORIGIN)
    verbatim: "NCT identifier NCT03850574: 'Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia' - Phase: Phase 1/Phase 2, Status: RECRUITING, Enrollment: 240"
    as of: 2026-06-11T19:18:07.144Z

[KURA-18] Tuspetinib appears in 0 FDA adverse-event reports (FAERS).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"tuspetinib"  (ORIGIN)
    verbatim: "FAERS query for medicinalproduct='tuspetinib': total=0, reactions=[]"
    as of: 2026-06-11T19:18:07.715Z

[KURA-19] Kura Oncology is testing its candidate in Thyroid Cancer: a Phase 2 trial (NCT02383927), completed at 63 patients, primary completion (registry) 2020-12-14.
    source: https://clinicaltrials.gov/study/NCT02383927  (ORIGIN)
    verbatim: "NCT identifier NCT02383927: 'Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations' - Phase: Phase 2, Status: COMPLETED, Enrollment: 63"
    as of: 2026-06-11T19:18:06.632Z

[KURA-20] A 2026 paper in The Journal of antibiotics reports that tuspetinib enhances the activity of polymyxin B by inhibiting the GlcNAc6P deacetylase (PMID 41963515).
    source: https://pubmed.ncbi.nlm.nih.gov/41963515/  (ACCOUNTABLE_RELAY)
    verbatim: "The past decade has witnessed the recognition of antibiotic resistance as an emerging threat to public health. Polymyxin B (PMB) is a last-resort antibiotic against multidrug-resistant (MDR) Gram-negative bacteria, but it has nephrotoxicity. A cocktail with molecules to sensitize microbes to PMB is..."
    as of: 2026-06-11T19:18:07.267Z

[KURA-21] A 2025 paper in Cancer research communications reports that preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia (PMID 39665627).
    source: https://pubmed.ncbi.nlm.nih.gov/39665627/  (ACCOUNTABLE_RELAY)
    verbatim: "Tuspetinib (TUS) is a well-tolerated, once daily, oral kinase inhibitor in clinical development for treatment of acute myeloid leukemia (AML). Nonclinical studies show that TUS targets key prosurvival kinases with IC50 values in the low nmol/L range, including SYK, wild-type (WT) and mutant forms of..."
    as of: 2026-06-11T19:18:07.267Z

[KURA-22] A 2026 paper in Frontiers in medicine reports that differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives (PMID 42232986).
    source: https://pubmed.ncbi.nlm.nih.gov/42232986/  (ACCOUNTABLE_RELAY)
    verbatim: "Clonal evolution, genetic heterogeneity, and impaired myeloid differentiation are characteristics of acute myeloid leukemia (AML), an aggressive hematologic malignancy. Many patients continue to have poor outcomes even after decades of relying on aggressive induction chemotherapy (7 + 3 regimen), pa..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-23] A 2026 paper in Blood reports that ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia (PMID 42227701).
    source: https://pubmed.ncbi.nlm.nih.gov/42227701/  (ACCOUNTABLE_RELAY)
    verbatim: "Ziftomenib - a potent, selective, oral menin inhibitor - is approved as monotherapy for adults with relapsed/refractory (R/R) NPM1-mutated acute myeloid leukemia (NPM1-m AML). The KOMET-007 phase 1 trial investigated clinical activity and tolerability of ziftomenib in combination with standard thera..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-24] A 2026 paper in Leukemia & lymphoma reports that emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia (PMID 42200794).
    source: https://pubmed.ncbi.nlm.nih.gov/42200794/  (ACCOUNTABLE_RELAY)
    verbatim: "Understanding the clinical significance of genetic aberrations in acute myeloid leukemia (AML) has led to the development of several specific treatment drugs that have improved clinical outcomes. Recently, several clinical trials have investigated new therapeutic drugs in this context, either alone..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-25] A 2026 paper in CPT: pharmacometrics & systems pharmacology reports that population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation (PMID 42081323).
    source: https://pubmed.ncbi.nlm.nih.gov/42081323/  (ACCOUNTABLE_RELAY)
    verbatim: "Ziftomenib, a potent, highly selective, oral menin inhibitor, has demonstrated significant clinical benefit and deep responses in relapsed and/or refractory (R/R) nucleophosmin 1-mutated (NPM1-m) acute myeloid leukemia (AML) patients. Here we present data from analyses conducted to characterize zift..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-26] A 2026 paper in bioRxiv : the preprint server for biology reports that combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2Ar and NPM1-m AML (PMID 41959134).
    source: https://pubmed.ncbi.nlm.nih.gov/41959134/  (ACCOUNTABLE_RELAY)
    verbatim: "Menin scaffolds the oncogenic histone-lysine-N-methyltransferase (KMT2A)-fusion protein (FP) complex in KMT2A-r and wild-type KMT2A complex in NPM1-m acute myeloid leukemia (AML). Menin inhibitors (MIs) are effective in KMT2A-r AML and NPM1-m AML. However, not all patients respond to MIs as monother..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-27] A 2026 paper in European journal of haematology reports that targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation (PMID 41923577).
    source: https://pubmed.ncbi.nlm.nih.gov/41923577/  (ACCOUNTABLE_RELAY)
    verbatim: "Acute leukemias characterized by a shared epigenetic dependency on the menin-KMT2A axis rely on aberrant HOX-driven transcriptional programs that sustain leukemic self-renewal and impair differentiation. This dependency is most evident in KMT2A-rearranged and NPM1-mutated acute myeloid leukemia (AML..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-28] A 2026 paper in Journal of personalized medicine reports that targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions (PMID 41893037).
    source: https://pubmed.ncbi.nlm.nih.gov/41893037/  (ACCOUNTABLE_RELAY)
    verbatim: "Acute myeloid leukemia (AML) is a molecularly heterogeneous neoplasm of hematopoietic stem and progenitor cells. The advent of high-resolution genomic sequencing has uncovered several genetic drivers of AML which spurred a surge of therapies that target the disease at a mutational, clonal, or epigen..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-29] A 2026 paper in Blood reports that discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models (PMID 41849234).
    source: https://pubmed.ncbi.nlm.nih.gov/41849234/  (ACCOUNTABLE_RELAY)
    verbatim: "The protein-protein interaction between menin and KMT2A (histone lysine methyltransferase 2A) plays a critical role in acute leukemia with KMT2A rearrangements, nucleophosmin 1 (NPM1) mutations and nucleoporin 98 rearrangements, and represents an emerging opportunity for therapeutic intervention. He..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-30] A 2026 paper in Oncology research reports that clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives (PMID 41799513).
    source: https://pubmed.ncbi.nlm.nih.gov/41799513/  (ACCOUNTABLE_RELAY)
    verbatim: "Acute myeloid leukemia (AML) remains a biologically heterogeneous disease with historically limited targeted therapies and poor outcomes. The development of menin inhibitors represents a promising shift, particularly for patients harboring KMT2A rearrangements (KMT2Ar) and NPM1 mutations (NPM1m). Th..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-31] A 2026 paper in American journal of hematology reports that the Care and Cure of the Leukemias in 2026 (PMID 41761287).
    source: https://pubmed.ncbi.nlm.nih.gov/41761287/  (ACCOUNTABLE_RELAY)
    verbatim: "It is an exciting era in leukemia owing to the development of novel targeted therapies and advances in genomics, pathophysiology, prognostication, and monitoring (e.g., highly sensitive measurable residual disease assays). Currently, most leukemias are effectively treated with immunotherapies (highl..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-32] A 2026 paper in International journal of molecular sciences reports that differentiation Syndrome in Acute Myeloid Leukemia: Molecular Mechanisms, Clinical Spectrum, and Emerging Therapeutic Paradigms (PMID 41751911).
    source: https://pubmed.ncbi.nlm.nih.gov/41751911/  (ACCOUNTABLE_RELAY)
    verbatim: "Acute myeloid leukemia (AML) is characterized by differentiation arrest, driving blast proliferation, and abnormal blood formation. While differentiation therapy revolutionized acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), its extension into non-A..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-33] A 2026 paper in Cancers reports that management of Acute Myeloid Leukemia: A Review (PMID 41749912).
    source: https://pubmed.ncbi.nlm.nih.gov/41749912/  (ACCOUNTABLE_RELAY)
    verbatim: "Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with historically poor outcomes, particularly among older adults and patients harboring high-risk molecular features. Advances in genomic profiling have enabled the development of targeted therapies, reshaping treatment algorithm..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-34] A 2026 paper in Cancers reports that menin Inhibition in Acute Myeloid MLL Rearranged Leukemias: A New Target for Precision Care (PMID 41749890).
    source: https://pubmed.ncbi.nlm.nih.gov/41749890/  (ACCOUNTABLE_RELAY)
    verbatim: "Menin inhibitors are the first targeted therapies for KMT2A-rearranged and NPM1-mutated acute leukemias, addressing a significant unmet need in these high-risk subtypes. Revumenib received approval in 2024-2025 for relapsed or refractory KMT2A-rearranged acute leukemia and NPM1-mutated AML. The AUG-..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-35] A 2026 paper in Drugs reports that ziftomenib: First Approval (PMID 41653248).
    source: https://pubmed.ncbi.nlm.nih.gov/41653248/  (ACCOUNTABLE_RELAY)
    verbatim: "Ziftomenib (KOMZIFTITM) is an oral, selective, once-daily menin inhibitor in development by Kura Oncology for the treatment of NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukaemia (AML), KMT2A-r acute lymphoblastic leukaemia and gastrointestinal stromal tumours (GIST). The meni..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-36] A 2025 paper in Hematology. American Society of Hematology. Education Program reports that the promise of menin inhibitors: from approval to triplet regimens (PMID 41347983).
    source: https://pubmed.ncbi.nlm.nih.gov/41347983/  (ACCOUNTABLE_RELAY)
    verbatim: "Pharmacologic targeting of the menin-KMT2A protein-protein interaction has emerged as a therapeutic breakthrough for acute leukemias harboring KMT2A rearrangements or NPM1 mutations. The first-in-class menin inhibitor (revumenib) achieved accelerated regulatory approval in November 2024 for monother..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-37] A 2025 paper in Medical oncology (Northwood, London, England) reports that menin inhibitors as targeted therapy in KMT2A-Rearranged acute leukemia: A comprehensive review of current advances and therapeutic implications (PMID 41320744).
    source: https://pubmed.ncbi.nlm.nih.gov/41320744/  (ACCOUNTABLE_RELAY)
    verbatim: "Acute leukemias harboring KMT2A rearrangements (KMT2A-r) or NPM1 mutations (NPM1-m) are aggressive subtypes with limited therapeutic options and high relapse rates. Their biology is sustained by aberrant HOXA9/MEIS1 transcription, critically dependent on the interaction between menin and the KMT2A c..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-38] A 2025 paper in Journal of clinical oncology : official journal of the American Society of Clinical Oncology reports that ziftomenib in Relapsed or Refractory NPM1-Mutated AML (PMID 40997296).
    source: https://pubmed.ncbi.nlm.nih.gov/40997296/  (ACCOUNTABLE_RELAY)
    verbatim: "Ziftomenib-a potent, highly selective, oral menin inhibitor-was well tolerated and demonstrated encouraging clinical activity as monotherapy for relapsed/refractory NPM1-mutated (NPM1-m) and KMT2A-rearranged AML in the KOMET-001 phase I trial.
In the registration-enabling phase II part of KOMET-001,..."
    as of: 2026-06-11T19:18:06.632Z

[KURA-39] OpenTargets catalogs MEN1 (menin 1) under Ensembl identifier ENSG00000133895.
    source: https://platform.opentargets.org/target/ENSG00000133895  (ACCOUNTABLE_RELAY)
    verbatim: "OpenTargets target search for 'MEN1': id=ENSG00000133895, name='MEN1', description='menin 1'"
    as of: 2026-06-11T19:21:01.329Z

[KURA-40] OpenTargets catalogs KMT2A (lysine methyltransferase 2A) under Ensembl identifier ENSG00000118058.
    source: https://platform.opentargets.org/target/ENSG00000118058  (ACCOUNTABLE_RELAY)
    verbatim: "OpenTargets target search for 'KMT2A': id=ENSG00000118058, name='KMT2A', description='lysine methyltransferase 2A'"
    as of: 2026-06-11T19:21:02.090Z

[COGT-1] Cogent Biosciences is testing CGT9486 in Advanced Gastrointestinal Stromal Tumors: a Phase 3 trial (NCT05208047), active not recruiting at 482 patients, est. primary completion 2030-01.
    source: https://clinicaltrials.gov/study/NCT05208047  (ORIGIN)
    verbatim: "NCT identifier NCT05208047: '(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors' - Phase: Phase 3, Status: ACTIVE_NOT_RECRUITING, Enrollment: 482"
    as of: 2026-06-11T19:18:12.657Z

[COGT-2] Cogent Biosciences is testing bezuclastinib in Systemic Mastocytoses, Indolent: a N/A trial (NCT06915766), available.
    source: https://clinicaltrials.gov/study/NCT06915766  (ORIGIN)
    verbatim: "NCT identifier NCT06915766: 'Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis' - Phase: N/A, Status: AVAILABLE, Enrollment: None"
    as of: 2026-06-11T19:18:12.657Z

[COGT-3] Cogent Biosciences is testing bezuclastinib in Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors: a N/A trial (NCT06948955), available.
    source: https://clinicaltrials.gov/study/NCT06948955  (ORIGIN)
    verbatim: "NCT identifier NCT06948955: 'Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors' - Phase: N/A, Status: AVAILABLE, Enrollment: None"
    as of: 2026-06-11T19:18:12.657Z

[COGT-4] Cogent Biosciences is testing bezuclastinib in SSM: a Phase 2 trial (NCT05186753), active not recruiting at 237 patients, est. primary completion 2030-04.
    source: https://clinicaltrials.gov/study/NCT05186753  (ORIGIN)
    verbatim: "NCT identifier NCT05186753: '(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 237"
    as of: 2026-06-11T19:18:12.657Z

[COGT-5] Cogent Biosciences is testing bezuclastinib in Advanced Systemic Mastocytosis (AdvSM): a Phase 2 trial (NCT04996875), recruiting toward 140 patients, est. primary completion 2027-07.
    source: https://clinicaltrials.gov/study/NCT04996875  (ORIGIN)
    verbatim: "NCT identifier NCT04996875: '(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis' - Phase: Phase 2, Status: RECRUITING, Enrollment: 140"
    as of: 2026-06-11T19:18:12.657Z

[COGT-6] Cogent Biosciences is testing bezuclastinib in Gastrointestinal Stromal Tumors: a Phase 2 trial (NCT06208748), active not recruiting at 40 patients, est. primary completion 2027-06.
    source: https://clinicaltrials.gov/study/NCT06208748  (ORIGIN)
    verbatim: "NCT identifier NCT06208748: 'SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST' - Phase: Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 40"
    as of: 2026-06-11T19:18:12.657Z

[COGT-7] Cogent Biosciences is testing its candidate in Solid Tumor: a Phase 1 trial (NCT03680560), terminated at 6 patients, primary completion on record 2020-03-12.
    source: https://clinicaltrials.gov/study/NCT03680560  (ORIGIN)
    verbatim: "NCT identifier NCT03680560: 'Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers' - Phase: Phase 1, Status: TERMINATED, Enrollment: 6"
    as of: 2026-06-11T19:18:12.624Z

[COGT-8] Cogent Biosciences is testing its candidate in Intrahepatic Cholangiocarcinoma (Icc): a Phase 1/Phase 2 trial (NCT06777316), active not recruiting at 110 patients, est. primary completion 2027-06.
    source: https://clinicaltrials.gov/study/NCT06777316  (ORIGIN)
    verbatim: "NCT identifier NCT06777316: 'A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors' - Phase: Phase 1/Phase 2, Status: ACTIVE_NOT_RECRUITING, Enrollment: 110"
    as of: 2026-06-11T19:18:12.624Z

[COGT-9] Cogent Biosciences is testing its candidate in B Cell Lymphomas: a N/A trial (NCT02840110), terminated at 22 patients, primary completion on record 2021-02-23.
    source: https://clinicaltrials.gov/study/NCT02840110  (ORIGIN)
    verbatim: "NCT identifier NCT02840110: 'Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product' - Phase: N/A, Status: TERMINATED, Enrollment: 22"
    as of: 2026-06-11T19:18:12.624Z

[COGT-10] Cogent Biosciences is testing its candidate in PIK3CA Mutations: a Phase 1 trial (NCT07383506), recruiting toward 90 patients, est. primary completion 2029-08.
    source: https://clinicaltrials.gov/study/NCT07383506  (ORIGIN)
    verbatim: "NCT identifier NCT07383506: 'A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors' - Phase: Phase 1, Status: RECRUITING, Enrollment: 90"
    as of: 2026-06-11T19:18:12.624Z

[COGT-11] Cogent Biosciences is testing its candidate in Advanced Solid Tumor, Adult: a Phase 1 trial (NCT07361562), recruiting toward 100 patients, est. primary completion 2028-11.
    source: https://clinicaltrials.gov/study/NCT07361562  (ORIGIN)
    verbatim: "NCT identifier NCT07361562: 'A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors' - Phase: Phase 1, Status: RECRUITING, Enrollment: 100"
    as of: 2026-06-11T19:18:12.624Z

[COGT-12] Cogent Biosciences is testing its candidate in Lymphoma: a Phase 1 trial (NCT03189836), terminated at 26 patients, primary completion on record 2020-09-21.
    source: https://clinicaltrials.gov/study/NCT03189836  (ORIGIN)
    verbatim: "NCT identifier NCT03189836: 'Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma' - Phase: Phase 1, Status: TERMINATED, Enrollment: 26"
    as of: 2026-06-11T19:18:12.624Z

[COGT-13] Cogent Biosciences is testing its candidate in Multiple Myeloma: a Phase 1 trial (NCT03266692), terminated at 15 patients, primary completion on record 2019-10-01.
    source: https://clinicaltrials.gov/study/NCT03266692  (ORIGIN)
    verbatim: "NCT identifier NCT03266692: 'Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma' - Phase: Phase 1, Status: TERMINATED, Enrollment: 15"
    as of: 2026-06-11T19:18:12.624Z

[COGT-14] Cogent Biosciences is testing its candidate in Lymphoma: a Phase 1 trial (NCT02776813), completed at 34 patients, primary completion (registry) 2020-02-12.
    source: https://clinicaltrials.gov/study/NCT02776813  (ORIGIN)
    verbatim: "NCT identifier NCT02776813: 'Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma' - Phase: Phase 1, Status: COMPLETED, Enrollment: 34"
    as of: 2026-06-11T19:18:12.624Z

[COGT-15] Cogent Biosciences is testing CGT9486 in Gastrointestinal Stromal Tumors: a Phase 1/Phase 2 trial (NCT02401815), completed at 51 patients, primary completion (registry) 2020-05-11.
    source: https://clinicaltrials.gov/study/NCT02401815  (ORIGIN)
    verbatim: "NCT identifier NCT02401815: 'CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors' - Phase: Phase 1/Phase 2, Status: COMPLETED, Enrollment: 51"
    as of: 2026-06-11T19:18:12.624Z

[COGT-16] Bezuclastinib appears in 23 FDA adverse-event reports (FAERS); the most frequent are bilirubin conjugated increased (2), blood alkaline phosphatase increased (2), blood bilirubin increased (2).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"bezuclastinib"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='bezuclastinib': total=23, top_reactions=[{"term": "BILIRUBIN CONJUGATED INCREASED", "count": 2}, {"term": "BLOOD ALKALINE PHOSPHATASE INCREASED", "count": 2}, {"term": "BLOOD BILIRUBIN INCREASED", "count": 2}]"
    as of: 2026-06-11T19:18:13.333Z

[COGT-17] CGT9486 appears in 6 FDA adverse-event reports (FAERS); the most frequent are bilirubin conjugated increased (1), blood alkaline phosphatase increased (1), blood bilirubin increased (1).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"CGT9486"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='CGT9486': total=6, top_reactions=[{"term": "BILIRUBIN CONJUGATED INCREASED", "count": 1}, {"term": "BLOOD ALKALINE PHOSPHATASE INCREASED", "count": 1}, {"term": "BLOOD BILIRUBIN INCREASED", "count": 1}]"
    as of: 2026-06-11T19:18:13.921Z

[COGT-18] A 2025 paper in Current opinion in allergy and clinical immunology reports that new treatments for systemic mastocytosis in 2025 (PMID 40471046).
    source: https://pubmed.ncbi.nlm.nih.gov/40471046/  (ACCOUNTABLE_RELAY)
    verbatim: "To provide an accessible, comprehensive overview of past, present, imminent, and future therapies for systemic mastocytosis.
Based on recent trials, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved two drugs for treating advanced systemic mastocytosis: avaprit..."
    as of: 2026-06-11T19:18:12.770Z

[COGT-19] A 2024 paper in Journal of blood medicine reports that management of Advanced Systemic Mastocytosis: Clinical Challenges (PMID 39279879).
    source: https://pubmed.ncbi.nlm.nih.gov/39279879/  (ACCOUNTABLE_RELAY)
    verbatim: "Advanced systemic mastocytosis (AdvSM) is a rare hematologic malignancy with organ damage and compromised life expectancy arising from organ accumulation of neoplastic mast cells. Identification of the gain-of-function KITD816V in the majority of cases has accelerated pharmaceutical development culm..."
    as of: 2026-06-11T19:18:12.770Z

[COGT-20] A 2024 paper in Current hematologic malignancy reports reports that systemic Mastocytosis: State of the Art (PMID 39187708).
    source: https://pubmed.ncbi.nlm.nih.gov/39187708/  (ACCOUNTABLE_RELAY)
    verbatim: "Since identification of Systemic mastocytosis (SM) as a distinct disease entity by the World Health Organisation (WHO), there has been a wealth of new research in therapeutic targeting of the pathogenic C-KIT D816V mutation.
Avapritinib, the first licensed drug in SM capable of disease modification..."
    as of: 2026-06-11T19:18:12.770Z

[COGT-21] A 2025 paper in Clinical lymphoma, myeloma & leukemia reports that sOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis (PMID 39168723).
    source: https://pubmed.ncbi.nlm.nih.gov/39168723/  (ACCOUNTABLE_RELAY)
    verbatim: "Systemic mastocytosis (SM) is a heterogeneous myeloid neoplasm, characterized by clonal proliferation of mast cells (MCs) in  1 extracutaneous organs, including the bone marrow (BM) and gastrointestinal tract. Aberrant MC proliferation is driven by mutation KIT D816V in 90-95% of SM patients. Indo..."
    as of: 2026-06-11T19:18:12.770Z

[COGT-22] A 2023 paper in Expert opinion on emerging drugs reports that systemic mastocytosis: 2023 update on diagnosis and management in adults (PMID 37256917).
    source: https://pubmed.ncbi.nlm.nih.gov/37256917/  (ACCOUNTABLE_RELAY)
    verbatim: "Systemic mastocytosis (SM) is a complex and heterogeneous disease, characterized by the clonal accumulation of mast cells in one or more organs. In 2022 both the World Health Organization (WHO) and the International Consensus Classification (ICC) modified the diagnostic and classification criteria o..."
    as of: 2026-06-11T19:18:12.770Z

[COGT-23] A 2022 paper in Hematology. American Society of Hematology. Education Program reports that available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms (PMID 36485158).
    source: https://pubmed.ncbi.nlm.nih.gov/36485158/  (ACCOUNTABLE_RELAY)
    verbatim: "The historically poor prognosis of patients with advanced systemic mastocytosis (AdvSM) and primary eosinophilic neoplasms has shifted to increasingly favorable outcomes with the discovery of druggable targets. The multikinase/KIT inhibitor midostaurin and the highly selective KIT D816V inhibitor av..."
    as of: 2026-06-11T19:18:12.770Z

[COGT-24] OpenTargets catalogs KIT (KIT proto-oncogene, receptor tyrosine kinase) under Ensembl identifier ENSG00000157404.
    source: https://platform.opentargets.org/target/ENSG00000157404  (ACCOUNTABLE_RELAY)
    verbatim: "OpenTargets target search for 'KIT': id=ENSG00000157404, name='KIT', description='KIT proto-oncogene, receptor tyrosine kinase'"
    as of: 2026-06-11T19:21:10.637Z

[CRBU-1] Caribou Biosciences is testing its candidate in Lymphoma, Non-Hodgkin: a N/A trial (NCT05332054), enrolling by invitation at 150 patients, est. primary completion 2041-12.
    source: https://clinicaltrials.gov/study/NCT05332054  (ORIGIN)
    verbatim: "NCT identifier NCT05332054: 'Long-Term Follow-up Study' - Phase: N/A, Status: ENROLLING_BY_INVITATION, Enrollment: 150"
    as of: 2026-06-11T19:18:09.940Z

[CRBU-2] Caribou Biosciences is testing CB-010 in Lymphoma, Non-Hodgkin: a Phase 1 trial (NCT04637763), unknown at 72 patients, est. primary completion 2025-09.
    source: https://clinicaltrials.gov/study/NCT04637763  (ORIGIN)
    verbatim: "NCT identifier NCT04637763: 'CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)' - Phase: Phase 1, Status: UNKNOWN, Enrollment: 72"
    as of: 2026-06-11T19:18:09.940Z

[CRBU-3] Caribou Biosciences is testing CB-010 in Systemic Lupus Erythematosus: a Phase 1 trial (NCT06752876), withdrawn, primary completion on record 2029-04.
    source: https://clinicaltrials.gov/study/NCT06752876  (ORIGIN)
    verbatim: "NCT identifier NCT06752876: 'CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)' - Phase: Phase 1, Status: WITHDRAWN, Enrollment: 0"
    as of: 2026-06-11T19:18:09.940Z

[CRBU-4] CB-011 appears in 271 FDA adverse-event reports (FAERS); the most frequent are febrile neutropenia (11), nausea (9), constipation (8).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"CB-011"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='CB-011': total=271, top_reactions=[{"term": "FEBRILE NEUTROPENIA", "count": 11}, {"term": "NAUSEA", "count": 9}, {"term": "CONSTIPATION", "count": 8}]"
    as of: 2026-06-11T19:18:11.663Z

[CRBU-5] Caribou Biosciences is testing CB-012 in Acute Myeloid Leukemia, in Relapse: a Phase 1 trial (NCT06128044), terminated at 12 patients, primary completion on record 2025-05-30.
    source: https://clinicaltrials.gov/study/NCT06128044  (ORIGIN)
    verbatim: "NCT identifier NCT06128044: 'CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia' - Phase: Phase 1, Status: TERMINATED, Enrollment: 12"
    as of: 2026-06-11T19:18:09.832Z

[CRBU-6] Caribou Biosciences is testing CB-011 in Relapsed/Refractory Multiple Myeloma: a Phase 1 trial (NCT05722418), recruiting toward 50 patients, est. primary completion 2027-12.
    source: https://clinicaltrials.gov/study/NCT05722418  (ORIGIN)
    verbatim: "NCT identifier NCT05722418: 'CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma' - Phase: Phase 1, Status: RECRUITING, Enrollment: 50"
    as of: 2026-06-11T19:18:09.832Z

[CRBU-7] CB-012 appears in 186 FDA adverse-event reports (FAERS); the most frequent are accidental overdose (9), drug dispensing error (7), vomiting (7).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"CB-012"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='CB-012': total=186, top_reactions=[{"term": "ACCIDENTAL OVERDOSE", "count": 9}, {"term": "DRUG DISPENSING ERROR", "count": 7}, {"term": "VOMITING", "count": 7}]"
    as of: 2026-06-11T19:18:12.468Z

[CRBU-8] CB-010 appears in 426 FDA adverse-event reports (FAERS); the most frequent are diarrhoea (22), colitis (15), dehydration (13).
    source: https://api.fda.gov/drug/event.json?search=medicinalproduct:"CB-010"  (ORIGIN)
    verbatim: "FAERS API result for medicinalproduct='CB-010': total=426, top_reactions=[{"term": "DIARRHOEA", "count": 22}, {"term": "COLITIS", "count": 15}, {"term": "DEHYDRATION", "count": 13}]"
    as of: 2026-06-11T19:18:10.591Z

[CRBU-9] A 2023 paper in Cytotherapy reports that allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness (PMID 37086241).
    source: https://pubmed.ncbi.nlm.nih.gov/37086241/  (ACCOUNTABLE_RELAY)
    verbatim: "Therapeutic disruption of immune checkpoints has significantly advanced the armamentarium of approaches for treating cancer. The prominent role of the programmed death-1 (PD-1)/programmed death ligand-1 axis for downregulating T cell function offers a tractable strategy for enhancing the disease-mod..."
    as of: 2026-06-11T19:18:10.053Z

[CRBU-10] OpenTargets catalogs MS4A1 (membrane spanning 4-domains A1) under Ensembl identifier ENSG00000156738.
    source: https://platform.opentargets.org/target/ENSG00000156738  (ACCOUNTABLE_RELAY)
    verbatim: "OpenTargets target search for 'MS4A1': id=ENSG00000156738, name='MS4A1', description='membrane spanning 4-domains A1'"
    as of: 2026-06-11T19:21:05.998Z

[CRBU-11] OpenTargets catalogs TNFRSF17 (TNF receptor superfamily member 17) under Ensembl identifier ENSG00000048462.
    source: https://platform.opentargets.org/target/ENSG00000048462  (ACCOUNTABLE_RELAY)
    verbatim: "OpenTargets target search for 'TNFRSF17': id=ENSG00000048462, name='TNFRSF17', description='TNF receptor superfamily member 17'"
    as of: 2026-06-11T19:21:06.726Z